Applications are invited for the 1998 Paul C. Aebersold Award for outstanding achievement in basic science applied to Nuclear Medicine. This award commemorates the contributions of Dr. Paul Clarence Aebersold to the applications of nuclear physics to Nuclear Medicine and radiation biology, as well as his contributions to the Society of Nuclear Medicine (SNM). Dr. Aebersold contributed greatly to the emergence of Nuclear Medicine as a discipline by his energetic leadership in the provision of cyclotron-generated and reactor-produced radionuclides, and by his numerous publications and lectures. In giving this award, the Society thus symbolically signifies its appreciation of the warm and vital person who became the Society’s first Honorary Member.

Nominations should be supported by the nominee’s curriculum vitae and at least two letters supporting the nomination. These letters should briefly describe the contributions in basic science for which the nominee is proposed. The nominee does not need to be a SNM member.

Nominations deadline: December 31, 1997. Please submit nominations and supporting documents to William J. MacIntyre, Ph.D., c/o Society of Nuclear Medicine, 1850 Samuel Morse Drive, Reston, Virginia 20190-5316.
Absolute ethanol, scintigraphic assessment of therapeutic success, treatment of aldosteronomas, transcatheter arterial embolization, 237

Absorptiometry
dual-energy X-ray, quantification of bone healing, 300(ab)
single photon, comparison with dual-energy X-ray and CT, postmenopausal females, 300(ab)

Accelerated gastric emptying, in longstanding diabetes after semisolid meal, supine position, 814

Accelerator Driver Operated New Irradiation System, new solution for isotope production, 99Mo, Belgian, 16N(3)

Accessory spleen
false-positive somatostatin receptor scintigraphy, gastroenteropancreatic tumors, 1979

noninvasive diagnosis with ""Tc-HDRCB SPECT, pancreas, 494

Accreditation, American Medical Association program for physicians, 17N(5)

Acetate, PET imaging of pancreas and related diseases, 1305

Acetazolamide challenge, ""Tc-ECG versus ""I-IMP SPECT in chronic occlusive cerebrovascular disease, linearization correction, 1463

Acetylcholine receptors, nicotinic, ""F NFEP PET studies, 80(ab)

Acetylcholinesterase
brain activity, Kinetic modeling alternatives for assessment with ""C PMP, constraint and, 198(ab)
cortical inhibition, PET quantification of, monkey and human, 146(ab)

ACNP proficiency testing, AMAP approved, 34N(11)

ACNP/SNM Government Relations Office, summary of activities June-September, 30N(11)

Acquired immune deficiency syndrome (AIDS)
""Tc-chloride, delayed positive uptake in non-Hodgkin’s lymphoma, 1213

""Tc uptake in CMV encephalitis, SPECT, 1386

Acquisition
rapid 3D, whole-body PET FDG images, cancer detection and, 197(ab)
whole-body PET, transmission and emission scan duration optimization in, 196(ab)

Acromegaly, renal function in, urinary growth hormone measurement for diagnosis and monitoring, 148(ab)

Activation states, measurement of regional stability of cerebral blood flow, repeated ""Tc-HMPAO SPECT scans, 6

Activation study
three-dimensional imaging for glioma resection, ""C-methionine PET, 1563

weighted summation of ""O-water PET data, signal-to-noise ratio, 334

Activity schedule, dosimetry of pediatric radiopharmaceuticals, effective dose and estimation, 1982

Acute life-threatening event, scintigraphic milk scan findings in pet, 24(ab)

Acute liver necrosis, ""I-MIBG treatment induced metastatic carcinoid tumors, 1024

Acute lymphoblastic leukemia, brain perfusion in children after treatment, SPECT, 82

Acute myocardial infarction
area at risk and quantification of defect size, BMIPP imaging, 1875

evaluation of ""Tc-pyrophosphate scintigraphy. ""TI SPECT and echocardiography, cardiac tissue necrosis caused by electrocution, 250

Acute pyelonephritis, ""Tc-MAG3 SPECT, rapid assessment of renal parenchyma, ectopic kidney, growth-arrested kidney, split function, 478

Addiction, detoxified cocaine abusers, straitial and enhanced thalamic dopaminergic responsibility in, PET, 36(ab)

Adenocarcinoma
colorectal, metastases from, ""FU PET, 137(ab) lung, peripheral, FDG uptake, 243(ab) prostate, therapy with glucosylsphamolide, changes in FDG uptake, 249(ab)

Adenosine myocardial perfusion imaging with dyspnea during, bronchial resistance and, 73(ab)
five-minute infusion protocol, stress testing, 73(ab)
""TI myocardial SPECT, pharmacological stress using, 174(ab)

Adenosine receptors, A2A, CNS mapping with ""I KF7837 PET, 183(ab)

Adenosine triphosphate compared to dipryridamole in coronary artery disease diagnosis, ""TI myocardial scintigraphy, 577
dobutamine versus, ""Tc septamibi myocardial SPECT with pharmacological stress and, 162(ab)

Adenosine bombesin localization in ovarian carcinoma, expression of GPR, gene transfer, 1221 recombinant, radioledale ligand binding using, cells induced to express epidermal growth factor receptor, 18(ab)

Adhesion molecules, ""I In labeled anti-intercellular, localization mechanism, bleomycin-induced rat model, 191(ab)

Adrenal gland benign and malignant tumors, FDG PET characterization of, 242(ab)
scintigraphic assessment of transcatheter arterial embolization therapeutic success using absolute ethanol, aldosteronomas, 237

Adrenergic receptor, cardiac, parameter estimation by single ""C CGP 12177 injection analysis, 41(ab)

Adrenocorticotropic hormone, adrenal gland imaging following ACTH therapy, ""I-DTPA octreotide, Crohn’s disease, 1489

Adverse reactions
drug product problem reporting program, 49N(9)
PET radiopharmaceuticals, safety study of, 112(ab)

Aerosol, chemical and physical nature of technegas, ""Te-pertechnetate, 1327

""Tc-DTPA, alveo-capillary permeability and ventilation studies of, 180(ab) ventilation imaging, factors influencing, 37(ab)

Aging, dopamine receptor binding with ""I IBF and, SPECT, 146(ab)
Agonist, localizing radioledale chemotactic peptides, receptor-specific mechanism, E. coli in rabbits, 1316

β-Agonist therapy, incidence in reverse mismatch, V/Q scan demonstration of, 38(ab)

Agreement analysis, measurement of plateauel survival time, Indium-111-oxine-labeled autologous cells, 977

AIDS, see Acquired immune deficiency syndrome

ALARA guidelines, written instructions for outpatients, NRC suggestions, 1831(1e)

Alcohol
acute effects, cerebral blood flow, lack of aldehyde dehydrogenase-1 and, 108(ab) addiction, reduced binding potential of serotonin transporters in, SPECT, 48(ab) dependence
brain mu opioid receptor binding measurement by PET, 34(ab)
GABA benzodiazepine receptor in, ""I iminodiazep SPECT study, 107(ab) naltrexone effects on cerebral blood flow, 108(ab)

Aldose reductase inhibitor, effects in streptozotocin-induced diabetic rats, cardiac sympathetic neuropathy, MIBG, 1677

Algorithms, GLLS, clinical validation using dynamic FDG-PET data, 202(ab)

Alpha-emitting radionuclides, targeting of HER2/new oncoprotein using lead-212-DOTA-AT1, ovarian cancer, 1944

Alpha-fetoprotein antibody imaging, AFF-SCAN, detection of hepatocellular cancer, 10(ab)

Alpha-particle emitters
dosimetric framework for, microdosimetry, 1923 pharmacokinetics and dosimetry of, leukemia patients, 231(ab)

Altropane, SPECT ligand for dopamine transporter, Parkinson’s disease, 219(ab), 61(ab)

Alzheimer’s disease
CBF oxygen metabolism changes, MRI white matter hyperintensities, 1471
cerebral dysfunction in, metabolic imaging severity rating scale for assessment, 129(ab) cerebral metabolic differences compared with Parkinson’s disease, emission computed tomography, ""F-FDG, 797

comparison of ""I-IMZ SPECT and ""Te-HMPAO SPECT, benzodiazepine receptor, 46(ab)
discriminating from frontal lobe-type dementia with ""Tc-HMPAO SPECT, 929 end stage renal failure and, 129(ab)
lacking apolipoprotein E allele, increased partial cerebral blood flow asymmetry in, 70(ab)

glucose metabolism, effect of level of education, PET, 95(ab)

medial temporal lobe blood flow measurements, MRI-guided SPECT, 914

preclinical prediction, SPECT use in, 70(ab) quantitative assessment of cerebral blood flow, SPECT, computer-assisted image processing, 1095

reduction of cerebellar glucose metabolism, ""F-FDG PET, 925

SPECT imaging, pre- and postynaptic dopamine system, 69(ab)

Tau protein in, FDG PET comparison, 128(ab) traumatic brain injuries and, cerebral distribution of ""Tc ECD and ""F FDG in, 70(ab)

AMA, see American Medical Association

Ambulatory radionuclide monitoring, effect of body position during ergometer exercise, LVEF, 1669

American Medical Association (AMA) accreditation program for physicians, 17N(5)
V79 cells exposed to, survival and DNA damage in, 227(ab)
Astatine-211 MABG, uptake mechanisms, in isolated rat heart, 30(ab)
Asthma. "F" fluorocarbazolol PET, high resolution beta-adrenergic receptor imaging, animal model, 75(ab)
Astrocytic tumors: "111Tc-sestamibi and "123I SPECT correlation, 238(ab)
Atherosclerosis
imaging techniques and role of nuclear medicine, atherothrombosis, 1788
"123I endothelin derivative imaging, rabbit balloon denudation model, 173(ab)
Atherosclerotic, imaging techniques and role of nuclear medicine, atherosclerosis, noninvasive evaluation, 1788
Athymic mice. "123I labeling and biodistribution, anti-TAC dsFv, monoclonal antibody, 294
Attention deficit hyperactivity disorder. ritalin, brain blood flow studies, children, 29(ab)
Attenuation correction
cardiac maps, SPECT systems, statistical algorithms for, 214(ab)
cardiac PET, postinjection transmission measurements, 202(ab)
collimator-detector response compensation and, dynamic myocardial SPECT, 19(ab)
dual isotope myocardial perfusion imaging, cardiac risk with, 83(ab)
effect on defect severity, anthropomorphic phantom with breasts, 85(ab)
effects in quantitative regional cerebral blood flow studies, SPECT, 285(ab)
extracardiac activity complicates SPECT imaging, transmission-emission approach, 1882
gated SPECT
effects of length of transmission scan, 64(ab)
Fourier phase tomography for body contours, 63(ab)
Improved quantification and image quality, "99mTc-ECD, brain SPECT, 157
map reconstruction, collimated line sources, 216(ab)
maps, cardiac SPECT, 217(ab)
mean attenuation coefficients for, PET, 67(ab)
misalignment between transmission and emission scans, myocardial SPECT, 218(ab)
myocardial perfusion imaging, assessment of lateral wall perfusion defects with, 84(ab)
myocardial SPECT impact, intrinsic dual energy processing in, 19(ab)
no correction versus, whole-body PET images, clinical oncology, 198(ab)
on-attenuation-corrected FDG PET versus, in thorax of patients with suspected lung cancer, 5(ab)
non-uniform "99mTc myocardial SPECT, comparison of two methods, 212(ab)
effect on defect detection in "99mTc myocardial SPECT, 19(ab)
new Fourier method, SPECT, 218(ab)
quantitative brain SPECT, 213(ab)
using emission data alone, 68(ab)
PET
singtransmission for, 113(ab)
singles versus coincidence, comparison, 114(ab)
polar map technique, SPECT myocardial perfusion normal database, 155(ab)
pulmonary perfusion and density gradients, SPECT and transmission tomography, 962
quantitation of perfusion defect size, 53(ab)
respiration-compensated, automated 4D segmented transmission images, cardiac PET, 203(ab)
scanning line source as a function of emission, myocardial perfusion imaging, 84(ab)
lesion contrast effects, 213(ab)
SPECT, dual opposing head scintillation camera, 217(ab)
scanning point sources, two half fan beam collimators and, measurements in SPECT, 216(ab)
scatter and, quantitative analysis of 8-CIT brain SPECT, 146(ab)
scatter correction combined with, effect on "99mTc phantom studies, 221(ab)
segmented post-injection transmission, FDG PET scan, 129(ab)
simultaneous iterative reconstruction, SPECT or PET emission sinograms, 101(ab)
SPECT
"99mGd, "99mCo, and "111In comparison, 222(ab)
detection of small myocardial defects in cardiac phantom, 64(ab)
Jaszczak heart phantom and, 168(ab)
SPECT transmission scans, multiple line-source array for, 215(ab)
stress only, cardiac SPECT, cost savings, medium probability for CAD. 84(ab)
"99mTc MIBI SPECT, "99mTc FDG PET versus, myocardial viability prediction, 170(ab)
transmission-emission tomographic systems, quality control protocol, 214(ab)
transmission-emission, myocardial SPECT, 84(ab)
triple head simultaneous Tc transmission Tc emission, 218(ab)
uniform, limitations, brain SPECT quantification, 211(ab)
Auger electrons, beta emitters versus, efficacy and toxicity in radioimmunotherapy of colorectal cancer with internalizing antibodies, 7(ab)
Autism
cerebral blood flow in, "99mTc ECD brain SPECT evaluation, 284(ab)
severity, correlation of rCBF SPECT abnormalities and, 13(ab)
Autograft, bone, after high-dose radiation, "99mTc HDP follow-up in, 304(ab)
Autofarction. Graves’ disease after an autonomously functioning thyroid adenoma, 260
Automatic quantitative left ventricular ejection fraction, assessed with gated "99mTc perfusion SPECT, qualitative regional function, 749
Autonomously functioning thyroid adenoma. Graves disease triggered by autoinfection, 260
Autopsy, cadaveric biodistribution studies after pain palliation with "99mTc-chloride, metastatic carcinoma, 380
Autosynthetic device, production of radiopharmaceuticals, 307(ab)
Avascular necrosis, patellar, in total knee arthroplasty, 304(ab)
Avidin
chemically modified, pharmacokinetics and biodistribution of, 178(ab)
"11In labeled, malignant ascites radiotherapy and, 195(ab)
"11In labeled, intraperitoneal tumor radiotherapy, 194(ab)
monoclonal antibody internalization, tumor pretargeting, streptavidin, 1378
Avidin chase, extracorporeal immunoadsorption comparison, tumor-to-normal tissue ratio for biotinylated "Re-chibI99, 1934
Avidity, effect of antigen density on mAb binding, in vivo and in vitro models, 190(ab)
Azmacort, dose administration evaluation by PET, 4(ab)

B
Baboon model. CBF differences among HMPAO, ECD and IMP, SPECT studies of drug-tracer interaction, 1897
Background correction. "99mTc-MAG3 renography, regions of interest, 74
Basal ganglia. "99mTc-HMPAO SPECT, perfusion in Tourette’s syndrome, 188
Basal ganglia disorders, use of "123I-epidepride SPECT in diagnosis of movement disorders, 1711
Becker muscular dystrophy, left ventricular function and perfusion, "99mTc SPECT, 563
Benzamidines
D3 receptor binding, technetium-labeled analogs of, 99(ab)
radiiodinated, high melanoma uptake, 134(ab)
SPECT imaging of ocular melanomas, 870
Benzodiazepine receptor
Alzheimer’s disease comparison of "111In-IMP SPECT and "99mTc-HMPAO SPECT, 467
comparison with blood flow and metabolism, "111In-IMP SPECT, 1693
detection of salvaged ischemic penumbra, MCA occluded rats, 117(ab)
Benzodiazepine receptor antagonist after cerebral ischemic stroke, 2(ab)
after transient middle cerebral artery occlusion, rat, thrombolysis therapy, 288(ab)
Benzodiazepines
abuse, during chronic administration, healthy subjects, 48(ab)
in cocaine abusers, regional brain metabolic responses, PET, 47(ab)
Beta imaging, gamma-ray guided intra-operative, dual detector probe for, 8(ab)
Beta-adrenergic receptor
fluorocarozol binding to, brain, 289(ab)
new tracers for visualization, PET, 77(ab)
Beta-adrenerceptor density, noninvasive measurement of regional pulmonary and myocardial uptake, "F-fluorocarozol, PET, 169
Beta-adrenceptors, brain imaging, (S)-1-"F-fluorocarozol-PET, 934
Beta-ray emitters, release criteria for patients treated with, 310(ab)
Biliary dyskinesia, quantitative cholescintigraphy to differentiate disease entities, sphincter of oddi, gallbladder, cholescystokinin, 1824
Biliary tract stasis, false-positive whole-body "111In scan, 1977
Bilirubin, competitive inhibition, "99mTc incorporation into hepatocytes, 51(ab)
Binding potential, two-scan graphical method,
effects of mass of injected ligand, 93(ab)

**Biodistribution**

"In labeled DTPA octapeptides, receptor binding and tissue distribution of, rats, 190(ab)

"I OMIMT versus IIT, 188(ab)
synthesis and imaging properties of "In-DTPA-Paclitaxel, gamma scintigraphy, 1042

"Tc-labeled chemotactic peptides in infection and inflammation, 1310

**Biodistribution studies**, "Sr-chloride, autopsy of cadaver, pain palliation for metastatic cancer, 380

**Biological dosimetry**, characteristics of a "Tc irradiator to simulate internal radionuclide patterns, mercury attenuator, 727

chromosome painting, "I1 treatment for differential thyroid carcinoma, 377

**Biopsy**

fine needle aspiration, "Tl scintigraphy comparison, thyroid nodules, 265(ab)

radio-directed system

accuracy of needle localization of scintigraphic abnormalities, 22(ab)

interventional nuclear scintigraphy, 143(ab)

**Biotin**

biomolecules, labeling versatility of, "Tc carbonyl and, 180(ab)

streptavidin and, controlled blood clearance by isoiohexanoyl-triglactose derivative biochemical modification with, 30(ab)

**Biotin analogs**, "F labeled, ligands for antibody-streptavidin conjugates, 142(ab)

**Biotinylated rhodamine-188-chibBR96**, extracorporal immunoadsorption compared to avidin chase, tumor-to-normal tissue ratio, 1934

**Bladder**, intraoperative leakage, quantitation, 293(ab)

**Bladder tumor**, incrustation and uptake of skeletal imaging agent, transitional cell carcinoma, "Tc-HMPAO, 1206

**Blood flow**

cerebral (see also Cerebral blood flow) acute effects of ethanol, lack of aldehyde dehydrogenase-I and, 108(ab)
amobartial distribution, "Tc HMPAO SPECT brain perfusion imaging, 91(ab)

autism, "Tc ECD brain SPECT evaluation, 284(ab)

changes with age and gender, PET, 129(ab)

dopaminergic drug effects on, "Tc ECT SPECT, 48(ab)
during cognitive mediatation, HMPAO-SPECT measurement of, 95(ab)
during mental stress-induced LV dysfunction, 86(ab)

FDG PET, measurement of traumatic remembrance, posttraumatic stress disorder, 145(ab)

lupus erythematosus, acetzolamide effects, 130(ab)

measurement, "I1 IMP SPECT, 279(ab)

mitochondrial encephalomyopathy, SPECT study, 279(ab)

naltrexone effects, alcohol dependent patients, 108(ab)

PET and stable XE-CT for quantitative determination, 276(ab)

posttraumatic stress disorder, PET measurement, 282(ab)

quantitative regional studies, scatter and attenuation correction effects, SPECT, 285(ab)

regional quantification, "Tc ECD continuous infusion and dynamic SPECT, 287(ab)

reproducibility, SPECT with "Tc HMPAO, 1217(ab)

rilotin effects on attention deficit disorder, children, 291(ab)

scatter and attenuation correction to quantification, 272(ab)

SPECT and PET comparison, computerized brain atlas, 216(ab)

SPECT with "Tc HMPAO, reproducibility, 307(ab)

transient global amnesia, evaluation with "Tc ECD SPECT, 273(ab)

visceral stimuli, male and female patients, 273(ab)

working and declarative memory, schizophrenia patients, 282(ab)

"Xe, multimodal approach, 278(ab)

hepatic, two-compartment model analysis with three components on "Tc GSA, children, 256(ab)

kidney, high-resolution SPECT with "Tc-Ir, 82(ab)

myocardial abnormal response to mental stress, coronary artery disease, 121(ab)

mental stress and, gender differences in. "In ammonia PET study, 171(ab)

quantitation with "In ammonia and PET, 93(ab)

regional, "Tc and SPECT in assessment, 165(ab)

response to cold and dipyridamole, long-term smoking effects, 85(ab)

response to mental stress, age and cholesterol effects, 121(ab)

tracer uptake related to, exponential model for, 209(ab)

tumor, effects of radiolabeled monoclonal antibody delivery of radiation, 59(ab)

**Blood-hepatic transport**, bidirectional, "Tc methrobenin, 209(ab)

**Blood-pool imaging**

coronary artery disease, changes with exercise, 106(ab)

exercise radionuclide cineangiography, in chronic aortic regurgitation, 109(ab)

gated, left ventricular ejection fraction from, European variability, 168(ab)

high-resolution collimation, right ventricular ejection fraction, 109(ab)

tomographic gated, aorta, 155(ab)

**Blood sampling**

micro volumetric, small animal PET studies, 205(ab)

one-point method, comparison for estimating "Tc MAG3 clearance, 293(ab)

single, estimation of blood-brain clearance constant, "F fluoro-L-dopa, 278(ab)

smoothing of blood time-activity curves, kinetic analysis, PET, 1161

**Blood vessels**, walls, model for calculation of radiation dose to, 107(ab)

**BMI**

negative myocardial uptake, free fatty acid metabolism, PET, 54(ab)

quantification of defect size and determination of at risk myocardium tomographic imaging, 1875

3(R)- and 3(S)-BMI, effects of configuration on myocardial uptake, fatty acid imaging, 1434

**Body contour**, registration, non-contour interferometry, 211(ab)

**Bone**

Bombesin, localization in ovarian carcinoma, expression of GPR, adenoviral vector-mediated gene transfer, "I, 1221

**Bone receptors**, high affinity technetium, synthesis and evaluation, 87(ab)

allograft, SPECT viability assessment, spinal surgery and, 28(ab)

metabolism, assessment by dynamic "O water and "F, porcine, 120(ab)

metastasis moderate and severe pain, "Sm EDTMP effects, 251(ab)

"Sm EDTMP for therapy, 252(ab)

mineral density absorptiometry and quantitative CT, 300(ab)

dual-energy X-ray absorptiometry, 300(ab)

quantitative ultrasound, 300(ab)

patellar avascular necrosis, total knee arthroplasty, 304(ab)

quantitative SPECT, bone loss prediction by, patients with hyperparathyroidism, 17(ab)

scatter due to, SPECT brain imaging, 212(ab)

scintigraphy, reflex sympathetic dystrophy and, 304(ab)

tumor
glucose metabolism in, 127(ab)

primary malignant, "Tc HDP follow-up after bone autograft and radiation therapy, 304(ab)

uptake, measurements by conventional three-phase bone scanning, 120(ab)

vascular scan and, scintigraphic staging of RSOS and, 29(ab)

**Bone densitometry**, how to code for, 13N(2)

**Bone marrow**

"At microdosing in, histological imaging, 227(ab)

evaluating metastasis of neuroblastoma with "I-MIBG scintigraphy and MRI, 1389

guancer disease, MRI and scintigraphic evaluation of femurs, 303(ab)

incorporated "Y citrate, biochemical dosimetry for, 118(ab)

involvement, lymphoma, FDG PET prediction of, 128(ab)

platelet transfusion refractory patient, "In-labeled platelets, scintigraphy, 1135

scintigraphy, "Tc antigranulocyte antibody in, malignant lymphoma, 10(ab)

uptake of FDG, granulocyte colony stimulating factor effects, during chemotherapy, 128(ab)

**Bone marrow edema syndrome**, avascular necrosis and, femoral head, diagnostic patterns, 301(ab)

**Bone marrow scintigraphy**, "Tc-labeled monoclonal AGAb, normal uptake values, 1755

**Bone metastases**, quantitative analysis based on image segmentation, skeletal mass, 1401

**Bone pain**, intractable, "T for, 193(ab)

therapy, safety and efficacy parameters of TIN-117m DTPA, 46(ab)

**Bone pain palliation**

research developments and therapeutic options, thyroid cancer, 19N(11)

Tin-117m(4+1)DTPA pharmacokinetics and imaging characteristics, bone metastases, 230

**Bone resorption**, biochemical markers after "Sr-chloride therapy, metastatic prostatic
Bone scan
baseline, newly diagnosed prostate cancer and low prostate-specific antigen level, 301(ab)
bone marrow edema syndrome, avascular necrosis and, femoral head, diagnostic patterns, 301(ab)
bone metastasis, facet osteoarthritits sign at lower lumbar spine for, 302(ab)
digital overlay, traumatized wrists, 301(ab)
dual pinhole, diagnosis of bone and joint diseases, 304(ab)
metastatic bone involvement, initially limited in prostate cancer, 303(ab)
neurogenic bone involvement, ossification, 305(ab)
obese patients, "hot skull" sign in, disparate soft tissue attenuation and, 29(ab)
pinhole, pediatric skeleton, 306(ab)
pinhole SPECT
diagnosis of skeletal disorders, 301(ab)
recompression therapy study, dysbaric osteonecrosis and, 29(ab)
"Tc-MDP, symptomatic postoperative colorectal cancer, 302(ab)
"Tc-MDP patterns, painful shoulder lesions, 1491
"Tc-sestamibi scintigraphy, recurrent medullary thyroid carcinoma, computed tomography, 227
Bone scintigraphy
diagnosis of idiopathic or rheumatic-related posterior tibial tendinitis, 247
dual-radionuclide, versus MRI, pedal ulcers and peripheral vascular disease, 159(ab)
incrustation and uptake of skeletal imaging agent, transitional cell carcinoma of bladder, "Tc-HMGP, 1206
sarcoïdosis
"Tc-MDP uptake in hilar lymph nodes, 262
"Tc-MDP uptake in primary breast adenocarcinoma with sarcoid metaplasia, 528
wrist fracture localization, digital overlay images, multimodality, 1600
Bone tumor, MIBI uptake in benign and malignant lesions, soft-tissue tumor, 3(ab)
Bone tumor, MIBI uptake in benign and malignant lesions, soft-tissue tumor, 3(ab)
Book review, Cardia: Nuclear Medicine, 3rd Edition, 1833
Boron neutron capture therapy, "F-BPA-Fr, PET, glioblastoma multiforme, 1762
Bowel, inflammation, assessment with "Tc-HMPAO white blood cells versus colonoscopy and biopsy, 24(ab)
Brain
ageing effects, distribution of "Tc-HMGP, healthy humans, 284(ab)
atlas, interactive whole-body PET system, 309(ab)
alfa-adrenergic receptors
imaging with (S)-1-"F]fluorocarazolol-PET, 934
corticobasal degeneration, SPECT, 274(ab)
crossed cerebellar diaschisis, hemispheric stroke, SPECT study, 271(ab)
death, cerebral perfusion imaging for diagnosis, cost-effectiveness of, 275(ab)
dopamine D1 receptor radioligand, PET imaging, 76(ab)

dosimetry for "In-pentetreotide, radiation safety, 1919
FDG PET studies, two-injection two-condition studies, 126(ab)
"F-altanserin pharmacokinetics, 56(ab)
fluorocarazolol binding to b-adrenergic receptors, 289(ab)
frontal lobe perfusion, mental performance after, 215(ab)
functional images, image registration in interpretation of, 277(ab)
functional SPECT imaging, 3D nonlinear registration algorithm, 135(ab)
glucose metabolic rate, quantification of, FDG PET studies, 94(ab)
glucose transport and metabolism, diabetes mellitus, 272(ab)
hemispatial neglect, SPECT lesion localization in, 281(ab)
imaging glutathione content, "Tc-MESO-HMPAO, 1125
imaging nicotinic acetylcholine receptors, "F-FPH, PET, 1737
infarction, mismatched uptake of "Tc ECD and "Tc-HMGO in, 275(ab)
MRI PET and tissue sections, baboon brain, 306(ab)
multi-modality images, mid-sagittal plane, 221(ab)
muscarinic acetylcholine receptor living in, triazolam-induced gabaergic transsynaptic modulation, 285(ab)
muscarinic receptors, new radioligand for visualization, 66(ab)
normal metabolism patterns, FDG PET and MRI imagery, 139(ab)
oxotrinucleotid mixed ligand complexes, synthesis and biodistribution data of, 185(ab)
perfusion SPECT maps, quantification, different denominators, 214(ab)
PET measurement of "C-methionine transport, role of insulin, 1967
prefrontal cortex, neonatal mesial temporal lesions, SPECT, MRlSI, amni microdialysis, monkey, 283(ab)
short-term memory loss, end stage renal failure effects, 129(ab)
SPECT
"O-18-F
simplified quantification and reproducibility studies of dopamine D2-receptor binding, 3(ab)
SPECT quantification, limitations of uniform attenuation correction, 211(ab)
SPECT, high-resolution imaging using half fanbeam collimators with right-angle dual-camera SPECT system, 32(ab)
three-dimensional SPECT, structured bias, interaction of penalized objective function and system matrix, 8(ab)
traumatic injury, Alzheimer's disease and, cerebral distribution of "Tc ECD and "F-FDG in, 70(ab)
tumor
amino acid uptake, "F FACBC and "F FECTN imaging, 158(ab)
"C acetate PET detection, 240(ab)
FDG and methionine concurrent study, 250(ab)
discrepancies between HMPAO and ECD SPECT, 59(ab)
low-grade, "C methionine trapping for detection, 238(ab)
malignant, dosimetry methods for "I 81C6, 106(ab)
metastases and surrounding edema, "Tc use in, 159(ab)
pentavalent "Tc-DMSA uptake, differentiating histologic malignancy.
SPECT, 20
PET imaging with ["C] choline, 842
PET with "F and "O water and GD-DTPA MRI in, 240(ab)
proliferative activity, histopathology compared to L-"F-CTYR PET, protein synthesis rate, 1369
reversal, versus radiation necrosis, "Tc MIBI compared to FDG PET, 158(ab)
RMP7 effects on spatial distribution of blood brain barrier permeability, 93(ab)
suspected recurrence, role of FDG PET studies, pediatrics, 12(ab)
"Tc-DMSA and "T1 imaging, correlation with histology and malignant grade, 1741
"T1 avidity versus MR contrast enhancement, pediatric, 116(ab)
"T1 SPECT in differential diagnosis, 116(ab)
Brain atrophy, medial temporal lobe blood flow measurements in Alzheimer's disease, MRI-guided SPECT, 914
Brain imaging
dual-photopack window method limitations, scatter correction, 1902
"F-FPH, PET visualization of nicotinic acetylcholine receptors, 1260 multimodality visualization
integrating functional and anatomical information, MRI, SPECT, 624
patients with whiplash injuries, 1002(le)
"Tc-ECD as radiopharmaceutical for children, neuropediatrics, 1115
Brain neoplasms, imaging pentose cycle glucose metabolism with PET, rat glioma, 617
Brain perfusion
discriminating frontal lobe-type dementia from Alzheimer's disease, "Tc-HMGP SPECT, 929
HMPAO and ECD SPECT discrepancies, brain tumor, 592
SPECT after treatment of childhood acute lymphoblastic leukemia, 82
Brain phantom, volumetric analysis of cerebral hypoperfusion, "Tc-HMGP SPECT, 1447
Brain SPECT
regional differences in "Tc-ECD clearance in healthy subjects, regional cerebral blood flow, 1253
scatter and attenuation correction, "Tc-ECD, 157
BrE-3, radioimmunotherapy for breast cancer, "Y, 1180
Breast
cancer advanced, "In MX-DTPA humanized BRE-3 monoclonal antibody studies, 252(ab)
analysis of neoadjuvant chemotherapy, "Tc-scintigraphy, 1546
bone metastases in, detection with FDG PET, 127(ab)
comparison of radiopharmaceuticals for PET and SPECT, 233(ab)
comparison of "Tc-sestamibi scintimammography with contrast-enhanced MRI, 58
detectability of FDG-PET and MIBI SPECT to, 68(ab)
detection by "Tc MIBI scintimammography, European trial, 20(ab)
diagnosis, Z-["F]MIVE estrogen receptor imaging for, 21(ab)
early, "Tc sestamibi scintimammography
Tc-furifosmin nonpalpable tumor outcome neovascularization mouse measuring inoperative fluorescence. Tc-MIBI, breast cancer. 1546

Bremsstrahlung, clinical fusion of three-dimensional images, SPECT and CT, 319

Bromine-76 investigating PET tumor-imaging agent, "F-FDB, "F-Met, monoclonal antibodies, 1029 pharmacokinetics and experimental imaging, MAb, radioimmune PET, 395

Bromine-76 FLB 457, extrastriatal binding, neuroleptic interactions in dopamine receptors, PET studies, 1459

Bronchial carcinoma, VQ scintigraphy and lung function testing, assessment of endobronchial stent efficacy, 1584

Bronchial obstruction, "F-phenylalanine scanning, prestenotic aerosol deposition signs, 71

Bronchial stenosis, VQ scintigraphy and lung function testing, assessment of endobronchial stent efficacy, 1584

Brookhaven National Laboratory, research delayed with management change, environmental and safety issues, 13N(9)

Buffer partition coefficients, "F-IMBA pharmacokinetics, melanoma imaging, 127

C

CAD, sry Coronary artery disease

Calcification, incrustation and uptake mechanisms of skeletal imaging agent, transitional cell carcinoma of bladder, "Tc-HMPD, 1206

Calcium antagonist, "F-MIBG uptake, effects of cilazapril and verapamil in cardiomyopathic hamartosis, 1540

Camera systems, small animal PET, prototype with avalanche photodiode arrays and LSO crystals, 45(ab)

Cancer, see also specific type "F FFAU, synthesis for PET, 177(ab) gene therapy, "F FHGP evaluation in HT-29 cells, 176(ab)

Cancer imaging, "F-labeled hydrazinonicotinamide-Fab' conjugates, antibody fragments, 133

Cancer staging, gamma probes to identify sentinel lymph nodes, 15N(6)

Capillary permeability, myocardial potassium and thallium uptake in dogs, 264

Capsules, therapeutic 131I, volatility of, 178(ab)

Captopril renography, detection of renovascular hypertension, 827(ed)

Carbon-11

Carbon-11 A-84543, studies of neuronal nicotinic acetylcholine receptors, 65(ab)

Carbon-11 choline, imaging, brain tumor, lung cancer, esophageal cancer, colon, cancer, prostate and bladder cancer, 250(ab)

Carbon-11 CPE-222, PET, serotonin receptor imaging with, 146(ab)

Carbon-11 epidermal growth factor receptor ligands, synthesis and biodistribution, 141(ab)

Carbon-11 KF17837, PET, mapping of CNS adenosine A2a receptors with, 183(ab)

Carbon-11 LY274601, radiotherapy and probe biodistribution, 50(ab)

Carbon-11 MBDB, synthesis and biodistribution of, 179(ab)

Carbon-11 McN5652, precursors of, new route, 57(ab)

Carbon-11 MDL 100.907(ab), 81(ab)

Carbon-11 methionine, sensitivity, detection of low grade brain tumors, 239(ab)

Carbon-11 NMIB, trichloro-induced gabaergic transynaptic modulation, brain, 285(ab)

Carbon-11 phenylephrine, PET, cardiac neuronal function assessed with, unstable angina patients, 86(ab)

Carbon-11 raclopride, biodistribution, radiation dose estimates and, 224(ab)

Carbon-11 Ro 20-1724, phosphodiesterase type IV inhibitor, evaluation of, 76(ab)

Carbon-11 Rolipram, phosphodiesterase type IV inhibitor, evaluation of, 76(ab)

Carbon-11 SKF 82957, R(+)-, dopamine D1 agonist radioligand for PET imaging, 78(ab)

Carbon-11 TAA, dose administration by PET, 4(ab)

Carbon-11 tyrosine, PET, pituitary adenomas with MRI and, 261(ab)

Carbon-11 WAY-100635, PET, serotonin receptor imaging, brain, 280(ab)

Carbon-11 WIN 35, 428(ab), 12(ab) cocaine venus dMP, assessment of dopamine transporter occupancy by cocaine, 11(ab) comparative imaging studies, acute myocardial infarction, 124(ab)

detection of brain tumors, 240(ab) oxidative metabolism by, in reverse redistribution regions on 201Tl SPECT, 170(ab)
simplifying dosimetry, PET, 654

Carbon-11 acetate, tracer kinetic model for measuring MVO2, PET, 459

Carbon-11-CFT, SPECT imaging of dopamine transporter sites, MPTP model of Parkinsonism, "F-IACFT, 144

Carbon-11-epinephrine, myocardial kinetics, suitability as tracer for evaluation of sym pathetic vesicular function of heart, PET, 780

Carbon-11-hydroxyephedrine, chronic cocaine use effects on cardiac sympathetic nerve function, PET, 451

Carbon-11-methionine, cancer recurrence in residual tumors after fractionated radiotherapy, "F-FDG, "C-thymidine, 290

comparative PET imaging of experimental tumors, "F-FDB, "B-labeled antibodies, 1029

Carbon-11-MTICU, nitric oxide synthase, in vivo evaluation and PET study, 1273

Carbon-11-thymidine, cancer recurrence in residual tumors after fractionated radiotherapy, "F-FDG, "C-methionin, 280

Carbon-11-tyrosine, standardized uptake value and quantification of metabolism, breast...
Carbon-14
Cardiomyopathy
Carcinoid
Carcinoembryonic antigen
Carbon-14 breath test
Carbon-urea breath test
Carcinoid
Carcinoid tumor
Cardiac function
Cardiac imaging
Cardiac MRD phenotype
Cardiac output
Cardiac sympathetic function
Cardiac sympathetic innervation
Cardiac volume
Cardiomyopathy
Cardiomyoplasty
Cardiotoxicity
Cancer imaging with PET, FDG, 692
Carbon-11-methionine, transport enhanced by insulin, PET, 1967
Carbon-14 urea breath test, single sample, diagnosis of H. pylori infection, 71(ab)
Carbon-urea, breath test, presence and eradication of helicobacter pylori, PUD, gastritis, 1141
Clinical evaluation of "in-labeled chimeric antibody, monoclonal antibodies, noninvasive imaging, medullary thyroid carcinoma, 232(ab)
Non-small-cell lung cancer, staging with two-step immunoscintigraphy using bispecific antibody, 507
tumor dosimetry in radioimmunotherapy, anti-CEA and antitumic monoclonal antibodies, 409
Carcinoid
detection with "Tc-MIBI in MEN type I, parathyroid hyperplasia, pituitary adenoma, 1767
false-negative "F-FDG PET, "F-123I-ocretotide scan, 1382
Carcinoid tumor, acute liver necrosis induced by "I-MIBG therapy, 1024
One-year effect of myocardial revascularization, thallium uptake in chronic CAD, 1684
procedure guideline for equilibrium radionuclide ventriculography, 1658
Cardiac imaging, myocardial uptake of no-carrier-added "I-MIBG, deiodination, 447
Cardiac MDR phenotype, "Tc-sestamibi and H-daunomycin myocardial cellular retention comparison, 1674
Cardiac output, absolute measurement, "Tc MAG3 in, 166(ab)
Cardiac sympathetic function, "I-MIBG imaging in obstructive sleep apnea syndrome, 567
Cardiac sympathetic innervation, myocardial kinetics of "C-EPI, radiotracer for PET assessment of neuronal function in the heart, 780
Cardiac sympathetic nerve function, effects of chronic cocaine use, assessed by "C-hydroxyephedrine, PET, 451
Cardiac sympathetic nerve system, effects of aldose reductase inhibitor in streptozotocin-induced diabetic rats, 1677
Cardiac volume, assessment of right ventricular and left ventricular indices, ejection fraction, tomographic gated blood-pool scintigraphy, 942
Cardiomyopathy
advanced stage dilated, active myocyte damage, "In antimony uptake in, 99(ab)
dilated, myocardial blood flow assessment in, nitrogen-13 ammonia PET in, 171(ab) hypertrophic, "I BMIPP uptake and oxygen and glucose metabolism impairment in, 163(ab)
"I-MIBG uptake, effects of clazapine and verapamil, 1540
Cardiomyoplasty, dynamic, left ventricular function after, radionuclide evaluation, 154(ab)
Cardiotoxicity, application of radionuclide left ventricular ejection fraction in oncology patients, reserve function versus fixed criteria, equilibrium gated radionuclide angiography, 702
Carfentanil, occupancy of opioid receptors measured by dual-detector probe, duration of naloxene compared to naloxone, 1726
Cardiomyopathy
Carotid artery diseases, hemodynamics of cerebral watershed infarction, assessment of perfusion reserve using "I-IMP SPECT, 1556
Cassen prize, 1998 nominations, 32N(5)
Catecholaminergic disease differentiation from malignant lymphoma, "F-FDG PET, 1211
Cat, solid-phase labeling of cat food for gastric emptying studies, "Tc-disofenin, 495
Catatonia, electroconvulsive therapy and cerebral perfusion, SPECT, 251
Cation transport, myocardial potassium and thallium uptake in dogs, 264
Cavity: myocardium, count ratio, detection of resting left ventricular dysfunction, "Tc-sestamibi SPECT, 766
CBF SPECT, "Tc-HMPAO, "Tc-ECD, and "I-IMP as tracers choices for specific examination, measurements with pharmacological interventions in primates, 1897
Cellular density, correlation with "I-IMT SPECT in gliomas, proliferative activity, 1551
Cellular dosimetry, distribution of "Tc-labeled microspheres in rat lungs, microautoradiography, 650
Cellular internalization, avidin/streptavidin for delivering toxic agents, tumor pretargeting, MAb, 1378
Center-of-rotation correction, quantifying, point source acquisitions, 219(ab)
Central nervous system (CNS), systemic lupus erythematosus, "Tc-HMPAO brain SPECT, 1112
Cerebral diaschisis, "F-FDG PET, head injury evaluation, 1717
Cerebellum, reduction of glucose metabolism, Alzheimer’s disease, "F-FDG PET, 925
Cerebral blood flow
"Tc-ECD as radiopharmaceutical for children, 1115
change, in perfusion and oxygen metabolism, MRI white matter hyperintensities in Alzheimer’s disease, CBF, 1471
measurement with "I-IMP autoradiography, SPECT, subarachnoid hemorrhage, 1102
MRI-guided SPECT measurements, median temporal lobe atrophy, Alzheimer’s disease, 91
postischemic hyperperfusion, "Xe SPECT, 602
volumetric analysis of hyperperfusion, "Tc-HMPAO SPECT, brain phantom, 1447
Cerebral blood volume, comparative quantitations, SPECT versus PET, 919
Cerebral gliomas, SPECT versus PET, amino acid uptake, 517
Cerebral glucose metabolism, reduction in Alzheimer’s disease, "F-FDG PET, cerebellum, 925
Cerebral infarction
crossed-diaschisis, "Tc-HMPAO, SPECT, MRI, 14
regional cerebral blood flow, "I IMP and, autoradiography, SPECT, SAH, 1102
Cerebral ischemia, hyperfixation of "Cu-PTSM reperfusion injuries in rat brains, 1130
Cerebral oxygen metabolism, MRI white matter hyperintensities in Alzheimer’s disease, CBF, 1471
Cerebral perfusion reserve
cerebrovascular disease, "I IMP and, 37(ab)
measurement, split-brain "I SPECT method, 279(ab)
Takayasu’s arteritis with severe carotid lesions, "I IMP SPECT assessment of, 37(ab)
Cerebral perfusion SPECT, uptake of "Tc-HMPAO, intracranial parasitic disease, sparganosis, 939
Cerebral postischemic hyperperfusion, assessment with "Xe SPECT, cerebral blood flow, 602
Cerebral vascular reserve, hyperventilation challenge, "Tc-HMPAO brain SPECT in moyamoya disease, risk assessment of natural childbirth, 1894
Cerebral vasospasm, balloon angioplasty versus paraendothelial anastomosis for, SPECT rCBF after, 36(ab)
Cerebrovascular disease
ischemia, cerebral blood flow and benzodiazepine receptor antagonist after, 283(ab)
stress studies, "Xe brain SPECT and, 37(ab) transient middle cerebral artery occlusion, benzodiazepine receptor agonist after, 288(ab)
Cesium-137, characteristics of a variable dose rate irradiator, biological dosimetry, mercury attenuator, 727
Charcoal, compared with ion exchange pellets for colonic transit scintigraphy, 1807
CHCPP, see Commission on Health Care Policy and Practice
Chelate, CHX-DTPA isomers, Y labeling of mAbs, stability and biodistribution, 192(ab)
Chelating agents
"F, biotin labeled with, 142(ab)
NHS-MAS, equivalent to MAG3, 185(ab)
Chemotactic infection, localization of radiolabeled peptide analogs, receptor mediated accumulation, agonist, antagonists, 1316
Chemotactic peptides
infection imaging, "Tc-labeling, 1322(ed)
"Tc-labeling, acute inflammation and sterile inflammation, 1310
Cemotaxis, relationship to apoptosis, "Tc-HMPAO-labeled lymphocytes, 1417
Chemotherapy
evaluating benign and malignant bone and soft-tissue lesions, "Tc-MIBI scintigraphy compared to, 501
"F-FDG PET, uptake in rat prostate adenocarcinoma during gemcitabine treatment, 1215
FDG uptake by human cancer xenografts after anticancer administration, PET, 714
Chemotherapy response, evaluation of treatment in children with untreated malignant lymphomas, "Tc and "F-sestamibi, 243
Chest pain
acute, prediction of cardiac events, emergent myocardial perfusion SPECT use in, 140(ab)
evaluation by ECG-gated SPECT, cost savings and, 140(ab)
evaluation, myocardial perfusion imaging as triage tool, 131(ab)
Chest syndrome, pulmonary vascular occlusion in sickle cell disease, scintigraphic
Cholangiocarcinoma. FDG PET evaluation of, 246(ab)

Cholecystitis
acute
morphine administration, gallbladder nonvisualization after, 260(ab)
patients with intrahepatic stones, cholecystography use in, 259(ab)
cholecystokinin pretreatment and M994 augmentation, 647(ed)
chronic, hepatobiliary scintigraphy in, salicylaldehyde pretreatment effects, 258(ab)
morpine augmentation gallbladder visualization in patients pretreated with cholecystokinin, cholecystography, 644
procedure guideline for hepatobiliary scintigraphy, liver function, 1654

Cholecystokinin
pretreatment for diagnosis of cholecystitis, morphine, 647(ed)
pretreatment for gallbladder visualization, morphine augmentation, 644
role of sphincter of Oddi and gallbladder in biliary dyskinesia, qualitative cholecystography, 1824

Cholecystokinin receptor ligands, unsulfated DTPA-cholecystokinin analogs for, human tumor expression and, 17(ab)

Cholecintigraphy
**"Tc DTPA, recurrence of intrahepatic stones, biliary retention significance in, 259(ab)
diagnosis of acute cholecystitis, patients with intrahepatic stones, 259(ab)

Choline. PET imaging of brain tumors, 842

Cholinergic neurons, presynaptic mapping agent, radioiodinated (-)M-IodosesamicoI, evaluation, 182(ab)

Chromosomal damage. "I recovery after, metastatic thyroid cancer, 226(ab)

Chronic exertional compartment syndrome. localization and follow-up with **"TI:SPECT, 972

Chronic mass-forming pancreatitis. glucose transporter 1 overexpression, FDG-PET, 1344

Chronic renal failure. evaluation of **"Te-L, L-EC as alternative to **"Te-MAG3, 809

Cigarette smoking, long-term, myocardial blood flow response to cold and dipryramidole, 85(ab)

Cirrhosis. liver flow evaluation, transjugular intrahepatic porto-systemic shunt, 51(ab)

Cisplatin. **"N labeled, synthesis in a full automated chemistry module, 113(ab)

Clearance, mucociliary, statistical parametric mapping of, inhaled radioaerosols and, 39(ab)

Clearance determination. **"Tc-Ec clearance from single plasma sample, effective renal plasma flow, 1784

Clinical outcome. six-month follow-up of patients with intermediate probability lung scans, 1593

CNS. see Central Nervous System

Cobalt-55. PET, use as calcium-tracer, MRI differences, 135(ab)

Cobalt-57. **"Te HMPAO-labeled leukocytes compared with, SPECT study, 278(ab)

Cocaine
abuse, age-related dopaminergic transporter loss in, 35(ab)
abuse, cardiac sympathetic neuronal function assessed by 123I-hydroxyephedrine, PET, 451
brain dopamine concentration changes by, Vigabatrin attenuation of, 11(ab)
chronic users, brain mu opioid receptor binding in, measurement during monitored abstinence, 35(ab)
dopamine transporter occupancy by, 123I cocaine versus 123I dMP assessment of, 11(ab)
dopamine transporters in abusers, concentration and degree of occupancy, 281(ab)
IV challenge, effects on brain perfusion in abusers, SPECT, 274(ab)
imaging dopamine transporters, **"F-FPET PET, Parkinson's disease, 119
prenatual exposure, neural development after, FDG PET studies, parietes, 105(ab)
rhesus monkey model of abuse and withdrawal, persistent downregulation of dopamine receptors, 81(ab)

Cocaine analogs. RTI-55, dopamine transporter occupancy by, 61(ab)

 Cochlear implant. function, deaf subjects, brain SPECT evaluation, 273(ab)

Coding and reimbursement. common questions, recommendations, 36(ab)

Coding system. Health Care Financing Administration, ICD-10, 18(ab)

Cognitive dysfunction, quantitative assessment of cerebral blood flow, Alzheimer's disease, SPECT, 1095

Coincidence detection camera. use of SPECT cameras for PET imaging, 13(N1)

Coincidence imaging
dual detector scintillation camera, simultaneous FPCT PET, Parkinson's disease, 125(ab)
dual head, performance characteristics, detection of small lesions, 206(ab)
gamma camera, axial filter for, 229(ab)
measured parameters, clinical dual-head scintillation camera, 221(ab)
newly emerging, cost-effectiveness, non-small cell lung cancer, 245(ab)

Collitis, experimental, scintigraphic evaluation, rabbits, 72(ab)

Collateral circulation. **"Te-MIBI to assess coronary flow during AMI, 1840

Collimation
electronic, reconstruction of Comptom-camera camera images, 58(ab)
performance comparison, surgical gamma probes, 208(ab)

Collimator design. improved precision for quantitative SPECT, ideal-observer models, 151

Collimators
cylindrical SPECT systems, off-center FOV, sensitivity and uniformity, 219(ab)

Computer simulation. estemab imaging of cardiac dedicated uniplanar, bone SPECT, 29(ab)
with right-angle dual-camera SPECT system, high-resolution brain SPECT with, 32(ab)

pinhole
analytical model of, SPECT, 38(ab)
ultra high resolution SPECT, 217(ab)
septal penetration, effects on 511 keV SPECT images, 229(ab)
slit/slant, SPECT imaging with stationary array of planar detectors, 8(ab)

Colon cancer
cells and macrophages, FDG uptake comparison, 248(ab)
radioimmunotherapy in, "labeled bivalent hapten with anti-CEA x anti-indium-DTPA antibody use in, 7(ab)
rectosigmoid fistula demonstrated by dynamic scintigraphic peritoneography, 1636
tumor detection, "In DTPA antibody equivalence with specific MAb in, mice, 191(ab)

Colonic transit, scintigraphy with labeled activated charcoal, ion exchange pellet comparisons, 1807

Colorectal cancer
"I labeled anti-carcinoembryonic antigen monoclonal antibody, prediction of myelotoxicity, 228(ab)
metastatic, confined to liver, FDG PET in, preoperative evaluation, 9(ab)
preoperative staging, whole-body FDG PET, 136(ab)
radioimmunotherapy in""I- and "Y-labeled IgG versus chemotherapy, mouse model, 6(ab)
internalizing antibodies in, efficacy and toxicity of Auger electron versus beta emitters in, 7(ab)
recurrent""F FDG PET, CT, and immunoscintigraphy in, 246(ab)
FDG PET staging of, cost-effectiveness, 134(ab), 90(ab)
whole-body FDG PET, comparison with CT, 136(ab)
symptomatic postoperative, **"Te MDP bone scan, 302(ab)

Colorectal carcinoma. radioimmunotherapy, comparison of "C and "I labeled anti-CEA monoclonal antibodies, 847

Commission on Health Care Policy and Practice (CHCPP). coding and reimbursement, common questions, 36(ab)

Compartmental model. scintigraphic determination of effective renal plasma flow, **"Te-meritidate, 1285

Compartmental models, pharmacokinetics and dose estimation for chimeric anti-CEA antibody, 1959

Compton camera. two one-dimensional, finite extent, transaxial SPECT with, 32(ab)

Computed tomography
**"Ga scintigraphy and correlation imaging, primary adrenal lymphoma, 1770
**"Te-estamibi scanning, recurrent medullary thyroid carcinoma, bone scan, 227

Computed tomography (CT)
staging recurrent metastatic colorectal cancer, **"FDG-PET, 1196
thoracic and abdominal image fusion with SPECT, endocrine carcinoma, 1234

Subject Index • 1997 271
nonpalpable breast abnormalities, cost effectiveness, 1772

Computer-assisted, automated interpretation of myocardial SPECT images, neural networks to support clinical decisions, ischemic heart disease, 1870

ing image processing
quantitative assessment of cerebral blood flow, Alzheimer’s disease, SPECT, 1095
volumetric analysis of cerebral hyperperfusion, ""Tc-HMPAO SPECT, 1447

COMT inhibition, graphical analysis of 6-FD trapping, PET, 1568

Congenital heart disease, children, lung perfusion scintigraphy after Fontan or Glenn shunt procedure, 25(ab)

Congestive heart failure, monitoring of left ventricular function during 6-min walk test and cardipulmonary exercise, vest, 948

Continuous infusion, quantification of CBF, ""Tc-ECD, 1699

Contrast-enhanced MRI, comparison of ""Tc-sestamibi in detection of breast stress, 58(ab)

Copper-62 hyperfixation of, transient cerebral ischemia in rats, 1130

""Zn and, PET, from monoprotic tetradeutate Schiff-base ligands, synthesis and evaluation, 183(ab)

Copper-62-MTS, hyperemia imaging agent, mitochondria, 1155

Copper-62 PETM, mitochondrial function diagnosis with, in tumor cells, 183(ab)

Copper-64 diphosphine complexes, assessment of multi-drug resistance, tumors, 133(ab)

Copper-64-1,1'-binaphthyl complexes, PET imaging and targeted therapy, liver tumors and hepatic metastases, 141(ab)

Copper-67 compared with ""I-labeled anti-CEA monoclonal antibodies, colorectal carcinoma, 847
tumor uptake
antineuroblastoma antibody chCE7, radiolabeled antibody therapy and metabolism, 53(ab)

Coronary artery bypass surgery, radionuclide ventriculography, preoperative contrast comparison, 110(ab)

Coronary artery disease, myocardial viability after, ""Tc MIBI SPECT assessment of, 42(ab)
bypass surgery
myocardial viability after, ""Tc MIBI SPECT use in, 155(ab)
prediction of complications, ""Tc ECD diastolic SPECT, 271(ab)
comparison of various imaging stress tests, 74(ab)
detection by ""Tc gated SPECT perfusion study, end-diastolic versus stress comparisons, 15(ab)
detection by ""Tc, myocardial scintigraphy, adenine triphosphate and dipyridamole comparisons, 577
detection, ""Tc tetrofosmin and ""Tc MIBI comparison, 122(ab)
dual isotope myocardial perfusion imaging, attenuation correction, cardiac risk with, 83(ab)
dyspnea during myocardial perfusion imaging, bronchial resistance and, 73(ab)
electron beam computed tomography,
Cytomegalovirus.

Cystometry, radionuclide voiding, measurement of intravesical pressure, 294(ab)

Cytomegalovirus, ²⁵⁷Tl SPECT, encephalitis, 1386

D

D-lysine, reduction of "In-DTPAOC and "Y-DOTATOC renal uptake, 1929

D2 receptors, "¹⁰⁵epidepride SPECT in diagnosis of Parkinson's disease, multiple system atrophy, and Huntington's disease, 1711

D2-like dopamine receptor density, PET measurement, Tourette syndrome, 1243

Dacrocystogram, radionuclide, evaluation of Sjogren's syndrome with xerophthalmia, 257(ab)

Data analysis

automated segmentation of cardiac PET images, polar transformations and, 198(ab)
global pharmacokinetics modeling, "C cocaine and, nonhuman primate brain, 201(ab)
PET, single "C CGP 12177 injection, cardiac beta-adrenergic receptor parameter estimation and, 41(ab)
slope weighted, dynamic FDG-PET studies and, 200(ab)

Database

European Association of Nuclear Medicine's partnership with SNM, 26N(11)
management of nuclear medicine images, multiple platforms and remote access of clinical data, 307(ab)
network-integrated functional storage, nuclear medicine applications, 306(ab)
SNM website, 2N(ab)

Deadline correction technique, simultaneous emission-transmission data, PET, 114(ab)

Decision analysis

non-small-cell lung carcinoma, PET, 1172(12)

Decision modeling, MIBI imaging of nonpalpable breast lesions, cost effectiveness, 1772

Deconvolution analysis, "¹⁰⁴-MAG3 renogram in kidney transplantation, utility of initial uptake measurement, 1295

Deep venous thrombosis

acute, early and delayed imaging with "⁹⁹Tc P₂₈₀, 123(ab)
clinical outcome of patients with intermediate probability V/Q lung scans, 1593
detection of, "⁹⁹Tc-labeled tissue plasminogen activator, 219
diagnostic test comparisons, antifibrin scintigraphy, contrast venography, 89
localization
"⁹⁹Tc P₂₈₀ safety and efficacy, 98(ab)
"⁹⁹Tc P₂₈₀ versus contrast venography, 98(ab)
"⁹⁹Tc P₂₈₀ detection, patients with prior history, 98(ab)

Defecography, scintigraphic, evaluation of rectal emptying, chronically obstipated children, 72(ab)

Deiodination, myocardial uptake of non-carrier-added "¹³¹I-MIBG, 447

Dementia

frontal lobe-type versus Alzheimer's disease, discriminative use of SPECT, 929
neural network classification of, 3D stereotactic surface projection PET data, 272(ab)
selective neuronal loss, "⁹⁹Tc ECD SPECT, brain, 71(ab)
with cortical Lewy bodies, distinguished from pure Alzheimer's disease, FDG PET use in, 70(ab)

Deoxyglucose, uptake, growth rate of tumors and, 247(ab)

Depression

antidepressant treatment, mu opioid receptor upregulation induced by, gender differences, 108(ab)
chronic fatigue syndrome, FDG PET, brain, 282(ab)
lorazepam treatment, benzodiazepine receptor occupancy during, "¹¹lromazepin SPECT, 282(ab)

Deseral, zirconium-labeled MAbS, biodistribution of conjugates visualized with PET, 112

Desipramine, myocardial ischemia changes in response to hypoxia, 954

Di-isopropylfluorophosphate, down-regulation of cardiac muscarinic receptors, PET, 1430

Diabetes

cardiac norepinephrine transporter distribution and, MIBG uptake and, 181(ab)
hyperreperfusion against dobutamine stress, severely denervated hearts, 11(ab)
insulin effects, sympathetic neuron targeting with, FDG, 248(ab)
myocardial denervation in, para-"¹⁵F FDG as marker, 41(ab)

Diabetes mellitus

glucose transport and metabolism in, cerebral, 272(ab)
predictive accuracy of PET flow/"¹⁵F FDG mismatch, myocardium, 55(ab)

Diabetic cardiomyopathy, effects of aldose reductase inhibitor in streptozotocin-induced diabetes, neuropathy, MIBG, 1677

Diabetic foot, infections of locomotor system, evaluation with "¹¹In-IgG scintigraphy, 1300

Diabetic neuropathy, effect of aldose reductase inhibitor, "¹¹l-MIBG and streptozotocin-induced diabetic rats, 1677

Diagnosis, neural networks as clinical decision support, computer-aided interpretation of myocardial SPECT perfusion images, 1870

Diagnostic test comparisons, contrast venography, antifibrin scintigraphy in patients with deep venous thrombosis, 89

Diagnostic tests, incremental value of, 241(ed)
Diomax, challenge, brain SPECT changes after, 280(ab)

Diastasis, characterization in sub-acute stroke, by rest and Diomax CBF brain SPECT and spectroscopy, 36(ab)

DICOM image display, World Wide Web-based viewer for, 310(ab)

Differentiated thyroid cancer, prognosis in children and adolescents, total thyroidectomy and "¹³¹I therapy, 669
"¹¹In and "¹³¹I follow-up scintigraphy, thyroglobulin, 686
whole-body scintigraphy in follow-up without thyroid hormone withdrawal, "¹³¹I-iodine, 348

Diactiltol-tyramine, radioimmunotherapy with residualizing "¹³¹I, lung cancer xenografts, 391

Diaphyloionid salts, as precursor of, NCA "¹¹In fluorination of halo- and alkyl-substituted areas, 43(ab)

Dipyridamole, compared to adenosine triphosphate in coronary artery disease diagnosis, "¹¹In myocardial scintigraphy, 577

evaluation of coronary artery disease with "¹⁵Tc-tetrofosmin, SPECT, 44
exercise stress comparison, gastrointestinal uptake of "¹⁵Tc sestamibi in cardiac SPECT, 156(ab)
pharmacological stress, Kawasaki disease, "¹¹In SPECT with, 290(ab)
postintervention discrepancy between evidence of impaired perfusion, "¹⁵Tc-MIBI SPECT, 553

Diuretic renography, procedure guideline in children, hydropnephrosis, 1647

Dobutamine

infusion, assessment of hibernating myocardium, gated SPECT imaging, 62(ab)
myocardial perfusion imaging, low peak heart rate effects on accuracy of, 72(ab)
stress, hyperreperfusion against, severely denervated diabetic hearts, 11(ab)
"¹⁵Tl stress test, patients with left bundle branch block and normal coronary arteries, 424

Dopamine

basal ganglia release, in Tourette syndrome, 12(ab)
brain concentrations, cocaine-induced changes, Vigabatrin attenuation of, 11(ab)
extracellular, regulation of dopamine transporters and, L-dopa and reserpine treatment effects, 286(ab)
"¹²-epidepride SPECT in differential diagnosis of movement disorders, Parkinson's disease, multiple system atrophy, Huntington's disease, 1711
intrasympathetic release, effect on Bmax and Bmax/KD in schizophrenia, PET and, 11(ab)
pre- and postsymptomatic system, SPECT imaging, Alzheimer's disease, 69(ab)
release, quantification of functional dopaminergic system, 60(ab)
striatal system, assessment with "F FDOPA and "¹¹C WIN 35, 428(ab), 12(ab)

Dopamine D2-receptors, "¹¹l-IBF SPECT, quantitative imaging without blood data, dopamine D2-receptors, 31

Dopamine neurons, evaluation of fluorinated m-tyrosine analogs as PET imaging agents, comparison with 6-fluoro-L-DOPA, 630

Dopamine receptors

abnormal brain dopamine system in hypertensive rats, "¹⁸F-CIT, 470
binding potential, measuring with PET, primates smaller than humans, 271(ab)
binding with "¹²⁵I IBF, quantification of, clinical SPECT studies, 286(ab)
binding with "¹²⁵I IBF SPECT, age effects, 146(ab)
differences in availability, function of social status, monkey, 105(ab)
extrastriatal, clozapine in, SPECT study, 94(ab)
"¹¹In epidepride imaging, kinetic and equilibrium studies, 81(ab)
measurement, schizophrenia, choice of outcome measures, SPECT, 95(ab)
neuroleptic interactions in, PET studies, 145(ab)
occupancy changes during a motor task, 105(ab)
sigma ligand EMD 57445, antipsychotic actions, 107(ab)
occupancy by D1 agonist, "¹³C SCH 39166
brain, PET, 286(ab)
persistent downregulation of, model of cocaine abuse and withdrawal, 81(ab)
radioligand for PET imaging
Dose precision, healthy volunteers, 1475

Dose estimation. chimeric anti-CEA antibody, pharmacokinetic modeling, 1959

Dose-volume histogram, patient-specific three-dimensional internal dosimetry, radiouclide therapy, 301

Dosimetry
absorbed dose estimates, FDG PET and MRI, 225(ab)
absorbed dose to bladder wall, "F FDG and "F DOPA, dynamic bladder phantom, 224(ab)
anti-CD20. pulmonary embolism, 229(ab)
bone marrow after "I125, renal cell carcinoma, 225(ab) incorporated "Y citrate, 118(ab)
calculations for therapeutic alpha-particle emitters, MIRD system and microdosing, 1923
calculations, walls of blood vessels, 107(ab) direct internal approach, non-uniform activity distributions, MIRD method, 106(ab)
electron absorbed fractions, MIRD schema, pediatric patients, 225(ab)
electron and photon transport, mouse model, 228(ab)
"I U4R, SPECT agent for human glioma, 210(ab)
"I 81C6, malignant CNS tumors, 106(ab)
"I MBG intraarterial application, tumor treatment by, 253(ab)
neuroblastoma, 106(ab) in nuclear therapy, automated scheme for, thyroid cancer, bone pain, and radioimmunotherapy, 225(ab)
infected imaging, "Tc Anti SSEA-1 antigranulocyte antibody and "Tc white blood cells, 157(ab)
inhalation scintigraphy with "I125. pulmonary deposition and dose escalation, 1475
internal calculations, head and brain models, pediatric, 105(ab)
immunotherapeutically administered "111 Lu CC49, ovarian cancer, 226(ab)
"Tc microdosing. At bone marrow, 227(ab)
"I anti-CD20, non-marrow ablative doses, 230(ab)
patient-specific "In-CC49 and "Y-CC49, 512
SPECT and three-dimensional discrete Fourier transform convolution, 308
patient-specific beta dose estimates, voxel source kernel method for, 106(ab)
pediatric radiopharmaceuticals, effective dose and estimation, 1982
peritoneal, after intraperitoneal administration of "I131 chitosan, 226(ab)
point kernel convolution and, whole-body PET and, 199(ab)
prediction of myelotoxicity, after "I131, colorectal cancer, 228(ab)
prediction of myelotoxicity, radiation to marrow from body, blood, marrow, RIT. "I-Lym
published data, release criteria for therapeutic amounts of radioactivity, 229(ab)
radiation dose estimates for "In-pentetetide, 1919

Double-tracer autoradiography. relationship between blood flow and glucose uptake in ischemic border zone, imaging plate, 1515

Down regulation, of cardiac muscarinic receptors, DFP induced, PET, 1430

Drug targeting. Glycoprotein, PET detection, brain, 117(ab)

Drug-tracer interaction, CBF measurements with pharmacological interventions, choice of tracer for specific examination, SPECT in baboon model, 1897

DTPA, radiolabeling of pactaizete, biodistribution and gamma scintigraphic imaging properties, "In, 1042

Dual-detector probe. measurement of opioid receptor occupancy, duration of naloxone, positron emission, 1726

Dual-isotope imaging
myocardial perfusion and function imaging at rest, gated SPECT, "T1 and "Tc, 432
"Tc-MIBI and "T1 scintigraphy, lung cancer, 1358

Dubbel isotope technique, duodenogastric reflux, migrating motor complex-associated, 72(ab)

Duodenogastric reflux, migrating motor complex-associated, duobel-isotope technique, 72(ab)

Dynamic SPECT. CBF quantification with continuous infusion of "Tc-ECD, 1699

Dyskinesis, complication by RV infarction, radionuclide ventriculography and tetrofosmin scintigraphy, 1421

Dyspnea, lung scintigraphy in post pneumonectomy patient, right-to-left shunt, platypnea-orthodeoxia, 1812

E
E-selectin. upregulation, adenovirus arthritis model prior to joint swelling, 125(ab)

ECG-gated SPECT assessment of left ventricular volume, "Tc-MIBI and "Tc-tetrofosmin, 53
systolic count increase, "Tc-MIBI, 1067

Echocardiography, myocardial necrosis by electrocution, "Tc-pyrophosphate scintigraphy, "Tc SPECT, 250

Ecstasy, experimental psychosis induced by, cerebral metabolic alterations, 47(ab)

Ectomography, compared with SPECT to evaluate myocardial perfusion imaging with "Tc-sestamibi, 754

Ecotropic Cushing syndrome. "In-pentetetide
Ectopic gastric mucosa. scintigraphic detection in jejunum and ileum. **Tc-pertechnetate, gastrointestinal bleeding, 818

Ectopic kidney. **Tc MAG3 SPECT. rapid evaluation of parenchyma, acute pyelonephritis, growth-arrested kidney, split renal function, 478

Ectopic lacrimal gland. differential diagnosis between benign lesion and intraorbital malignancy. **Tc-pertechnetate, SPECT, 1498

Effective dose, pediatric radiopharmaceuticals, aid for estimation, dosimetry, 1982

Effective renal plasma flow

SPECT: 246(ab) with/without cognitive impairment. **Tc ECD SPECT, 284(ab)

Encephalopathy, diffuse, pathological heterogeneity, fractal dimension on cortical projection images, 207(ab)

Endocrine carcinoma, thoracoabdominal image fusion with standard CT and dual-isotope SPECT acquisitions, 1234

Endothelin derivatives. **Tc, atherosclerosis imaging, rabbit balloon denudation model, 173(ab)

Enthesopathy, bone scan findings in patients with inflammatory spondyloarthropathy, **Tc-MDP, 2003

Enzyme inhibitors. protective effect on CCL4- induced hepatotoxicity, study by **Tc-MAG3-biocytein hepatobiliary scintigraphy, 183(ab)

Enzyme therapy, reticuloendothelial system scintigraphy with **Tc-SC, Gaucher disease, 890

Epibatidine. nicotinic acetylcholine receptors with **F-FPH. PET studies, nonhuman primate brain, 1737

Epibatidine, analogs of. studies of nicotinic acetylcholine receptors, 65(ab)

Epidepide. SPECT studies in Parkinson’s disease, multiple system atrophy, and Huntington’s disease, D2 receptors, 1711

Epidermal growth factor. **Tc radiolabeling via NHS-MAG3, new tumor probe, 31(ab)

Epidermal growth factor receptor new monoclonal antibodies directed against, 224(ab)

radiolabeled ligand binding to cells induced to express, recombinant adenovirus and, 18(ab)

Epilepsy

amobarbital distribution, intracarotid amobarbital procedure. **Tc HMPAO SPECT, 91(ab)

area localization. **Tc HMPAO SPECT for, post-ictal difference-image perfusion and, 22(ab)

cerebral blood flow and glucose utilization, EL mouse, 613

cryptogenic neocortical, FDG PET and ictal SPECT-ERs in, 272(ab)

extratemporal, ictal ECD SPECT in, 92(ab)

gelastic, hypothalamic hamartomas in, ictal **Tc HMPAO brain SPECT evaluation, 22(ab)

localization of epileptogenic zones, ictal SPECT for, 277(ab)

localization of seizure foci, FDG PET and **Tc ECD ictal SPECT, 290(ab)

medically intractable complex partial seizures, presurgical localization with interictal and postictal **Tc ECD SPECT brain scans, 23(ab)

newly diagnosed and chronic complex-partial seizures, SPECT, 92(ab)

partial, high resolution ictal SPECT and phased array MRI diagnosis, 91(ab)

seizure foci localization, ictal and interictal SPECT scans co-registered to MRI, children, 12(ab)

seizure focal, parametric mapping analysis comparison to FDG PET, brain, 275(ab)

sensorimotor, seizure focus localization in, semiquantitative ictal rCBF Brain SPECT and, 23(ab)

temporal lobe

FDG PET hippocampal hypometabolism in, 261(ab)

interictal SPECT, 280(ab)

visual and semiquantitative analysis of FDG-PET scans, childhood encephalopathies, 1891

Equilibrium gated radionuclide angiography. left ventricular ejection function of oncology patients, reserve function versus fixed criteria, cardio toxicity, 702

Erythrocyte bound fraction, pharmacokinetics of **T-MIBA for melanoma imaging, radiiodinated benzamides, 127

Erythrocytes. **Tc-N-OET interaction with blood components, myocardial redistribution, perfusion imaging agent, 138

Esophageal cancer

CT and FDG PET comparison in, 246(ab)

pre- and post-therapy staging, PET FDG use in, 247(ab)

Esophageal scintigraphy. further data request, 1653(ab)

Estrogen receptor ligand, imaging, breast cancer, 227(ab)

Estrogen receptors, Z-[**T]IVE radioligand, breast cancer detection, 21(ab)

Ethylenedicysteine. **Tc, synthesis and biological evaluation, mice, 186(ab)

Eustachian tube function. middle ear ventilation scintigraphy with **Xe, 66

Evidence-based practice centers. institutions designated to develop strategies for health and improvement, 25N(11)

Ewing sarcoma. **Tc MIBI scintigram evaluation, children, 13(ab)

Exercise

continuous ambulatory radionuclide monitoring, effect of body position during ergometer exercise, LVEF, 1669

renography in hypertensive disease. **Tc-MAG3, **In-DTPA, 1146

Exercise capacity, left ventricular function and, heart failure patients and, 163(ab)

Extended graphical method. 6-FD trapping, effect of inhibition of COMT, PET, 1568

Extracellular matrix. lung cancer imaging using synthetic laminin derivative radiolabeled peptide, YIGSR, 1940

Extracorporeal immunoadsorption. avidin chase comparison, tumor-to-normal tissue ratio for biotinylated **Re-chiBR96, 1934

Extrahepatic biliary atresia. hepatobiliary scanning in neonatal hepatitis syndrome. **Tc-DISDA, 1279

Facial abnormalities. splenogonadal fusion, diagnosed by radiocolloid spleen scintigraphy, 1153

Factor analysis

dynamic data, new algorithm for unique basis for factor space, 209(ab)

non-invasive quantitation with, FDG PET, 93(ab)

Factors. arteriovenous shunts in patients with hepatic cancer, lung shunting, 1201

Fast Fourier transform. patient-specific dosimetry, SPECT imaging, Monte Carlo calculations, 308

Fatty acid imaging. effects of configuration on myocardial uptake, 3(R)- and 3(S)-BMIPP, 1434

Fatty acid metabolism. influence of blood substrate levels, myocardial kinetics of
**Fatty acids**
- analogs, myocardial/organ ratios, differences, 157(ab)
- 13C octanoate PET, liver function diagnosis, new conceptual radiopharmaceutical for, 179(ab)
- coronary artery disease, external counterpoint in myocardial perfusion imaging for, 167(ab)
- 9F FTHA, effect of lactate loading on retention kinetics of, 174(ab)
- improved uptake and myocardial function after revascularization, assessment using 13BMIPP, 1503

**metabolism**
- detection of myocardial stunning, SPECT, 110(ab)
- discordant perfusion and function after myocardial infarction, 110(ab)
- ischemic heart disease, 919MPA versus 13BMIPP myocardial SPECT detection of, 16(ab)
- left ventricular hypertrophy regression and, hypertensive rats, 42(ab)
- myocardial kinetics of 13BMIPP in canines, SPECT evaluation of ischemic heart disease, 1857
- quantitative 13BMIPP SPECT, unstable angina, 97(ab)
- radiolabeled, potential marker of myocardial metabolism, 124(ab)
- uptake, myocardial blood flow and, exponential relationship of, 42(ab)

**FIDA**, see Food and Drug Administration

**FDG**
- see Fluorine-18-fluoro-2-deoxy-D-glucose

**FDG-PET**
- expression of glucose transporters in pancreatic tumors, immunohistochemistry, 1337
- false-positive imaging of thymus in patient with Hodgkin’s disease, pediatrics, 889

**FDOPA** PET, controversies related to recent articles, 1267(ab)

**Fever, unknown origin**
- immunoscintigraphy in, neonates and infants, 158(ab)
- 99mTc leukocyte scintigraphy in evaluation, 159(ab)
- utility of 13In-IgG, 484

**Field uniformity**
- SPECT, quantitative evaluation of, 206(ab)

**Filtering**
- post-reconstruction, distance-dependent resolution compensation and, myocardial SPECT reconstruction using EM and OSEM with, 20(ab)

**Fine-needle aspiration biopsy**
- 99mTc-MIBI scintigraphy of thyroid nodules, 62

**First-pass radionuclide angiocardiogram** detection of subclavian vein thrombosis, permanent pacemaker, 101

**Flow metabolism dissociation**
- cerebral blood flow and glucose utilization in epileptic EL mice, interictal, ictal, postictal states, 613

**Flow-velocity index** scintigraphic, comparison, complications of renal transplants, 49(ab)

**Fluorine-18**
- biodistribution of 9F FUDR, PET tumor imaging and, 177(ab)
- fluorine kinetics measured in vivo, PET, metabolic bone disease, 1970
- fluorooxyalkylarenes, direct NCA fluorination, diphenyliodonium salts as precursors for, 43(ab)
- labeled choline analogue, 2-fluoroethyl-
- dimethyl-2-oxoethylammonium, automated synthesis, 44(ab)
- PET, primary breast cancer, 234(ab)
- PET, breast cancer, 234(ab)
- PET, multiple myeloma, 1208
- PET versus 99mTc-estamibi, multiple myeloma, 1208
- reduction of cerebellar glucose metabolism, Alzheimer’s disease, PET, 925
- reperfusion, glucose and fatty acid utilization in stunned myocardium, PET, 91-BMIPP, 1835
- standardized uptake value and quantification of myocardial metabolism, breast cancer imaging with PET, tyrosine, 692
- uptake in rat prostate adenocarcinoma during gemcitabine therapy, PET, 1215

**Fluorine-18-FDG imaging**
- acute and chronic osteomyelitis, 120(ab)
- bone marrow uptake, granulocyte colony stimulating factor effects, during chemotherapy, 128(ab)
- bone metabolism, dynamic 99mTc water and 99mTc porcine, 120(ab)
- brain chronic fatigue syndrome, 282(ab)
- systemic lupus erythematosus, 274(ab)
- bronchial lavage lung adenocarcinoma, 79(ab)
- collimator specific treatment of data, 211(ab)
- Crohn’s disease patients, 255(ab)
- CT and immunoscintigraphy, recurrent colorectal cancer, 246(ab)
- CT comparison, esophageal carcinoma, 246(ab)
- detection of bone metastases, breast cancer, 127(ab)
- dual head coinccidence camera, performance characteristics, detection of small lesions, 206(ab)
- dual isoie 99mTc imaging and, cross-talk correction, 243(ab), 67(ab)
- evaluation of muscarinic-cholinergic neuron 99mTc MPPP high-field radiosynthesis, cat brain, 56(ab)
- tissue distribution, rat, 56(ab)
- glucose uptake in, acipimox for promotion of, 140(ab)
- head and neck tumors, 152(ab)
- inluss constant, lung cancer patients, 244(ab)
- kinetic rate constants, untreated breast and lung cancer patients, 244(ab)
- MIBI SPECT and, detectability of breast tumor, 68(ab)
- movement disorders, 274(ab)
- myocardial perfusion and metabolism, histological changes in ischemic myocardium, man, 169(ab)
- 99mTc ammonia and, cardiac PET, effects of left bundle branch block on, 170(ab)
- non-Hodgkin’s lymphoma, kinetic rate constants of, 153(ab)
- normal brain metabolism patterns, PET and MRI imagery, 135(ab)
- 99mTc water and GD-DTPA, brain tumors, 240(ab)
- pancreatic and peri-pancreatic masses, 51(ab)
- pancreatic cancer, 246(ab)
- peripheral adenocarcinoma, lung, 243(ab)
- PET lumped constant, in insulin-stimulated myocardium, 42(ab)
- myocardial/blood pool concentration ratio evaluation, myocardial FDG uptake parameter, 170(ab)
- potential, breast cancer, 69(ab)
- primary colorectal carcinomas, preoperative staging of, 136(ab)
- radiation absorbed dose estimates, whole-body PET and MRI, 225(ab)
- residual or recurrent malignant lymphoma, 153(ab)
- tumor detectability, 99mTc oxymyoglobin and 99mTc oxymyoglobin.
Gastric emptying
acceleration in patients with insulin-resistance syndrome, hypertension, increased body mass index, 207
gastric peristalsis and, evaluation, detection of subgastric dysfunction and, 258(ab)
half emptying time, intrathoracic stomach, 71(ab)
in Parkinson’s disease, levodopa treatment effects, 261(ab)
lipid and solid, dual energy, dual head technique for assessment, 126(ab)
measurement, feeding volume and, infants, 24(ab)
pediatric gastric scintigraphy, cost-benefit analysis, 291(ab)
scintigraphy and, solid-phase acceleration measurement,
identification comparison and, 495
total and regional, antral motility and, comparison between men and women, 255(ab)
Gastrin releasing peptide receptor, bombesin localization in ovarian carcinoma, adenoviral vector-mediated gene transfer,
Tc-disofenin. 1, 1221
Gastritis, C-urea breath test, presence and eradication of helicobacter pylori infection, PUD, 1141
Gastroenteropancreatic tumors
detection, somatostatin receptor scintigraphy, 237(ab)
false-positive somatostatin receptor scintigraphy, accessory spleen, 1979
somatostatin receptor scintigraphy, neuroendocrine tumors, 853
Gastroesophageal cancer, half emptying time in patients, 71(ab)
Gastroesophageal reflex
patients fed by percutaneous endoscopic gastrostomy, radionuclide evaluation of, 260(ab)
scintigraphic milk scan findings and, patients with acute life-threatening events, 24(ab)
Gastrointestinal bleeding
disseminated islands of gastric mucosa jejenum and ileum, Tc-percethenate scintigraphy, 818
studies, image quality in, in vitro labeling experiments, 254(ab)
Gastrointestinal tract, cancer, FDG PET in staging and evaluation, 144(ab)
Gated blood-pool imaging
calculated quantitative left ventricular ejection fraction, qualitative regional function, 26, 71, 79
Tc-DMP-HAS and Tc-labeled RBCs, equilibrium ventriculography, 1521
evaluation of RV and LV volume and EF, cardiac torso phantom, 1528
procedure guideline for equilibrium radionuclide ventriculography, cardiac function, 1658
Gated SPECT
automatic quantitative left ventricular ejection function, qualitative regional function, 26, 71, 79
dual-isotope imaging
left ventricular function and myocardial perfusion at rest, 201Tl and 201Tc. 432
image enhancement for computation of EF, myocardial hyperperfusion, 1411
MRI comparison to assess left ventricular contraction
Tc-tetrofosmin, 438
Tc-sestamibi imaging identification of severe right ventricular
dysfunction, pulmonary emboli, 254
Gaucher disease
femurs, MRI and scintigraphic evaluation of bone marrow in, 303(ab)
reticuloendothelial system scintigraphy with 99mTc-SC, enzyme replacement therapy, 890
Gemcitabine, Tc-FDG PET, uptake in rat prostate adenocarcinoma during chemotherapy, 1215
Gender differences
cerebellar metabolic responses to lorzapam, 283(ab)
cerebral blood flow, visceral stimuli effects, 273(ab)
effect of mental stress and, myocardial blood flow and, N-ammonia PET study, 171(ab)
high exercise tolerance women, myocardial perfusion imaging in, 155(ab)
total and regional gastric emptying, antral motility and, 256(ab)
Gene expression, associated with cell replication, imaging of, 250(ab)
Gene therapy
HSV thymidine kinase, FDG uptake during, PET studies, 249(ab)
HSV-tk expression, quantitative PET imaging, 249(ab)
HT-29 cells, 18F-FHPG evaluation in, 176(ab)
monitoring with herpes simplex virus thymidine kinase in hepatoma cells, PET, 287
multitracer PET studies, hepatoma cells with HVsik and GCV, glucose metabolism, 1048
role of hepatitis C virus, 1230(ed)
Gene transfer, bombesin localization in ovarian carcinoma, GRPr, adenovirus, 1221
Generator, radionuclide, portable nuclear angiography camera with, 310(ab)
Geometric point response correction, 511 keV SPECT, small 2D convolution kernels for, 214(ab)
Glioblastoma, 21T and Y-labeled antititin MABS, locoregionally infused, radioimmunotherapy, 60(ab)
Glioma
detection of recurrence, IMT-SPECT and FDG PET comparison, 239(ab)
Tc-FDG PET for evaluation, 240(ab)
Tc-IMT SPECT compared with Tc-FDG PET in evaluation of brain tumors, 802
Tc-IMT SPECT, correlation with cellular density and proliferative activity, 1551
11I IUDR dosimetry, SPECT agent, 210(ab)
malignancy grade, 57Tc, C methionine, or Tc-FDG for, 158(ab) methionine and glucose uptake, PET-guided stereotactic biopsy, 1459
PET studies, membrane potential-dependent tumor imaging, canine brain, 117(ab)
supratentorial, follow-up with 125I, Tc-sestamibi, and Tc-HMPAO SPECT, 237(ab)
three-dimensional dosimetry for intracerebral therapy, image registration, 1059
three-dimensional imaging for tumor resection, C-methionine PET, 1563
Gliosarcoma, intracranial administration of 51I-UdR in leptomeningeal metastases, rats, 386
Glomerular filtration rate
captopril effects, liver cirrhosis and ascites patients, 294(ab)
estimating in pediatric population, 1665(le)
modified method of assessment, 1662(le) single-sample method, 295(ab)
Glucose metabolism, bone tumors, 127(ab)
oral loading, effect on 18F-BMIPP biodistribution, normal volunteers, 97(ab)
skeletal muscle energy metabolism, thermal injury effects, PET, rabbit, 268(ab)
uptake response, in myocardial ischemia, 2-D and 3-D PET assessment, 169(ab)
Glucose loading, 131I myocardial SPECT, hibernating myocardium, 573
Glucose metabolic rates, simplified calculation using PET, 1334(le)
Glucose metabolism, imaging the pentose cycle in gliomas with PET, rat brain neoplasms, 617
initial changes in Tc-FDG uptake during radiotherapy, 1384
multitracer studies during gene therapy of hepatoma cells, HVsik and GCV, PET, 1048
negative myocardial uptake of 131I-BMIPP, free fatty acid metabolism, PET, 548
Glucose transporter, 131I-labeled FDG, human colon cancers transplanted in nude mice, 247(ab)
Glucose-6-phosphatase, role, retention of FDG, cancer cells, 248(ab)
GLUT expression, in pancreatic tumors compared with FDG accumulation in PET study, immunohistochemistry, 1337
Glut-1, overexpression, FDG uptake in pancreatic cancer, 1344
Gluthathione, cerebral imaging, Tc-MESO-HMPAO, 1125
Goiter
diabetic, MRI in, scintigraphy in incidental thyroid lesions, 263(ab)
multi-nodular, incremental radiodiode treatment, 261(ab)
nodular
basal thyroid hormones in the development of, 262(ab)
otoxic, iopanoic acid for 131I ablution, 266(ab)
thyroid, regulatory peptide receptors in, 266(ab)
GPIIb/IIIa receptor, potential use of Tc-P748, imaging agent for detection of venous thromboembolism, 105
Grading, diagnostic accuracy of FDG-PET, assessment of meningiomas improved with overnight fasting, 26
Graft arteriosclerosis, detected by 131I myocardial SPECT in heart transplant recipients, intravascular ultrasound, 760
Granulocytopenia, focal infection in, Tc-labeled radioactive agents, 270(ab)
Graphical plot cerebral blood flow, quantification of rCBF, continuous infusion of Tc-ECD, 1699
Graves’ disease, autoinfection of an autonomously functioning thyroid adenoma, 260
consistent thyro-ablation in, optimal 131I sodium iodide dosing, 262(ab)
Tc-FDG uptake changes in, 16(ab)
Growth-arrested kidney, Tc-MAG3 SPECT, rapid evaluation of renal parenchyma.
ectopic kidney, acute pyelonephritis, 478

H

HCFA, see Health Care Financing Administration

Head and neck cancer. **99mTc-chloride, SPECT imaging for diagnosis, 873

Head and neck hemangiomas, perfusion and blood-pool scintigraphy in the evaluation of, **99mTc-RBCs, **99mTc-HSA-D, 882

Head and neck tumors

**99mTc FDG PET in evaluation, 152(ab)
primary or recurrent, accuracy of FDG PET, 161(ab)
recurrent, staging by whole-body FDG PET, 153(ab)

Head injury, evaluation of crossed cerebellar diaschisis, **99mTc-FDG PET, 1717

Head neoplasms, prediction of survival with **99mTc-FDG PET, tumor grading, 1907

HEAD PENN-PET scanner, three-dimensional imaging characteristics, brain imaging and pediatric whole-body studies, 636

Health Care Financing Administration (HCFA) ICD coding system, 18N(3)
proposed rule on practice expense, Medicare, 35N(8)
prospective payment system, 13N(2)

Healthy volunteers, inhalation scintigraphy with **131I-IgG, pulmonary deposition and dose escalation study, 1475

Heart

cardiac phantom, small myocardial defects, attenuation correction SPECT imaging in, 64(ab)
down-regulation of cardiac muscarinic receptors, DFP induced, PET, 1430
failure
ace inhibition, reduction of **131I-MIBG release, 1085
exercise capacity and left ventricular function in patients with, 163(ab)
new surgical treatment, radionuclide
normal partition and distribution, 108(ab)
hybrid method for measuring myocardial wall thickness, gated PET, SPECT, 324
procedure guideline for equilibrium radionuclide ventriculography, cardiac function, 1658
SPECT, anatomical variations affecting, female patients, 20(ab)

Heart transplantation, graft atherosclerosis detected by **99mTc myocardial SPECT, intravascular ultrasound, 760

Heart wall motion, probe imaging and, improved myocardial perfusion imaging due to, 156(ab)

Helicobacter pylori

capsule based **13C urea breath test for, comparison with liquid-based test, 259(ab)**13C-urea breath test, documentation of presence and eradication of infection, PUD, gastritis, 1141
single sample **13C urea breath test for diagnosis, 71(ab)

Hemangioma, 1-VIP/**99mTc-OCT receptor scans, differential diagnosis of liver carcinoid metastasis, 880

Hemodialysis, vascular access patency in, radionuclide evaluation, 30(ab)

Hepatectomy, partial, assessment of liver function with **99mTc GSA, rat, 259(ab)

Hepatic abscess, rim sign on hepatobiliary scan, 1282

Hepatic cancer, arteriovenous shunts, correlation of lung shunting with tumor size and vascularity, 1201

Hepatic focal nodular hyperplasia, differentiation from malignant liver lesions, **99mTc-NGA SPECT, 1912

Hepatitis C, **Ga-citrate, scanning after interferon therapy, interstitial liver disease, 216

Hepatobiliary imaging agent. **99mTc MAG3

Hepatobiliary scan
outcome in neonatal hepatitis syndrome, **99mTc-DISIDA, 1279
rim sign in hepatic abscess, 1282

Hepatocellular cancer

detection with alpha-fetoprotein antibody imaging kit, AFP-SCAN, 10(ab)
differentiation from hepatic focal nodular hyperplasia, **99mTc-NGA SPECT, 1912

Hepatocytes
**99mTc incorporation into, bilirubin effects, 51(ab)
transplantation, safety analysis, **99mTc-human serum albumin microspheres, 258(ab)

Hepatitis, Morris, HSBI thymidine kinase, gene therapy with, PET studies of FDG uptake during, 249(ab)

Hepatotoxicity
CCL4-induced, synthetic enzyme inhibitors, study by **99mTc MAG3-biocytin hepatobiliary scintigraphy of protective effects of, 185(ab)
**99mTc MAG3-biocytin, scintigraphy, 254(ab)

HER2, radioimmunotherapy targeting using lead-212-DOTA-AE1, ovarian tumor, 1944

Herpes simplex virus thymidine kinase

monitoring gene therapy in hepatoma cells, uptake of specific substrates, ganciclovir, 287
multiracer studies during gene therapy, glucose metabolism, PET, 1048

Heterogeneity
DMIPP uptake and relationship with myocardial blood flow, 1424
tissue partition coefficient and, regional myocardial blood flow estimate with O2 water and, 172(ab)

Heterotopic ossification, three-phase bone scan in, 305(ab)

Hibernating myocardium, glucose-loading **99mTc SPECT, 573

Hilar lymphadenopathy, **99mTc-tetrofosmin uptake in sarcoidosis, SPECT, 1786

Hippocampus, differences between **99mTc-HMPAO and **99mTc-ECO in normal medial temporal lobe, SPECT, 1109

Histologic malignancy

correlation with brain tumor imaging, **99mTc-DMSA and **99mTc SPECT, 1741
uptake of pentavalent **99mTc-DMSA in primary brain tumors, SPECT, 20

HMPAO, SPECT, spinocerebellar degeneration in Lyme disease, 1120

Hodgkin's disease
false-positive FDG-PET imaging of the thymus, pediatrics, 889
post-treatment **Ga SPECT, faint hilar activity after, pediatric patients, 13(ab)
whole body FDG-PET imaging cost-effective method for staging and restaging, lymphoma, 343

Holmium-166, radionuclide therapy using topical skin patch for skin cancer, Bowen's disease, 697

Human cancer xenograft, influence of chemotherapy on **F-FDG uptake, PET, 714

Human immunodeficiency virus (HIV), FDG-PET scanning, combined with MET to define cerebral lesions, 1575

Human monoclonal antibody, In-lgM 16.88, imaging infection, LiLo, 1054

Huntington's disease, central motor processing in, PET activation study, 104(ab)

Hybridization. **99mTc-labeled peptide nucleic acid, pharmacokinetics, 907

Hydrocephalus
mismatches, regional perfusion and metabolism, neuronal viability, 279(ab)
 viable neurons with luxury perfusion, perfusion and metabolism mismatch, 1467

Hydrogen-3-daunomycin. **99mTc-sestamibi, comparison, myocardial cellular retention, MDR reversing agents, 1674

Hydroxyurea, therapy for functional asplenia, scintigraphic evaluation, 160(ab)

HYNICA, peptide, **99mTc labeling, NS2 as co-ligand, 188(ab)

HYNICA-maleimide, thiol-specific linker for **99mTc labeling of peptides, conjugation/lowering/in vivo evaluation, 19(ab)

Hypercortisterolemia, improved reduced coronary flow in, after lipid lowering therapy, 85(ab)

Hyperfixation, of **Cu-PSM, following global ischemic episodes in rats, 1130

Hyperglycemia

effect of tumor uptake of FDG, thymidine, L-methionine, and L-leucine, PET, 382
insulin resistance versus, coronary flow reserve reduction and, in angiographically normal coronary arteries, in NIDDM, 4(ab)

Hyperlipidemia
correction, endothelium independent microvascular function with ischemic heart disease, 30(ab)
women versus men, coronary flow reserve and, 173(ab)

Hyperostosis frontalis interna, leukocytomegalo scintigraphy, skull, 1283

Hyperparathyroidism

**99mTc/**99mTc MIBI scan, normal variants, 267(ab)**99mTc-MIBI in localizing pathology, MEN type 1 syndrome, 1767
bone loss prediction, quantitative bone SPECT and, 17(ab)
parathyroid imaging comparisons, **99mTc-pertechnetate/sestamibi subtraction, double-phase **99mTc-sestamibi and **99mTc-sestamibi SPECT, 834

Hyperplastic parathyroid. **99mTc-tetrofosmin imaging to localize parathyroid glands, 706

Hypertension
accelerated gastric emptying, insulin-resistance syndrome, 207
brain dopamine transporter in rats, **11C-B CIT, 470
coronary flow reserve in, patients with normal perfusion imaging, 172(ab)
esential, protein loading-renal scintigraphy
myocardial SPECT, using EM and OSEM, with distance-dependent resolution compensation and post-reconstruction filtering, 20(ab)
OS-EM versus filtered back projection, neurologic FDG PET studies, 204(ab)
streak artifacts, removal from PET images, 199(ab)
transaxial SPECT, two one-dimensional Compton cameras of finite extent for, 32(ab)

Image registration
3D algorithm for, based on MSE, performance evaluation, 204(ab)
body contour, non-coherent interferometry, 211(ab)
FDG PET and spiral CT, staging of non-small cell lung cancer, 244(ab)
interpretation of functional brain images, 277(ab)
multi-resolution, medical imaging, 207(ab)
modularity brain, 3D surface, 310(ab)
three-dimensional dosimetry for intravascular therapy, radioimmunotherapy glioma, 1059

Image smoothing, effect on disease-specific pattern of cerebral atrophy, PET FDG, HIV seropositive patients, 199(ab)

Image figure of merit, selection of antibody type and time, tumor imaging and, 10(ab)

Imaging plate, glucose uptake in myocardial ischemic border zone, double-tracer autoradiography, 1515

Immunoadsorption, enhanced radioimmunotargeting of \(^{111}\)I-labeled BR96-biotin MAb, rats, 895

Immunomagnets, bispecific antibody, quantitation of myosin heavy chain fragments, 148(ab)

Immunon conjugates, radionuclide antibodies, radionuclide uptake in tumors, 231(ab)

Immunohistochemistry, expression of glucose transporters in pancreatic tumors, FDG-PET, 1337

Immunoscintigraphy
CEA-SCAN, non-palpable breast cancer, 9(ab)
tumor-targeting
\(^{99m}\)Tc-labeled hyaluronic acid-Fab conjugates, 133

Improvement of images, fluorine-18 planar, 500(ab)

In memoria, Maxfield, James Robert, 1336

In vitro, metabolism of \(^{99m}\)Tc-ECD, hydrophilic conversion mediated by enzymes, 1731

Index Medicus, selection of JNMT for inclusion, MEDLINE, MEDLARS(tm), 32n(10)

Indium-111
avidin, malignant ascites radiotherapy and, 195(ab)
clinical evaluation of radiolabeled chimeric anti-CEA monoclonal antibody, 1951
DTPA-D-Ph(1)-octreotide labeled with, tumor imaging, 19(ab)
DTPA-paclitaxel labeling, synthesis, biodistribution, and imaging properties, gamma scintigraphy, 1042

human monoclonal antibody for infection imaging, IgM, LiLo, 16,88, 1054

Infection
bacterial-specific imaging, \(^{99m}\)Tc, 157(ab)
FDG-PET scanning, HIV-positive patient, MET, 1575
human monoclonal antibody for, pilot study, 26(ab)
imaging of, \(^{99m}\)Tc anti-SSEA-1 antigranulocyte antibody and white blood cells, 157(ab)
inflammation and, rapid imaging with \(^{99m}\)Tc anti-
SSEA, 25(ab)
orthopedic prosthesis, FDG PET in diagnosis of, 120(ab)

\(^{99m}\text{Tc}-\text{labeled chemotactic peptides, sterile administration, 1310}

Infection imaging
dual radiolabeled liposomes, infection imaging, rats, 112(ab)
high affinity chemotactic peptide antagonist for, 268(ab)
\(^{99m}\text{Tc}-\text{labeled human monoclonal antibody, IgM 16.88, Lilo, 1054}
interleukin-1, receptor antagonist, and chemotactic peptide comparison, 269(ab)
labeled stealth liposomes for, 268(ab)
S. aureus infection, polyethylene glycol liposomes for infection imaging, particle size and circulation time, 489
strategy using an anti-DTPA MAb as pretargeting agent and \(^{99m}\text{Tc}-\text{DTPA} as targeting radiopharmaceutical, MAH priming, 901

\(^{99m}\text{Tc} \text{chemotactic peptides, specific localization of, 269(ab)}

Infection/inflammation scintigraphy, practice guideline for \(^{99m}\text{Tc}-\text{HMPAO}-\text{labeled leukocyte imaging, 987}

Inflammation
hyperoxia-induced lung, \(^{99m}\text{Tc} \text{liposomes versus Ga citrate labeling for detection, 185(ab)}
initial changes in \(^{99m}\text{Tc-FDG} \text{uptake during radiotherapy, glucose metabolism, 1384}
\(^{99m}\text{Tc} \text{labeled} \text{biontin imaging for, versus In} \text{labeled leukocytes, patients with osteomyelitis, 26(ab)}
\(^{99m}\text{Tc} \text{chemotactic peptides, acute infection, 1310}

Inflammation/infection imaging, practice guideline for \(^{99m}\text{Tc} \text{leukocyte scintigraphy, 997}

Inflammatory bowel disease
\(^{99m}\text{Tc-FDG imaging use in, 255(ab)} \text{distribution of} \(^{99m}\text{Tc} \text{HMPAO, bowel segments, 253(ab)}
\(^{99m}\text{Tc} \text{labeled} \text{biontin imaging, case report of patient with peritonitis, 1138}
late abdominal accumulation of \(^{99m}\text{Tc} \text{HMPAO} \text{white blood cells, normal children, 290(ab)}
scintigraphic evaluation in rabbits, gamma globulin, \(^{99m}\text{Tc} \text{In, 1596}

Inhalation drugs, treatment efficacy of aerosol administration, 1482(ed)

Inhalation scintigraphy, pulmonary deposition and dose escalation study, \(^{131} \text{I} \text{IFNg, 1475}

Input function, measurement with in vivo detector, serial PET with primates, 203(ab)

Instrumentation
BGO array with miniature position-sensitive phototube, detector performance, accuracy of event positioning in PET, 197(ab)
high-resolution LSO PET, 16-channel Hamamatsu R9500-M16 PMT and, 45(ab)
KFA tier PET, flexible system for small animals, 198(ab)
PET and NMR, simultaneous acquisition in high field magnet, 45(ab)
PET resolution improvement, detector depth of interaction information, 45(ab)
small animal PET imaging device, preliminary design study, 44(ab)
Insulin, \(^{13} \text{C}-\text{methionine transport, PET, 1967}
Insulin-dependent diabetes mellitus, accelerated gastric emptying after semisolid meal, supine position, 814
Insulin resistance, Hyperglycemia versus, coronary flow reserve reduction and, in angiographically normal coronary arteries, in NIDDM, 4(ab)
Insulin-resistance syndrome, accelerated gastric emptying in patients with hypertension, noninsulin-dependent diabetes mellitus, body mass index, 207
Insulinosomas, functional somatostatin receptors, in vitro and in vivo detection, hypoglycemia in dogs, 1036
Interferometry, non-coherent, body contour registration by, 211(ab)
Interferon-alpha, scanning after therapy for chronic hepatitis C, Ga-citrate, interstitial lung disease, 216
Intercital, cerebral blood flow and glucose utilization in epileptic El mice, ialtal and postictal states, 613
Interleukin-2, radiolabeled antibodies conjugated with, radionuclide uptake in tumors, 231(ab)
Interleukin-2 receptor biodistribution, adverse effects of circulating antigen on, 231(ab)
impact on biodistribution of T1 anti-tac dsFv, 252(ab)
International Society of Radiolabeled Blood Elements (ISORBE), 31N(10)

Internet
interactive nuclear medicine image display system, Java programming language, 210(ab)
interactive whole-body PET system, brain atlas and, 309(ab)
technologies, PACS for nuclear medicine, 311(ab)
World Wide Web image analysis, 309(ab)
interpretative accuracy of \(^{99m}\text{Tc} \text{myocardial perfusion scans, 53(ab)}
PACS for nuclear medicine, 307(ab)
viewers for DICOM-formatted medical images, 310(ab)
Intestinal lung disease, Ga-citrate, scanning after interferon therapy for chronic hepatitis C, 216
Intracranial tumors, \(^{99m}\text{Tc} \text{uptake and retention after radiation therapy, 223}
Intracereosional therapy, three-dimensional dosimetry for radionuclide therapy, glioma, 1059
Intrapitoneal chemotherapy, rectosigmoid fistula demonstrated by dynamic scintigraphic peritoneography, 1636
Intrapitoneal tumor, radiotherapy, \(^{131} \text{I} \text{avidin and, 194(ab)}
Intrathelial tumor, \(^{131} \text{I} \text{IodR administration in rat model, leptomeningeal metastases, 386}
Intrapineal penetration, radiolabeled streptavidin, pretargeting with biotinylated antibody, 192(ab)
Intravascular ultrasound
diarydramol scintigraphy after successful coronary intervention, discrepancy between angiographic and scintigraphic findings, \(^{99m}\text{Tc} \text{MIBI SPECT, 553}
myocardial perfusion in heart transplant recipients, \(^{99m}\text{Tc} \text{SPECT, graft atherosclerosis, 760}

Iodide ingestion, induced thyrotoxicosis, Jod-Basedow syndrome after oral administration, 1816
Iodinated fatty acids, DMP1 uptake and relationship with myocardial blood flow, heterogeneity, 1424

Iodine-123
24-hour thyroid uptake, proper management of, 268(ab)
BCTT, SPECT, measurement of dopamine transporters, Parkinson’s disease, 1453
comparison, scanning agent for metastatic thyroid cancer, 150(ab)
radioligand, preclinical testing, autoradiography and phosphor-imaging device, 149(ab)
Iodine-123 \(^{99m}\text{Tc} \text{MPA} \text{, SPECT,} \(^{99m}\text{Tc} \text{ redistribution-reinjection images versus, myocardial viability evaluation, 162(ab)}
Iodine-123-[alpha]-methyl tyrosine, correlation with cellular density and proliferative activity, SPECT imaging in gliaomas, 1551
Iodine-123 allopurinol, SPECT, quantification of dopamine transporters, 223(ab)
Iodine-123 AM281, imaging of cannabinoid receptors with, 77(ab)
Iodine-123-anti-CEA, murine monoclonal antibody IgG, radioimmunotherapy, 858
Iodine-123-\(^{131} \text{I} \text{CT}
plasma concentrations of, at extended times, TLC of ultrafiltrates, 287(ab)
ngrostriatal dopaminergic damage, Wilson’s disease, 147(ab)
SPECT imaging of dopamine transporters, Parkinson’s disease, correlation to clinical parameters, 1
use in alcohol addiction, 48(ab)

Iodine-123 BMIPP
biodistribution, oral glucose loading effects, normal volunteers, 97(ab)
diagnosis of coronary artery disease, fatty acid metabolic imaging, myocardial metabolism, 171(ab)
effects of configuration on myocardial uptake, fatty acid imaging, 1434
imaging as a guide for interventional strategy, unstable angina, PTCA, 1407
myocardial kinetics in canines, use as radiopharmaceutical for evaluation if ischemic heart disease, 1857
myocardial kinetics of, fatty acid metabolism, 1079
myocardial washout and cardiac work during exercise in normal and ischemic myocardium, pressure rate product, SPECT, 559
reperfusion, glucose and fatty acid utilization in stunned myocardium, \(^{99m}\text{Tc-FDG PET, 1835}
SPECT
severity of hibernating myocardium with, comparison with myocardial blood flow and \(^{99m}\text{Tc-FDG PET, 174(ab)}
stress \(^{99m}\text{Tc} \text{SPECT versus, patients with ischemic heart disease, 165(ab)}
\(^{99m}\text{Tc} \text{tetrofosmin and,} \(^{99m}\text{Tc} \text{T versus, SPECT imaging in predicting functional recovery after revascularization, 167(ab)}
thallium and radioiodinated branched fatty acid uptake, ischemic myocardium, 97(ab)
uptake, oxygen and glucose metabolism impairment and, hypertrophic cardiomyopathy patients, 163(ab)
Iodine-131 epidepride, imaging of dopamine receptors, kinetic and equilibrium studies, 81(ab)
Iodine-123 fatty acid, cardiac SPECT imaging, chronically dysfunctional myocardium, 62(ab)
Iodine-123 FP-CIT, biodistribution, radiation dosimetry and, 228(ab) dopamine transporter labeled with, rats and MPTP-lesioned monkeys, 60(ab)
Iodine-123 IACPT, SPECT imaging of dopamine transporter sites, MPTP model, (I-
CFT, 144
Iodine-123 IAZA, imaging, rheumatoid arthritis, 300(ab)
Iodine-123 IBFM brain SPECT, effect of haloperidol on imaging, schizophrenic patients, 203 dopamine receptor imaging with, children with hypoxic-ischemic brain injury, 292(ab) frontal lobe dysfunction, neonatal mesial temporal lesions, monkey, 283(ab)
Iodine-123-IFNγ, inhalation scintigraphy, pulmonary deposition and dose escalation study, 1475
Iodine-123 IMP evaluation of port circulation, superior mesenteric vein, 255(ab) regional cerebral blood flow measurement, comparative study, SPECT, 597 measurement, with autoradiography, SPECT, 1102(ab) regional cerebral blood flow, partition coefficient and, 279(ab) SPECT, perfusion reserve assessment in cerebrovascular disease, 37(ab) split-dose SPECT method, measurement of cerebral perfusion reserve, 279(ab)
Iodine-123-IMT, SPECT and F-FDG PET evaluation of brain tumors, gliomas, 802
Iodine-123 IMZ, benzodiazepine receptor changes, during chronic administration, healthy subjects, 48(ab)
Iodine-123-lodoamphetamine assessment of cerebral perfusion reserve, hemodynamics of watershed infarction, SPECT, 1556 cerebral blood flow quantification, partition coefficient SPECT, 1248
Iodine-123-Iodozenfururan, brain SPECT, quantitative imaging without blood data, dopamine D2-receptors, 31
Iodine-123-lomatuzumab benzodiazepine receptor in chronic CV disease, blood flow and metabolism comparisons, 1693 comparison with (201)Tc-HMPAO, SPECT imaging in Alzheimer’s disease, 467
Iodine-123 MBG after reperfusion therapy, acute myocardial infarction, 111(ab) assessment of cardiac reinnervation, after heart transplant, 111(ab) assessment of cardiac sympathetic function, obstructive sleep apnea syndrome, 567 evaluation effects of ACE inhibition on cardiac sympathetic system, CHF, 1085 imaging comparison, pheochromocytomas, 151(ab) myocardial imaging in normal subjects, autonomic nerve activity, 49 myocardial sympathetic innervation assessment, familial amyloidosis in, 165(ab) myocardial sympathetic innervation changes in response to hyposxia, desipramine, 954 reversible cardiac uptake, adrenal tumor patients, 263(ab) serial assessment of sympathetic reinnervation peri-infarcted and infarcted tissue, 457 Iodine-123 SAP, kinetics, clinical value in patients with systemic amyloidosis, 26(ab)
Iodine-123 VIP receptor, pancreatic cancer patients, 103(ab)
Iodine-123-vasoactive intestinal peptide, carcinoid liver metastasis mimicking a hemangiomia, (°In-DTPA-D-Phe1-ooctreotide, 880
Iodine-125 compared with °Cu-labeled anti-CEA monoclonal antibodies, colorectal carcinoma, 847 DNA-incorporated, double-strand break formation, mammalian cells, 119(ab) localization of bombesin in ovarian carcinoma, expression of GRPR by adenoviral vector-mediated gene transfer, 1212 Iodine-125 anti-Tac dsFv, biodistribution, adverse effects of interleukin-2 receptor, 231(ab)
Iodine-125 IUdR, intrathelial administration in rat model, leptomeningeval metastases, 386 mathematical model, hepatic metastases, 119(ab)
Iodine-125-MIBG evaluation of °I-FIBG, neuroendocrine tumor and myocardial imaging radiopharmaceutical, 330 uptake in cardiomyopathic hamsters, effects of cilazapril and verapamil, 1540 Iodine-131 avidin, intraperitoneal tumor radiotherapy, 194(ab) false-positive whole body scan due to intraperitoneal duct dilatation, 1977 frontal sinus mucocele mimicking thyroid carcinoma, 1022 high-dose, radioprotection on salivary glands, rabbit, 224(ab) interleukin-2 receptor effects, 252(ab) kinetics, anti-B1 Lymphoma radioimmunotherapy, 251(ab) OMMT versus IMT, biodistribution, 188(ab) sequential biological dosimetry after treatment, differentiated thyroid cancer, 377 therapeutic, volatility of, 178(ab) therapy chromosomal damage after, metastatic thyroid cancer, 226(ab) differentiated thyroid carcinomas, evaluation, 16(ab) thyroid cancer, 46(ab) thyroid cancer metastases, evaluation of °I-MIBI scintigraphy for early detection of recurrence, °Tl, 352 total-body scintigraphy in the follow-up of differentiated thyroid cancer, °Tl, thyroglobulin, 686 uptake changes in Graves’ disease, 16(ab) uptake test, intratherapeutic thyroid dosage and, radiodine therapy, 261(ab) °Y-labeled IgG and, versus chemotherapy, in colorectal cancer, 6(ab)
Iodine-131-FIBG, evaluation of an MBG analog, neuroblastoma, neuroendocrine tumors, 330 Iodine-131-labeled anti-CEA monoclonal antibody, regression of advanced refractory ovarian cancer, radioimmunotherapy, 257
Iodine-131-Lym-1, predicting myelotoxicity, radiation doses to marrow from body, blood, 1374
Iodine-131 MBG acute liver necrosis induced by treatment of metastatic carcinoid tumors, 1024 intraarterial application, tumor treatment by, 253(ab) therapy for pheochromocytoma, exacerbation of symptoms after, hypersecretion of catecholamines and, 263(ab)
Iodine-131 OIH, °Tc MAG3 comparison, model analyses, 295(ab)
Iodine-131 sodium iodide, optimal dosing, consistent thyro-ablation in Graves’ disease, 262(ab)
Iodine-131 sodium therapy accumulation and clearance, salivary glands, postoperative thyroid cancer patients, 266(ab) extensive thyroidectomy, management of thyroid cancer, 263(ab)
Iodine-131 treatment, predicting efficacy in differentiated and thyroid cancer, thyroglobulin, 1362
Iodine-131 whole body scan, hepatic visualization whole-body scan, thyroid cancer, 1191
Iododeoxyuridine, °I, intratumoral infusion, radiotherapy of solid tumors, 194(ab)
I-°I[L-iodo-[alpha]-methyltyrosine, amino acid uptake in gliomas, SPECT versus methyl-°I-L-MET PET, 517
Lodothyryonines, in urine, after °I whole-body scintigraphy, differentiated thyroid cancer, 267(ab)
Lopanoic acid, °I ablation, high risk toxic nodular goiter patients, 266(ab) IPT, usefulness as an imaging agent for measuring changes in transporter concentrations, Parkinson’s disease, 1703
Iridium-191m, continuous infusion, high-resolution SPECT of renal blood flow, 82(ab)
Ischemia flow versus uptake comparisons of °Tl with °Tc perfusion tracers, canine myocardium, 1847 myocardial infarction prevention, °I BMIPP SPECT in detecting hibernating myocardium, comparison with myocardial blood flow and °F FDG, 174(ab)
Ischemic heart disease °I-BMIPP myocardial washout and cardiac work during exercise, pressure rate product, SPECT, 559 computer-aided interpretation of myocardial SPECT perfusion images, neural networks, 1870 myocardial kinetics of °I-BMIPP in canines, SPECT, 1857
Ischemic left ventricular dysfunction, regional perfusion assessed at one-year after revascularization, thallium tomographic imaging, 1684
Ischemic penumbra, salvaged, detection with benzodiazepine receptors, 117(ab)
Isolated cortical atrophy, anterior operculum syndrome, SPECT localization, orofacial apraxia, anarthria, 1122
ISORBE, see International Society of Radiolabeled Blood Elements
Isotopes, accelerator-produced for research
Iterative reconstruction, improved resolution, 3-D volume imaging. PET, 1623

K
Kawasaki disease, pharmacological stress in. 207Ti SPECT with, 290(ab)

Kidney
accretion, dose rate and, influence on toxicity and anti-tumor efficacy of complete versus fragmented 111In- and 125I-labeled antibodies, radioimmunotherapy for CEA-expressing cancers, 31(ab)
accumulation of radioactive antibody fragments, reduction through novel chemical strategy, 30(ab)
cortical scarring and length measurement, DMSA and ultrasound in detection of, pathological correlation, pig, 24(ab)
depth correction, 99mTc MAG3 scintigraphy, 294(ab)
end stage failure, Alzheimer’s disease and, 129(ab)
function quantification of, 99mTc MAG3, adults and children, 294(ab)
transplant MAG3 percent uptake and ERPF clearance, 296(ab)
plasma flow, captopril effects, liver cirrhosis and ascites patients, 294(ab)
radioactivity quantification, conjugate-emission and transmission data, 208(ab)
sclerosis, in transplants, 99mTc DMSA SPECT use in, 50(ab)
99mTc DMSA uptake, nphron-sparing and, 293(ab)
uptake of 111In DTPA-octreotide, D-lysin and, 191(ab)
vesicoureteral reflux, 99mTc DMSA scans in, children, 50(ab)

Kidney transplantation, 99mTc-MAG3 scintigraphy, assessment of prognosis for recovery, radioisotope renography, 475

Kinetic analysis, smoothing of blood time-activity curves, PET, 1161

Kinetic modeling
5-HT transporter, binding potential with 123I MCN-5652, quantification of, 202(ab)
AChE in brain activity, 123I PMP and, constraint and, 198(ab)
123I MCN5652X, PET binding studies of serotonin transporters, 196(ab)
cardiac dynamic SPECT, input function extraction using factor analysis in, 8(ab)
dynamic imaging with, 8(ab)
FDG lumped constant, normal human brain and, 200(ab)
neurologic FDG PET, non-invasive quantification, 204(ab)
neurotransmitter release measurement, bolus or infusion delivery receptor-binding tracers, 11(ab)
opimum sampling schedule, 99mTc dynamic SPECT, 223(ab)
parameter estimation, cardiac SPECT projection measurements, 222(ab)
PET, ligand receptor binding in, reference region approach to parametric imaging, 205(ab)
population-based tissue classification and segmentation of dynamic 123I thymidine PET with, 205(ab)
serotonin receptors, cWAY, 80(ab)

Kinetics, 99mTc-teboroxime, reperfused nonviable myocardium, 274

L
L-lysine, D-lysine for reduction of 111In-DTPAOC and 99mTc-DOTATOC renal uptake, 1297
L-111I CYTR, PET compared to histopathology, proliferative activity in brain tumors, protein synthesis rate, 1369
Labor stress, hyperventilation challenge to assess risk of natural childbirth, 99mTc-HMPAO brain SPECT in moyamoya disease, 1894
Laminin peptides, lung carcinoma imaging using radiolabeled peptide, YIGSR, 1940
Lanthanum-134, 99Ce and, generator system, lanthanum complexes as PET perfusion tracers based on, 183(ab)
Late redistribution, 99mTc imaging after rest injection, myocardial viability, 1073
Laterality, temporal lobe perfusion asymmetries, schizophrenia, 607
Left bundle branch block, effects on 15FDG and 18F ammonia cardiac PET, 170(ab)
septal perfusion and wall thickening in patients assessed by 99mTc-sestamibi gated tomography, SPECT, 545
septal perfusion, authors’ reply to letter, 2008(le)
septal perfusion, diagnostic accuracy of myocardial SPECT, 2008(le)
99mTc SPECT using dobutamine as stress agent, patients with normal coronary arteries, 723
Left ventricle ejection fraction, equilibrium gated radionuclide angiography, cardiotoxicity of chemotherapeutic agents, 702

Left ventricular dysfunction, prognostic value of thallium injection after stress-redistribution imaging, previous myocardial infarction and left ventricular dysfunction, 195
walk and bicycle exercise, vest system to evaluate responses in patients with congestive heart failure, 948
Left ventricular ejection fraction, ambulatory radionuclide imaging, effect of body position during ergometer exercise, 1669
Left ventricular function
adenoine-induced vasodilatation, 99mTc-tetrofosmin tomography vs. 2D-echo, myocardial perfusion, 1089
after dynamic cardiomyoplasty, radionuclide evaluation, 154(ab)
cardiotoxic chemotherapy with, children, 291(ab)
disease, coronary artery disease and, 15FDG PET assessment in, CAGB-related risk, 169(ab)
ejection fraction, serial reproducibility of gated sestamibi SPECT in, 28(ab)
gated 99mTc-tetrofosmin SPECT and cine MRI comparison, 438
mass in, ungated perfusion images versus MRI, 20(ab)
quantification with 99mTc and 99mTc-sestamibi myocardial gated SPECT, 958
simultaneous 99mTc and 99mTc blood-pool imaging, dual-isotope gated SPECT, myocardial perfusion, 432

systolic, measurement by 99mTc sestamibi SPECT, resting versus post-stress images, 14(ab)
99mTc-sestamibi SPECT in detection of resting left ventricular dysfunction, cavity-to-myocardium count ratio, 766
validation of quantitative defect size, rest 99mTc-sestamibi myocardial perfusion imaging, 1441
Left ventricular volume, myocardial assessment using ECG-gated SPECT, 99mTc-MIBI and 99mTc-tetrofosmin, 53

Leptomeningeval metastases, intrathecal 111IUDR administration, gliosarcoma, 386
Leukemia, alpha-particle emitter labeled anti-CD33 antibody, pharmacokinetics and dosimetry, 231(ab)
Leukocytes
labeling procedure, 11In and 99mTc HMPAO and, 180(ab)
99mTc exematatime, plasma effects on, 112(ab)
99mTc-labeled effects of treatment with leukocyte apheresis in ulcerative colitis, 159(ab)
evaluation of fever of unknown origin, 159(ab)
experimental pancreatitis, 52(ab)

Lewy body disease, cerebral metabolic differences in Parkinson’s and Alzheimer’s disease, emission computed tomography, "F-FDG, 797
Life support, procedure guideline for pediatric sedation, nuclear medicine studies, 1640
LIo, 11In-labeled human monoclonal antibody, IgM 16.88, infection imaging, 1054
Linearity test, 99F radioassay using the radionuclide dose calibrator, liquid scintillation, 724
Linearization correction, acetazolamide challenge test in chronic occlusive cerebrovascular disease, "Tc-ECD versus 99Tc-IMP SPECT, 1463

Lines from the president, 20N(1)

Liposomes
dual radiolabeled, infection imaging, rats, 112(ab)
stealth, imaging infection and inflammation, 268(ab)
"Tc, shelf stability, glutathione-HMPAO and, 179(ab)
"Tc-labeled, "Ga citrate versus, detection of hyperoxidized lung inflammation, rats, 185(ab)
use in scintigraphic evaluation, experimental colitis, rabbits, 72(ab)

Liquid scintillation, use of radionuclide dose calibrator, "Y, 723

Liver
asialo-glycoprotein measured by dynamic SPECT with "Tc GSA, 257(ab)
sequential changes of hepatocyte death and regeneration, 258(ab)
flow evaluation, cirrhotic patients, transjugular intrahepatic porto-systemic shunt, 51(ab)
hepatic visualization on "I scan, thyroid cancer, 1191
intrahepatic stones diagnosis of acute cholecystitis in, 259(ab)
recurrence, biliary retention in, "Tc DISIDA cholecsntigraphy use in, 259(ab)
metastases continuous infusion regimens, "I IUDR model, 119(ab)
FDG PET and intraoperative ultrasound
comparison, 137(ab)

FDG PET detection and differential diagnosis, 137(ab)
from pancreatic cancer, FDG PET diagnosis, 145(ab)

I"I anti-CEA mAb radioimmunothrapy for, 194(ab)
neoplasms, FDG PET assessment of, 137(ab)
"Tc colloid and portal scintigraphy. "I"I IMP with, chronic liver disease, 260(ab)
tumors, "Cu lipophilic complexes for PET imaging and targeted therapy, 141(ab)
uptake. "Tc DTPA-galactosyl human serum albumin, 255(ab)

Liver carcinoid metastasis, "I"I vasoactive intestinal peptide and "I"In-OCT receptor
images, differentiated diagnosis, hemangioma, 880

Liver clearance, "Tc-tetrofosmin and "Tc-
sestamibi kinetics, patients with and
without coronary artery disease, myocardial uptake, 428

Liver disease, chronic quantification with "Tc
PMT and dynamic scintigraphy, 253(ab)

Liver function, procedure guideline for
hepatobiliary scintigraphy, cholecystitis, 1654

Liver malignancies, intra-tumoral injection of "Y
microspheres, radiation safety, 1169(e)

Localization, imaging cerebral glutathione
content, "Tc-MESO-HMPAO, 1125

Lorazepam treatment for depression, benzodazepine
receptor occupancy during, "I"I iomazenil
SPECT, 282(ab)
cerebellar metabolic responses, gender
differences, 283(ab)

Low flow, quantitative measurement of skeletal
muscle using "O-H2O, PET, 314

Lung acute injury, "I"I labeled anti-intercellular
adhesion molecule-1, localization mechanism, bleomycin-induced rat
model, 191(ab)
aerosol ventilation imaging, factors
influencing, 37(ab)
cancer, attenuation corrected versus non-
attenuation-corrected FDG PET in thorax, 5(ab)
chemical and physical nature of technegas,
"Tc-pertechnetate, 1327
chronic obstructive airway disease, intelligent
radioaerosol delivery device, 299(ab)
inhaled radioaerosols, statistical parametric
mapping of mucociliary clearance of,
39(ab)
reduction surgery, patients with chronic lung
disease, lung scintigraphic patterns in,
38(ab)
scan, low probability, long-term outcome,
modified PIOPED criteria, 123(ab)
scintigraphic segmental anatomy of, creation of
digital phantom for Monte Carlo
simulation, 21(ab)
stripe sign, pulmonary scintigraphic
model, 299(ab)
"Tc sestamibi stress-induced uptake, sustained
versus transient, 140(ab)
thorascopic volume reduction surgery, "Xe
SPECT in assessment of, 299(ab)
V/Q scans, reverse mismatch demonstration by,
high f agonist therapy in, 38(ab)
ventilation, below closing volume, measurement with
SPECT, 296(ab)
virtual scintigraphy

segmental defect size underestimation in
pulmonary embolism by, 38(ab)
"I"I "I""I best view" of segmental anatomy in, 5(ab)

Lung cancer
bronchioloalveolar carcinoma, FDG PET
findings in, 79(ab)
dynamic PET scans, influx-constant for FDG
in, 244(ab)
FDG PET, accuracy, comparison with
CT, 79(ab)
non-small cell
coincidence imaging, cost-effectiveness of,
245(ab)
detection of metastases, FDG PET, 80(ab)
efficacy of FDG PET, 80(ab)
FDG PET and spiral CT staging, 244(ab)
mediastinal lymph node staging with FDG
PET, 79(ab)
staging with whole-body FDG PET, 245(ab)
primary
preoperative staging with FDG PET, 243(ab)
radiotherapy with "Tc MIBI or "Tl, 299(ab)
small and large lesions, FDG PET comparative
efficacy in, 79(ab)
small cell, response to chemotherapy,
dipyridamole-modulated "Tc sestamibi
scintigraphy, 240(ab)
small cell, CYPRa 21-1 as tumor
marker, 149(ab)
"Tc-MIBI compared with "Tl scintigraphy,
dual-isotope imaging, 1358
untreated, FDG kinetic rate constants
in, 244(ab)

Lung cancer xenograft, residualizing iodine
radiolabel for radioimmunotherapy,
monoclonal antibodies, dilactitol-
yramine, 391

Lung clearance, radiation pneumonitis, detection of
impaired permeability, "Tc-
DTPA, 966

Lung perfusion, pulmonary vascular occlusion in
sickle cell disease, scintigraphic
evidence, 1151

Lung scintigraphy DTPA aerosol in V/Q scans for PE
diagnosis, 1781
model of segmental anatomy, Monte Carlo
simulation and PE diagnosis, 1987

Lung shunting, arteriovenous shunts in patients with
hepatic cancer, factors, 1201

Lung ventilation DTPA aerosol in V/Q scans, diagnosing
PE, 1781
use of pertechnegas as a ventilation agent, x-ray
photoelectron spectroscopy, 163

Lupus erythematosus cerebral blood flow changes in, acetazolamide
effects, 130(ab)
evaluation of brain in, FDG PET, 274(ab)

Lyman disease, brain SPECT in, 278(ab)

Lyman neuroborreliosis, brain perfusion SPECT,
HMPAO, 1120

Lymph node mediastinal, staging with FDG PET, non-small
cell lung cancer, 79(ab)
tumor-infiltrating, detection with 2- and 3D
PET, 77(ab)

Lymphadenopathy, sarcoidosis, "Tc-MDP
uptake, hilar nodes, 262

Lymphedema, axillary lymph node uptake of
radiotracers, lymphoscintigraphy of
lower limbs, 522

Lymphocytes, "Tc HMPAO labeled, decreased
chemotaxis, apoptosis relations, 270(ab)

Lymphoma CNS, differentiation from benign lesions, AIDS
patients, 115(ab)
evaluation of therapy response in children with
untreated malignancy, "Tl and "Tc-
sestamibi, 243

Hodgkin's
gallium scan in staging and follow
up, 115(ab)
somatostatin receptor scintigraphy for staging of,
102(ab)

Hodgkin's and non-Hodgkin's, novel SSTR
binding peptide "Tc P829, 236(ab)
malignant
PET studies of FDG metabolism in, 152(ab)
residual or recurrent, FDG PET, 153(ab)
"Tc antigranulocyte antibody in bone
marrow scintigraphy for, 10(ab)
non-Hodgkin's
gallium scan in staging and follow
up, 115(ab)
"I I L2 (Anti-CD22) radioimmunotherapy of,
59(ab)
kinecic rate constants of FDG PET, 153(ab)
quantification of "Ga avidity in, 238(ab)
primary adrenal disease, "Ga scintigraphy and
correlating imaging, 1770
tumor progression during, "Ga scintigraphy for
diagnosis, 115(ab)
whole-body FDG-PET imaging
cost-effective method for staging and
restaging Hodgkin's disease, 343
"Y anti-CD20 monoclonal antibody
dosimetry, 251(ab)

Lymphoscintigraphy gammates, detection probe, sentinel node in
melanoma, "Tc aggregated
albumin, 362
intraoperative, sentinel lymph node melanoma
identification, 235(ab)
preoperative, sentinel lymph node melanoma
identification, 235(ab)
primary lymphedema
bilaterial axillary lymph node uptake, lower
extremity, 522
sentinel node identification with "Tc-colloidal
albumin in breast cancer, gamma
probe, 366
sentinel node imaging via receptor-binding
radiopharmaceutical, 530
"Tc sulfur colloid
gamma detecting probe and, melanoma
sentinel lymph node mapping, 33(ab)
gamma probe and, breast cancer sentinel node
detection, 34(ab)
"Tc TCK-17 for, particle size
evaluation, 112(ab)

Lysine, FMB dSFV coinjection, kidney uptake
and, 232(ab)

M

MAB BR96, "I"I labeled, whole-blood
immunosorption, enhanced
radioimmunotargeting, rats, 895
Mabs, pharmacokinetics and PET imaging.
"Br, 395

Magnetic resonance imaging (MRI)
assessment of right and left ventricular volumes and
ejection fractions, tomographic gated
blood-pool scintigraphy, 942
coregistration to ictal and interictal SPECT,
seizure foci localization by.
children, 12(ab)
crossed-cerebeller diabetes in cerebral infarction, ""Tc-HMPAO SPECT, 14
evaluating bone marrow metastases of neuroblastoma, 13(ab)
functional recovery, ""Tc tetrofosmin myocardial viability assessment, 164(ab)
gated ""Tc-tetrofosmin SPECT comparison to assess left ventricular contraction, 438
multimodality visualization
combination of complementary data for diagnostic information, brain SPECT, 624
PET, temporal lobe volume measurements, hypometabolism and post-surgical outcome, 22(ab)
""P, myocardial metabolism alterations detection, myocardial infarction patients and, 174(ab)
tagging, evaluation of function recovery of PET match areas after myocardial infarction, 4(ab)
Malignant disease, practice guideline for gullain scintigraphy, 990
Mallory Weiss syndrome, complication of ""T therapy for metastatic thyroid cancer, 18311(ab)
Management Analysis Company, response to JNM article, 17N(3)
Maple reactor, plans approved in Canada, 30N(6)
Marijuana, cannabinoid receptors brain, SPECT imaging, 116(ab)
radiolabeled ligands for imaging of, 77(ab)
evaluating, predicting myelotoxicity from RIT, semiquantitative score, 1749
Marrowscintigraphy, hyperostosis frontalis interna, activity due to marrow not infection, 1283
Mass effects, injected ligand, two-scan graphical method for binding potential, 93(ab)
Mathematical modeling, radioimmunodetection and radioimmunotherapy with monoclonal antibodies, radiation dosimetry, 731
MDR reversing agents, ""Tc-sestamibi and H-daunoumycin comparisons, myocardial cellular retention times, cardiac MDR phenotype, 1674
Mean square error, 3D registration algorithm based on, performance evaluation, 204(ab)
Medical equipment donation program, nuclear medicine in Vietnam, 17N(1)
Medicare, documentation guidelines for evaluation and management services, 25N(11)
Medullary thyroid carcinoma, ""Tc-sestamibi, medullary thyroid carcinoma, computed tomography, bone scan, 227
Melanoma gamma probe detection of the sentinel node, detection of, ""Tc-nanocolloid, 362
malignant S100 IRMA as new tumor marker for, 148(ab)
whole-body FDG PET staging of, 331(ab), 90(ab)
metastatic, whole-body FDG PET, cost-effectiveness of, 90(ab)
sentinel lymph node theory, 235(ab)
identification with preoperative lymphoscintigraphy, 235(ab)
identification with intraoperative lymphoscintigraphy, 235(ab)
""Tc complexes for imaging of, 86(ab)
Malignoma scintigraphy, pharmacokinetics of ""Tc-IMBA, radioidinated benzamides for detection of metastases, 127
Meningioma FDG-PET metabolic grading of, improvement of diagnostic accuracy with overnight fasting, 26
radiation necrosis and FDG hypermetabolism distinguishing brain tumor recurrence, PET, 1027
Mental performance, frontal lobe perfusion effects, after aneurysm surgery, 215(ab)
Mercury attenuator, characteristics of a ""Tcs irradiator to simulate internal radionuclide patterns, biological dosimetry, 727
Mesothelioma, malignant, PET, 244(ab)
Metastatobenzynuganidinie, ""Te, uptake mechanisms in isolated rat heart, 30(ab)
Metabolic bone disease, fluoride kinetics of skeleton measured with ""F-fluoride PET, 1970
Metabolism hydrophobic conversion of ""Te-ECDF, in vitro studies, 1731
trapping of radioiodinated PHIPA 3-10, rat myocardium, 1864
Metabolism of benzynuganidinie (MBIG) assessment of cardiac sympathetic neuropathy, abnormalities prevented by ARI therapy after STZ injection, 1677
evaluating bone marrow metastasis of neuroblastoma with scintigraphy and MRI, 1389
scintigraphy, modulation of myocardial sympathetic activity, 64(ab)
specificity of, neural crest tumors in children, 1352
transcapillary transport mechanism, in isolated rat heart, 175(ab)
Metalloflullerenes, endohedral, neutron-activatable, as potential tracers, 194(ab)
Metastasis hepatic visualization on ""Te whole-body scan, thyroid carcinoma, 1191
lung cancer imaging using synthetic laminin derivative radioiodinated peptide, YIGSR, 1940
Metastatic carcinoma, pain palliation with ""Sr-chloride, autopsy of a cadaver for biodistribution studies, 380
Metastatic thyroid cancer, ""Te-MIBI scintigraphy evaluation, 352
Methionine compared with FDG-FDG uptake in gliomas, PET-guided stereotactic biopsy, 1459
FDG-PET scanning and the HIV-positive patient, cerebral imaging, 1575
Method, importance of methods section in scientific papers, 37(ab)
Methotrexate neurotoxicity, brain perfusion in children after treatment of acute lymphoblastic leukemia, SPECT, 82
methyl""C-L-methionine, amino acid uptake in gliomas, PET versus 3-11 iodos-[alpha]-methyltyrosine SPECT, 517
Methyl-quinuliddinylobenzaldehyde (MQNB), down-regulation of cardiac macarinsic receptors, DFP induced, 1430
-Methyl trytophan, PET and, serotonin synthesis rate images using, 195(ab)
Microangiopathy, cerebral, PET/SPECT/MRI vs. neurorpsychology, 275(ab)
Microautoradiography, distribution of ""Te-labeled microspheres in rat lungs, cellular dosimetry, 650
Microdosimetry, dosimetric framework for alpha-particle emitters, MIRD, 1923
MicroPET I, very high resolution PET scanner, small animal imaging, 7(ab)
Microsphere model, 1-IOMP SPECT, comparison of methods to measure regional cerebral blood flow, microsphere model, two-compartmental model, 597
Microspheres flow versus uptake comparisons in canine model of myocardial ischemia, 99(ab) and ""Te perfusion tracers, 1847
Fontan or Glenn shunt procedure, lung perfusion scintigraphy after, children with congenital heart disease, 25(ab)
Middle ear ventilation, scintigraphy in evaluation of eustachian tube function, 66
Migraine, central response and, sumatriptan and placebo effects, PET, 281(ab)
Milrinone, hypoxic vasoconstrictive response, reversed ventilation-perfusion mismatch in pediatric patient with DCM, 1681
MIRD method, internal dose estimation using TLD method, continuous "O inhalation, 1603
Mitochondria Cu-ATSM as new hypoxia imaging agent, 1155
Na-K ATP synthesis, ""Te uptake and, 182(ab)
Modeling, fatty acid uptake and myocardial blood flow, exponential relationship of, 42(ab)
Modeling software, requirements and implementation of kinetic modeling tool, coupled fitting, 1818
Molecular nuclear medicine, theme of SNM 1997 meeting, impact of information technology on physicians, scientists, and the public, 15N(8)
Molybdenum-99, shortage due to strike at NRU reactor, 18N(8)
Monoamine oxidase B, SPECT exploration of, 181(ab)
Monoamine oxidase inhibitors, Prozac and, 284(ab)
Monoclonal antibodies anti-CEA medullary thyroid cancer patients, 264(ab) radioimmunotherapy of medullary thyroid cancer, 267(ab)
anti-CEA, radioimmunotherapy of colorectal cancer, 26(ab) anti-TAC dSfV, radiolabeling and biodistribution, ""Te, athymic mice, 294
delivery of radiation with, tumor blood circulation, 59(ab)
comparative PET imaging of experimental tumors, Br-38S1, F-FDB, Sr-C, Met, 1029
directed against human epithelial receptors, 224(ab)
factors that influence tumor dosimetry, radioimmunotherapy of CEA-expressing cancers, 409
human, for infection, pilot study, 26(ab)
imaging prostate cancer with ""Te-CYT-351, prostate-specific antigen, 675
""I Nofetumomab, stability of, scale-up radiodimidation, 179(ab)
""I-labeled MN-14(ab) anti-CEA, advanced
421

The Journal of Nuclear Medicine

medullary carcinoma, 47(ab)
internalization of avidin, streptavidin, tumor pretargeting, 1378
patient-specific dosimetry
radioimmunotherapy, "In-IC99, "Y-
CC99, 512
radioactively labeled anti-CEA, reparation after surgery
for medullary thyroid carcinoma, 232(ab)
radioactively labeled therapies for treatment of cancer,
peptide therapeutics, 19N(10)
radioactively labeled, monovalent and multivalent single
chain, 231(ab)
use of residuaizing radioactively labeled dilactitol-
tyramine compared to "I-labeled RS11, xenograft of non-small-cell cancer of
lung, 391
"Tc anti-SSEA rapid imaging,
infeciton/inflammation and, 25(ab)
"Y anti-CD20 labeled, non-Hodgkin's
lymphoma, 251(ab)
Monoclonal antibody priming, infection imaging
with "Tc-DTPA, pretargeting
protocols, 901
Monoclonal antibody therapy, targeting of
HER2/new oncoprotein on ovarian
malignancy, lead-212-DOTA-AE1, 1944
Monte Carlo calculations, patient-specific
dosimetry, SPECT and three-dimensional
discrete Fourier transform
convolution, 308
Monte Carlo simulation
compton scatter data, determination of patient
boundaries, 135(ab)
creation of digital phantom for, scintigraphic
segmental anatomy of lungs, 21(ab)
"F-FMISO radiation dosimetry in imaging studies,
PET, 1631
point source comparison, dose per unit
cumulated activity, radioactive
materials, 228(ab)
scintigraphic segmental anatomy of lungs, PE
diagnosis, 1987
transmission data acquisition, large field-of-
view dual-headed SPECT
system, 220(ab)
Morphine-augmented cholecistography,
effects on gallbladder nonvisualization, acute
cholecystitis, 260(ab)
for diagnosis of acute cholecystitis,
cholecystokinin, 647(ab)
increased gallbladder visualization in patients
pretreated with cholecystokinin, 644
Motion artifacts, correction algorithms for
myocardial perfusion imaging, "TI
SPECT, 765
Motion correction
head motion artifacts, SPECT, 3D
reconstruction and 6 degree of freedom
head tracker, 126(ab)
isotype type and, myocardial SPECT perfusion
scans, 154(ab)
respiration-compensated attenuation correction,
automated 4D segmentation of gated
transmission images, cardiac
PET, 203(ab)
respiratory compensation, cardiac PET, 114(ab)
Motor activation, changes in dopamine receptor
occupancy, 105(ab)
Movement disorders, 18F FDG imaging in
in, 274(ab)
Moyamoya disease, hypertention challenge to
assess risk of natural childbirth, 99mTe-
HMPAO brain SPECT, 1894
MPTP, SPECT imaging of dopamine transporter
sites, model of Parkinsonism, "I-IACFT,
"C-CFT, 144
MRI, see Magnetic resonance imaging (MRI)
Mu opioid receptor, brain
binding in alcohol dependence, PET
measurement, 34(ab)
binding in chronic cocaine users, measurement
during monitored abstinence, 35(ab)
uregulation of M2, Z-(R)-IQNP for SPECT study of, 66(ab)
Muscarinic acetylcholine receptor, down-
regulation induced by DFP, LV
concentration changes, PET, 1430
Muscarinic cholinergic ligand, competition
studies, 285(ab)
Muscarinic receptors
activity, "F PET evaluation of, 66(ab)
cerebral, new radioligand for
visualization, 66(ab)
M2, Z-(R)-IQNP for SPECT study of, 66(ab)
Muscular blood flow
"O-water PET assessment, peripheral vascular
disease, 93
quantitative measurement of skeletal muscle,
"O-water, 314
Musculoskeletal sarcoma, comparison of "Tc-
MIBI and "Tc-tetrofosmin uptake,
study, 662
Myelotoxicity
dose-response relationship, RIT, 1753(ab)
prediction of, using radiation doses to marrow
from body, blood, marrow, RIT, "I-Lym-
1, 1374
use of semi-quantitative marrow image scores to
predict, RIT, 1749
Myocardial blood flow
effects of SF adrenergic receptor blockade,
vasodilatory capacity and myocardial
flow reserve, PET, 442
relationship with DMPPII uptake,
prognosis, 1424
"Rb dynamic PET data to compare at rest and
stress, physiological models, 660
Myocardial fatty acid metabolism, relationship
between blood flow and glucose uptake in
ischemic border zone, imaging
plate, 1515
Myocardial flow reserve, effects of SF adrenergic
receptor blockade, myocardial blood
flow, PET, 442
Myocardial gated SPECT, quantification of left
ventricular function, "TI and "Tc-sestamibi, 958
Myocardial glucose metabolism, relationship
between blood flow and glucose uptake in
ischemic border zone, fatty acid
metabolism, 1515
Myocardial hyperperfusion, BMIPP and flow
tracers, 1171(ab)
Myocardial imaging agents, potassium and
thallium uptake in dogs, capillary
permeability, 264
Myocardial infarction
acute
24-h delay scan, 62(ab)
"C acetate PET assessment of blood flow and
oxygen consumption, 54(ab)
comparative imaging studies, ex vivo imaging
in rats, 124(ab)
reperfusion therapy for, "I MIBG imaging
after, 111(ab)
reverse redistribution and microvascular
perfusion relations, 131(ab)
chronic phase, residual stenosis of infarct-
related artery, 131(ab)
discordant perfusion and function after, fatty
acid metabolism effects, 110(ab)
discordant perfusion and function, pre-infarction
angioplasty and recovery, 110(ab)
experimental, "Tc glutaric acid as marker of
necrosis, 98(ab)
function recovery of PET match areas after,
evaluation by MRI tagging, 4(ab)
nontransmural, myocardial metabolism
alterations in, "P MRI
assessment, 174(ab)
PET perfusion and vasodilator function after
angiology, 77(ab)
prognostic value of thallium reinfusion after
stress-redistribution imaging, left
ventricular dysfunction, 195
regional noninvasive resource use patterns
after, 122(ab)
rest-redistribution "TI and rest "Tc-sestamibi
SPECT, stable coronary artery disease
and ventricular dysfunction, 419
right ventricular, prognostic value of
radiouclide measurements, 109(ab)
serial assessment of sympathetic reinnervation
post-myocardial infarction. "111-
MBG, 457
sublingual nitroglycerin in, gated "111 Tc MIBI
SPECT before and after, 140(ab)
"111 Tc-sestamibi SPECT and pathologic
correlation, thrombolytic therapy, 1837
validation of quantitative defect size, rest "111-
Tc-sestamibi perfusion SPECT, 1441
Myocardial ischemia
coronary flow reserve and, remote region,
perfusion scintigraphy use in, 64(ab)
fatty acid metabolic imaging for the diagnosis
of coronary artery disease, "111 Tc-sestamibi and
glucose loading, 175
glucose uptake response, 2-D and 3-D PET
assessment, 169(ab)
histological change, "111 F FDG PET myocardial
perfusion and metabolism, 169(ab)
intermediate probability of, stress-induced ST
elevation in Q-wave leads and, 121(ab)
"111 Tc-sestamibi kinetics, myocardial viability
determination and, 175(ab)
Myocardial metabolism, diagnostic imaging for
coronary artery disease, "111 Tc-sestamibi and
glucose loading, 175
Myocardial oxygen consumption, compartment model for measuring, [1-14C]acetate
PET, 459
Myocardial perfusion
abnormalities in patients with left bundle branch
block, "111 Tc-sestamibi gated tomography,
wall thickening, 545
adenosine-induced vasodilation, "111 Tc-
tetrofosmin tomography vs. 2D-
echo, 1089
combined x-ray CT and SPECT system, image
coregistration, 1535
evaluation with "111 Tc-sestamibi, comparison of
SPECT and echotomography, 754
function imaging at rest
simultaneous "111 Tl and "111 Tc blood pool dual-
isoimage imaging, gated SPECT, 432
LV function and thallium uptake in chronic
CAD, one-year effect of revascularization, 1684
motion-correction algorithms, "111 Tl SPECT, 785
noninvasive detection of coronary collaterals,
dipyridamole stress and "99m Tc, PET, 39
"99m Tc-MIBI SPECT, diagnostic accuracy with
right lateral positioning, arteriography
comparisons, 1510
validation of quantitative defect size, rest "111-
Tc-sestamibi SPECT imaging, 1441
Myocardial perfusion imaging
analysis of heart wall motion, prone imaging and,
156(ab)
arbitrime, routine stress testing, 73(ab)
artifacts and quality control, 154(ab)
attenuation correction, scanning line source,
lesion contrast effects, 213(ab)
differentiating fixed effects from attenuation
artifacts in, gated cine-images for,
139(ab)
dobutamine, low peak heart rate effects on
accuracy of, 72(ab)
dual isotope, iterative reconstruction, cross-
contamination, 88(ab)
dyspnea during, bronchial resistance and, 73(ab)
emergent, acute chest pain patients, prediction
of cardiac events, 140(ab)
exercise, automatic quantitative defect,
comparison with visual analysis, 53(ab)
external counterpulsation in, coronary artery
disease patients and, 167(ab)
FDG/sestamibi, comparison of quantitative and
visual assessment of, 54(ab)
first-pass extraction fraction, "111 Tc-
N-NOET, 65(ab)
first-pass radionuclide angiography, thallium
and sestamibi gated SPECT, LVEF
correlations by, 27(ab)
high exercise tolerance, women, 155(ab)
lateral wall perfusion defects, attenuation
correction effects on assessment, 84(ab)
lesion size and count level effects, estimation of
ejection fraction and, 221(ab)
measurement of wall thickening, multiple time-
point fitting, 127(ab)
metabolic studies and, quantitative analysis of
nuclear M-mode images, 126(ab)
metabolism and, Nuclear M-Mode, 4(ab)
MRI versus, left ventricular mass
detection, 20(ab)
"O water PET, computed by factor analysis,
differentiation of viable from infarcted
myocardium by, 173(ab)
polar maps method, summed stress score and,
comparison, 52(ab)
potassium-38 distribution, comparison with "22-
Na, 85(ab)
quantitation of defect size, attenuation
compensation, 53(ab)
scanning line source attenuation correction,
function of emission isoimage, 84(ab)
serial stress radionuclide, 140(ab)
SPECT
mean and variability of myocardium
in, 168(ab)
rest "123Tl stress "111 Tc sestamibi dual isoimage,
prognostic value in diabetic
patients, 40(ab)
role of history of coronary artery disease and
patient sex in cardiac risk and
catheterization referral, 164(ab)
stress only attenuation correction, cost savings,
medium probability for CAD, 84(ab)
stress SPECT, coronary angiography versus,
utilization rate of revascularization, 166(ab)
"111 Tc Q12 and "111 Tc sestamibi comparison,
plasma clearance, 99(ab)
"111 Tc Q4, washout in human hearts, 165(ab)
"111 Tc sestamibi artifacts related to intestinal activity, 75(ab)
gallbladder nonvisualization during, 74(ab)
pediatric patients, 290(ab)
severe LV dysfunction, nitrate effects on
perfusion and function, 75(ab)
"99m Tc, PC web browser, 53(ab)
"99m Tc SPECT versus "99m Tc PET,
attenuation artifacts and, obesity
and, 166(ab)
three-headed SPECT system, transmission data
acquisition apparatus for, 219(ab)
tomographic, predicting coronary artery disease
index by, 40(ab)
tracer uptake, exponential model for, 209(ab)
triage tool, evaluation of chest pain, 131(ab)
ultra-fast gated SPECT, 3-head gamma camera
and cardiacfocal collimators, 28(ab)
upright cardiac SPECT imaging, 74(ab)
uptake of "111 Tc tetrofosmin, impact of stress
protocol on, 73(ab)
Myocardial reinnervation, serial assessment of
sympathetic changes post-myocardial
infarction, "111 Tc-MIBG, 457
Myocardial scintigraphy, "111 Tc SPECT using
dobutamine as stress agent in patients
with left bundle branch block and normal
coronary arteries, 424
Myocardial SPECT, glucose-loading "111-
Tc imaging, hibernating myocardium, 573
Myocardial uptake, "99m Tc-tetrofosmin and "123-
tc-sestamibi kinetics, normal subjects and
patients with coronary artery disease,
liver clearance, 428
Myocardial viability
"99m Tc SPECT versus PET, 582
combined SPECT and PET assessment of, effect
on clinical outcome in coronary artery
disease, 742
late redistribution "111 Tc imaging after rest
injection, 1073
Myocardial wall thickening, hybrid index for
measurement, gated PET, SPECT, 324
Myocardium
coronarily dysfunctional segments, dobutamine
echocardiography and SPECT
comparison in, 62(ab)
diabetes mellitus patients, predictive accuracy
of PET flow/"111 F FDG mismatch, 55(ab)
dysfunctional, "111 Tc-sestamibi gated SPECT in,
96(ab)
flow uptake comparisons of "111 Tl with
"111 Tc perfusion tracers, canine
heart, 1847
functional analysis, cardiovascular PET use in,
55(ab)
hibernating, PET use in transplant
evaluation, 55(ab)
hyperperfused, wall motion, enhanced gated
perfusion SPECT in, 156(ab)
"111 In-AMA scintigraphy, assessment of cardiac
damage in systemic sclerosis, 1759
influence of blood substrate levels, kinetics of
"111 Tc-MIBI, 1079
LV dysfunction, mental stress-induced, regional
cerebral activation patterns
during, 86(ab)
metabolism, radiolabeled fatty acids as potential
marker for, 124(ab)
organ ratios and, relative myocardial/organ
ratios of "111 Tc BMIPP and "123-
I BMIPP, 157(ab)
perfusion, increased right ventricular activity,
severe proximal left coronary artery
disease and, 122(ab)
reperfused nonviable cardiac tissue, kinetics of
"22 Na, 127(ab)
stunned, early and late "111 Tc tetrofosmin images
as marker, recent myocardial infarction
patients, 162(ab)
stunning, detection with "111 Tl and "123-
I IPPA SPECT, 110(ab)
"99m Tc Q12 and "111 Tc sestamibi comparison,
plasma clearance, 99(ab)
transcapillary transport of MBG, in
isolated rat heart, 175(ab)
viability
assessment by different imaging techniques,
cost effectiveness, Italy, 163(ab)
available imaging techniques, 63(ab)
detection by hypoxia a avid imaging agents "111-
Tc HLL91, 173(ab)
detection in myocardial infarction patients,
comparison of methods, 63(ab)
differentiation from infarcted, "O water PET
computed by factor analysis in, 173(ab)
FDG PET and FDG SPECT for,
intraindividual comparison, 169(ab)
"N FDG SPECT, acipimox in promotion of glucose uptake, 140(ab)
functional outcome after revascularization, FDG SPECT prediction, 130(ab)
functional recovery after revascularization, "I BMIPP vs "Tc-tetrofosmin versus "Tc SPECT imaging, 167(ab)
in severe left ventricular dysfunction, "Tc tetrofosmin SPECT assessment of, 97(ab)
measurement of wall thickening, gated perfusion myocardial studies, 127(ab)
"N ammonia/"F FDG PET, 55(ab)
ontransmissive attenuation and scatter corrected "Tc MIBI SPECT versus "F FDG PET, 170(ab)
pre-infarction angina and recovery effects, 110(ab)
prediction after bypass surgery, "Tc MIBI SPECT use in, 155(ab)
rest-redistribution "Tc Tc imaging, 63(ab)
thatium and radioiodinated branched fatty acid uptake in, 97(ab)
"Tc Tc-redistribution-rejection images versus "I1 9MPA SPECT, 162(ab)
"Tc reination imaging and, coronary angiography in patients with chronic ischemic left ventricular dysfunction, 165(ab)
"Tc-sestamibi wall thickening compared to FDG PET, 96(ab)
Myocardium redistribution, "Tc-N-NOET interaction with blood elements, perfusion imaging agent, 138
Myosin heavy chain, fragments, quantification by bispecific immunoassay, 148(ab)

N
Nalmefene, longer occupancy of opioid receptors, comparison to naloxone, dual-detector system measurements, 1726
Naloxone, longer occupancy of opioid receptors by nalmefene, dual-detector system measurement, 1726
Naltrexone, cerebral blood flow changes induced by, alcohol dependent patients, 108(ab)
Nasopharyngeal carcinoma
CYFRA 21-1 as tumor marker in, 149(ab)
therapy response, "Tc Tc and "Tc-sestamibi SPECT, 1009
National Atomic Museum, new exhibit unveiled, 34N(11)
National Institutes of Health, Nuclear Medicine Department, 30 years overview, 15N(3)
Natural pixel, generalized, truncated fan beam transmission data reconstruction, 101(ab)
NCA fluorination, synthesis of "F fluoro-L-dopa, 43(ab)
Neck neoplasms, prediction of survival with "F FDG PET, tumor grading, 1907
NEMA protocol, performance evaluation of whole-body PET scanner, 1614
Neoadjuvant chemotherapy, "Tc-MIBI scintigraphy, monitoring breast cancer treatment, 1546
Neonatal hepatitis syndrome, hepatobiliary scanning, "Tc-DISDA, extrahepatic biliary atresia, 1279
Neoplasm chemotherapy, evaluation of retroperitoneal metastases before and after treatment of testicular cancer, FDG-PET, 99
Neoplasms
initial changes in "F FDG uptake during radiotherapy, glucose metabolism, 1384
pancreatic imaging, use of "Tc-acetate as tracer, PET, 1305
staging recurrent metastatic colorectal carcinoma, "F FDG-PET, 1196
new proto-oncogene, radioimmunotherapy targeting using lead-212-DOTA-AE1, ovarian tumor, HER2, 1944
Neural crest tumors, specificity of MIBG, childhood tumors, 1352
Neural networks
classification of dementia, 3D stereotactic surface projection PET data, 272(ab)
computer-aided interpretation of myocardial SPECT perfusion images, detection of CAD, 1870
probabilistic, diagnostic accuracy of brain SPECT, 13(ab)
Neuroblastoma
evaluating bone marrow metastasis with "I-MIBG scintigraphy, 1389
"I-FIBG evaluation of an MIBG analog, neuroendocrine tumors, 330
pediatric, "I MIBG radionuclide therapy, dosimetry for, 100(ab)
Neuroendocrine tumors
somatostatin receptor scintigraphy, gastroenteropancreatic tumors, 853
"I-FIBG evaluation of an MIBG analog, neuroblastoma, 330
Neuroimaging, SPECT analysis with statistical parametric mapping, "Tc-HMPAO and "Tc-ECID, 1721
Neuroleptic treatment, "Tc-HMPAO SPECT, regional cerebral blood flow, positive and negative syndrome scale of schizophrenia, 181
Neuronal viability, mismatches in hydrocephalus, 279(ab)
Neuropediatrics, "Tc-ECD as radiopharmaceutical for children, cerebral blood flow, 1115
Neurophysiology, lateralization of temporal lobe blood flow, perfusion asymmetries in schizophrenia, 607
Neuropsychology
D2-like dopamine receptor density, Tourette syndrome, 1243
PET/SPECT/MRI vs, cerebral microangiopathy, 275(ab)
Neurotransmitters, release measurement, receptor-binding tracers, bolus or infusion delivery, 11(ab)
Neuropil quantitation, marginated, plasma tumor percent factor during cardiopulmonary bypass, 270(ab)
Nicotinic acetylcholine receptors
analogs of epibatidine for studies of, 65(ab)
cholinesterase inhibitor binding to, PET comparison, 289(ab)
"F-FPH for PET imaging, 1260
neuronal, enantiomeric ligand for studies of, 65(ab)
Nicotinic receptors, brain imaging with "F-FPH, epibatidine analog, PET, 1737
Nicotinyl hydrazine derivative, immunoglobulin G, "Tc labeled to, 157(ab)
Nitric oxide
inducible, upregulation in the experimental autoimmune encephalomyelitis model, 116(ab)
synthes upregulation, detection and comparison using "F FEITU, cardiac transplant model, 175(ab)
Nitric oxide synthase, in vivo evaluation and PET study, "C-MTICU, 1273
NMDA receptor, imaging, "F labeled memantine derivative for, 65(ab)
No-carrier-added iodine-123-MIBG, effect of specific activity on cardiac uptake, deiodination, 447
Non-Hodgkin's lymphoma, whole-body FDG-PET imaging, method for staging and restaging, 343
Non-small-cell lung carcinoma, two-step immunoscintigraphy using a bispecific antibody, carcino-embryonic antigen, 507
Non-small-cell lung carcinoma, decision tree sensitivity analysis, FDG-PET, 1173(ab)
Nontoxic goiter, "T1 therapy for volume reduction, 372
Non-uniform activity, distribution, direct internal dosimetry approach for, MIRD schema, 106(ab)
Nontiviable, reperfused myocardium, kinetics of "Tc-teboroxime, 274
Norepinephrine transporter, cardiac, distribution in diabetic rats, MIBG uptake and, 181(ab)
Normal cerebral blood flow, regional stability measured by "Tc-HMPAO SPECT, replicability of resting state, activation states, 6
Normal uptake, "Tc-labeled monoclonal AGAb, bone marrow scintigraphy, 1755
NRC, see Nuclear Regulatory Commission
Nuclear M-Mode
new gated myocardial perfusion/metabolism studies, 4(ab)
quantitative analysis, cardiac gated perfusion/metabolic studies, 126(ab)
Nuclear medicine
data processing methods, community-wide evaluation, 215(ab)
ensuring the future, Society of Nuclear Medicine, 17N(4)
importance of existence and public perception, 19(ab)
neuron-activatable endohedral metallofullerenes, as potential tracers, 194(ab)
Nuclear medicine studies, increased demand, 34N(11)
Nuclear medicine technologists, plan for future, 24N(5)
Nuclear pharmacy, in large hospital, radiation exposure trends in, 178(ab)
Nuclear Regulatory Commission(NRC) government relations update, 23N(3)
medical program reform, 40N(5)
reform efforts guided by steering group and working group, 28N(10)
regulation testimony submitted by nuclear medicine groups, 24N(1)
Nuclear therapy, radiation dosimetry in, automated scheme for, thyroid cancer, bone pain, and radioimmunotherapy, 225(ab)
Nucleotide and amino acid uptake, effect of hyperglycemia on tumor cell uptake of
Obesity
bone scans, “hot skull” sign in, disparate soft tissue attenuation and, 29(ab)
myocardial perfusion imaging and, "Tc"/P-PET SPECT versus "Rb PET, SPECT
attenuation artifacts and. 166(ab)

Oblique views routine thyroid imaging, thyrotoxicosis. 150(ab)

Obstipation, chronic, scintigraphic defecography in evaluation of rectal emptying.
children. 72(ab)

Obstructive sleep apnea syndrome, assessment of cardiac sympathetic function, "I-
MBI imaging. 567

Occtreotide
potential radiopharmaceuticals, targeting to somatostatin receptors and, 190(ab)
somatostatin receptors in canine insulomas. 1036
SPECT imaging
ectopic secreting carcinoid characterization with "In-DTPA-D-Phe-nmctreotide, Cushing syndrome, 711
"Y-DOTA-Tyr" measured by "Y and PET. 60(ab)

Ocular melanoma, "I-IDAB scintigraphy.
SPECT. 870

Office of Management and Budget, limited clearance for quality management rule, 28N(6)

Oligodeoxynucleotide
antisense, fluorinated nucleosides for, PET. 134(ab)
breast cancer oncogene antisense, labelling with "Tc, 87(ab)

Oligodeoxynucleoside, radiolabeled, methylphosphonate-neoglycopeptide conjugates, tissue distribution and metabolism of, 181(ab)

Orbit, ectopic lacrimal gland, differential diagnosis, "Tc-pertechnetate, SPECT. 1498

Ordered subsets expectation maximization (OSEM)
image reconstruction myocardial SPECT, 57(ab) phantom evaluation. 57(ab)

Orificial apraxia, anterior operculum syndrome, SPECT localization, isolated cortical atrophy. 1122

Osseous metastases, markers of bone resorption following "Sr-chloride therapy, pyridinium cross-link. 1175

Osteitis, chronic, FDG PET and immunoscintigraphy detection of, 132(ab)

Osteogenic sarcoma, "Tc sestamibi uptake, multidrug resistance. 241(ab)

Osteomyelitis
acute and chronic, "F scintigraphy in. 120(ab)
FDG PET in diagnosis. 119(ab)
infec tions of locomotor system, evaluation with "In-IgG scintigraphy, diabetic foot, 1300 foot, pedal, dual-radionuclide bone scintigraphy in, 159(ab)
soft tissue infection with, "Tc, 132(ab)
"Tc MDP and "Ga imaging. comparison of dual radiolabeled liposomes, 182(ab)
"Tc P483H diagnosis. 132(ab)
"Tc-T1PS1 scintigraphy for detection of, "In-
vertebral
dual-head SPECT and MRI assessment, 153(ab)
photopenia in, "Tc anti-granulocyte antibody use in, 132(ab)
Osteonecrosis, dysbaric, bone scanning in recompression therapy study in. 29(ab)

Osteosarcoma
extremity, quantitative "Tc scintigraphy and MRI as predictors, 293(ab)
preoperative chemotherapy response, monitoring with FDG PET, 127(ab)
Outcomes assessment, SPECT technology, 33N(9)
Output efficiency
assessment of pediatric hydrourephrosis, 1483
hydrophrosis in pediatric patient, 1487(ed)

Ovarian cancer
intraperitoneally administered "Lu CC49, radiation absorbed dose estimates, 226(ab)
rectosigmoid fistula demonstrated by dynamic scintigraphic peritoneography, 1636
treatment with "I-labeled anti-CEA monoclonal antibody, radioimmunotherapy, 257
Ovarian tumor, radioimmunotherapy targeting of HER2/new oncogene, lead-212-
DOTA-AE1. 1944

Oxidative metabolism, negative myocardial uptake of "I-BMIPP, free fatty acid metabolism, PET. 548

Oxygen 15 inhalation, internal dose estimation using the thermoluminescent dosimeter method. 1603

Oxygen-15 water
3D activation studies, during motor stimulation, pediatric, 292(ab)
3D PET and, neural networks for covert word generation, 104(ab)
PET
brain myocardial blood flow experiment with, phantoms for, 196(ab)
regional myocardial blood flow and, partition coefficient and tissue heterogeneity in, 172(ab)
Oxyphil cell, "Tc-tetrofosmin imaging to localize parathyroid glands, parathyroid adenoma, 706

Paclitaxel, radiolabeled as an imaging tool, "In-
DTPA, gamma scintigraphy, 1042
PACS, nuclear medicine
using Internet technologies. 311(ab)
World Wide Web. 307(ab)

Paget's disease.
"F-FDG PET, "Tc-MDP bone scintigraphy, differentiating benign changes from sarcoma, 1495

Pain
low back, management, bone SPECT versus structural imaging, 29(ab)
tonic heat, cerebral response to, PET activation study, 104(ab)

Pancreas
1-'C-acetate as tracer for PET imaging, 1305
accessory spleen diagnosis with "Tc-HDRBC SPECT. 494
cancer
differentiation of malignant and benign disease, 257(ab)
FDG PET indications. 542(ab), 144(ab)
"T1 VIP receptor scanning in, 103(ab)
differential diagnosis of masses, FDG PET role in, 51(ab)
experimental pancreatitis. "Tc-labeled leukocytes in localization of, 52(ab)
small lesions, evaluation with FDG PET, 245(ab)

Pancreatic tumor, expression of glucose transporters, FDG-PET, 1337

Pancreatic cancer, "17FDG SPECT imaging. 246(ab)

Pancreatic carcinoma, overexpression of glucose transporter 1, FDG-PET, 1344

Pancreatitis, PET imaging of, use of 1-'C-acetate as tracer, 1305

Parametric imaging, GLLS algorithm, clinical validation using dynamic FDG-PET data, 202(ab)

Parasympathetic nerve activity, "I-MIBG, myocardial imaging in normal subjects, sympathetic nerve activity, 49

Parathyroid, comparison of imaging with "Tc-
pertechnetate/sestamibi subtraction, double-phase "Tc-sestamibi and "Tc-
sestamibi SPECT, 834

Parathyroid adenoma
"Tc-MIBI in localizing pathology in patients with MEN type 1 syndrome. 1767
"Tc-tetrofosmin imaging to localize parathyroid glands, 706

Parathyroid glands
abnormal. "Tc sestamibi in localization, primary hyperparathyroidism, 150(ab)
adenoa
preparative localization with "Tc sestamibi, P-glycoprotein and histological subtype, 263(ab)
"Tc chloride versus "Tc MIBI, 151(ab)
transient uptake of "Tc sestamibi, 297(ab)
multiple hyperplasia, optimized statistical detection, 152(ab)
"Tc MIBI scintigraphy, patterns and pitfalls, 267(ab)

Parathyroid imaging, radionuclide techniques, controversy in management of hyperparathyroidism, 840(ed)

Parathyroid scintigraphy, "Tc-tetrofosmin compared with sestamibi, 831

Parkinson's disease
neurological metabolic differences compared with Alzheimer's disease, emission computed tomography "F-FDG, 797
dopamine transporter loss in, detection, 139(ab)
dopamine transporter, selective marker for, rat model, 76(ab)
dopamine transporters in, "F B-CIT PET imaging of, 138(ab)
early presentation, "I FP-CIT SPECT. 138(ab)
first degree relatives of patients, "I B-CIT SPECT, 138(ab)
gastric emptying and gastric motility in, levodopa treatment effects, 261(ab)
imaging and quantification of dopamine transporters with "I-1 IPT, SPECT, 1703
imaging of dopamine transporters with "I B-
CIT and SPECT, 1
occipital hypometabolism in, clinical correlates, 139(ab)
progression, "I B-CIT SPECT as marker of, 138(ab)
reproducticity of "I-B-CIT SPECT, brain measurement of dopamine transporters, 1453
serotonin transporters in. "I B-CIT SPECT in, 280(ab)
SPECT imaging of dopamine transporter sites.
MPTP model, 11B-ACFT, 11C-CFT, 144 SPECT with allopurinol, selective ligand for dopamine transporters, 219(ab), 61(ab) stereotactic thalamotomy, FDG PET evaluation of, 270(ab)
Parotid gland, tumors, FDG PET and salivary gland scintigraphy in, 242(ab)
Partial volume effect, limit in gated sestamibi tomograms, patient data and, 27(ab)
Partition coefficient, quantification of cerebral blood flow using 18F-IMP, SPECT, 1248 Pediatrics
assessment of hydrenephrosis using output efficiency, 1483
attention deficit disorder, ritalin effects on cerebral blood flow, 291(ab)
brain tumor, 131 T1 avidity versus MR contrast enhancement, 116(ab)
cardiotoxic chemotherapy, left ventricular function with, 291(ab)
chronically obipated, scintigraphic defecography in evaluation of rectal emptying, 72(ab)
diagnosis of vesico-ureteric reflux, during renal scintigraphy, 291(ab)
encephalopathy and encephalitis, follow-up rCBF SPECT, 277(ab)
false-positive FDG-PET imaging of the thymus, Hodgkin's disease, 889
Ewing sarcoma, 35, 105 Tc MIBI scintigram evaluation, 13(ab)
feeding, volume, gastric emptying measurement in infants, 24(ab)
fever of unknown origin, immunoscintigraphy in, neonates and infants, 158(ab)
gastric scintigraphy, cost-benefit analysis, 291(ab)
hepatic blood flow, two-compartment model analysis with three components on 99m Tc GSA, 226(ab)
Hodgkin's disease, 111 Ga SPECT after treatment, faint hilar activity after, 13(ab)
hypoxic-ischemic brain injury, dopamine receptor imaging with 131 I IBZM, 292(ab)
labeled bombesin analog in, 188(ab)
motor stimulation, 36 F water activation in tumors, 24(ab)
Moyamoya disease, rest/diastom 111 Tc HMPAO brain SPECT, 276(ab)
myocardial perfusion imaging, 111 Tc sestamibi, 290(ab)
neuroblastoma, 111 IMIBG radionuclide therapy, dosimetry for, 13(ab)
neuromaging, internal dosimetry calculations, head and brain models for, 105(ab)
ORNL mathematical models, electron absorbed fractions with MIRD schema, 225(ab)
portal hypertension, usefulness of radionuclide spleno-portography in, 225(ab)
procedure guideline for diagnostic radionuclide renography, hydrenephrosis, 1647
procedure guideline for radionuclide cystography, vesicoureteral reflex, 1650
procedure guideline for renal cortical scintigraphy, 1644
procedure guideline for sedation in nuclear medicine, 1640
radioisotope voiding cystography, grading system in, 292(ab)
radiopharmaceutical dosimetry, effective dose and estimation, 1982
skeleton, pihole scintigraphy, 306(ab)
suspected brain tumor recurrence, role of FDG PET studies in, 122(ab)
**Tc, late abdominal accumulation of, 290(ab)
thymic rebound, 111 Ga SPECT patterns and, 13(ab)
thyroid cancer, 18F PET prediction of postoperative recurrence, 265(ab)
vessicoureteral reflux, **Tc DMSA scans in, 50(ab)
PEGylated liposomes, imaging focal infections, S. aureus, 489
Pentavalent technetium-99m-DMSA. uptake in primary brain tumors, relationship between retention and histologic malignancy, SPECT, 20
Pentose cycle. PET imaging, glucose metabolism in rat gliomas, 617
Peppe ulcer disease, 131 C-urea breath test, presence and eradication of helicobacter pylori infection, gastritis, 1141
Peptide
localization of focal sites of E. coli infection in rabbits, receptor-specific mechanism, 1316
preclinical evaluation of 123 I-P748, detection of venous thrombosisobliteration, GPHII/IIIa receptor, 105
Peptide nucleic acid, antibody-conjugated, 1311 Tc labeling, and tumor localization by pretargeting, 189(ab)
Peptide receptor imaging
radionuclide therapy, 131 I DTPA-D-PHE-octreotide, 47(ab)
thyroid goiter, 266(ab)
Peptide-receptor radiotherapy, D-lysine reduction of 131 I-DTPA-OC and Y-DOTATOC renal uptake, 1929
Peptides
EGF ligand, 111 Tc radiolabeling via NHS-MAG3, new tumor probe, 31(ab)
experimental allergic EAE, 1311 Tc RP128 in, animal model of MS, 187(ab)
HYNIC, 1311 Tc labeling, N52 as co-ligand, 188(ab)
labeling, 1311 Tc, new reagent for, 101(ab)
radiolabeled RGD, tumor targeting and, new class of tracers for, 190(ab)
**Tc conjugates, ternary ligand system, 100(ab)
**Tc labeling, NHS-MAG3 bifunctional chelator in, tumors, 24(ab)
**Tc RP128, stability in vivo and in vitro, 189(ab)
Peptidic chelator
**Tc and Re Oxo complexes with N. N',S. peptide ligands, synthesis and structural characterization, 184(ab)
Percutaneous endoscopic gastrostomy, patients fed by, evaluation of GER in, 260(ab)
Percutaneous transluminal coronary angioplasty (PTCA), 18F-BMIPP imaging in unstable angina, interventional treatments, 1407
Perfusion and metabolism mismatch, viable neurons with luxury perfusion, hydrocephalus, 1467
Perfusion imaging, myocardial flow versus uptake comparisons of 131 I Tc with 131 I tracers, canine model, 1847
Perfusion lung scan, postpneumonecomy dyspnea due to right-to-left shunt, platypnea-orthodoxia, 1812
Perfusion reserve, cerebral assessment using 111 IMP SPECT, hemodynamics of watershed infarction, 1556
Pericardial effusion, severe RV contraction asynchronism revealed by gated blood-pool scintigraphy, Fourier phase analysis, 127(ab)
Peripheral facial nerve palsy, salivary gland scan in, 257(ab)
Peripheral vascular disease, dual-radionuclide bone scintigraphy in, MRI, 159(ab)
Peripheral vascular diseases, 131 O-water PET assessment, muscular blood flow, 93
Peristalsis, gastric, evaluation, detection of subtle gastric dysfunction and, 256(ab)
Peritoneography, rectosigmoïd fistula demonstrated by dynamic scintigraphic imaging, peritoneal metastases, 1636
Peritonitis, 18F In leukocyte imaging, scintigraphic appearance of IBD, 1138
Pertechnegeus
dosimetry and biodistribution, pulmonary embolism, 229(ab)
properties and use as a ventilation agent, x-ray photodetection, 163
PET, see Positon emission tomography
PET carbon-11-methionine, three-dimensional imaging of cortical function and structure, glialia resection, 1563
PET nonhuman primate, imaging nicotine acetylcholine receptors with 11F-FPH, epibatidine, 1737
PET quantitation, home made to camera calibration procedures, 1334(ab)
PET tumor tracers, effect of hyperglycemia on in vivo tumor uptake, FDG, 382
P-glycoprotein
histological subtype and, localization of parathyroid adenomas with 111 Tc sestamibi, 263(ab)
influence on 111 Tc-sestamibi uptake, multidrug resistance in treatment of patients with cancer, 1003
knockout, pharmacokinetics of 111 Tc Q58 and 111 Tc sestamibi, mice, 100(ab)
multidrug resistance, in vivo detection with 111 Tc-sestamibi, 369
pharmacokinetics mediated by, alterations, brain, PET detection of, 117(ab)
retention of 111 Tc-sestamibi as an index of P-glycoprotein expression, breast cancer, 1348
18F-Tc-furifosin for functional imaging of MDR tumors, 1915
P-glycoprotein inhibitor PSC833, effects on pharmacokinetics of 111 Tc sestamibi, multidrug resistance, 241(ab)
PharmacoKinetics
biodistribution and, chemically modified 111 MIBG labeled peptide, in vivo hybridization of **Tc-labeled peptide nucleic acid, radiopharmaceuticals, 907
measuring ASGP-R and hepatic blood flow, dynamic images of 111 Tc-GSA, 1798
radioimmunotherapy with 131 I labeled anti-CEA murine monoclonal antibody IgG, 838
Ti-18F N4-DTPA characteristics, bone pain palliation, metastatic cancer, 230
Pharmacologic stress agent, arbutamine, computer-controlled closed-loop delivery system, 154(ab)
Pharmacologic stress test, adenosine-induced vasodilation, 111 Tc-tetrofosmin tomography vs. 2D-echo, 1089
Pharmacokinetic studies, microvolumetric blood sampling, small animal PET studies, 205(ab)
Phaeochromocytoma
111 MIBG imaging, 4-hour and 18-24 hour comparison, 151(ab)
111 MIBG localization of, adrenal tumor patients, 265(ab)
**Phosphor-imaging**

Phosphodiesterase I°HII'A

Plasma

Pituitary

Platypnea-orlhodeoxy.

"I

2D

l-'C-acctate and

3-10.

attenuation,

clearance,

comparison

tyrosinePET,

SPECTandCT.

duration
dyspnea,

oxinc.

quantilation

transmission

emission

"In-labeled

camera

ity

image

triggers,

blood

activation

in

Alzheimer’s disease, language performance in,

effect of level of education, 95(ab)

amino acid transport systems, "C-methionine transport enhanced by insulin, 1967

antisense oligodeoxynucleotide imaging with,

patients, 103(ab)

attenuation correction, mean attenuation coefficients for, 67(ab)

B_max and B_max/RD measurement by, effect of intrasynaptic dopamine release on, in schizophrenia, 11(ab)

benzodiazepine effects, cognic, abusers, 47(ab)

benzodiazepine receptors in chronic CV disease, blood flow and metabolism comparison, "I-IMZ SPECT, 1693

B1 adrenergic receptor blockade, effects on myocardial blood flow and vasodilatory capacity, 442

blood flow of skeletal muscle using "O-H2O and PET, 314

brain tumor imaging

"C]choline, 842

brain, SPECT comparison, cerebral blood flow imaging, 21(ab)

bromine-76 labeled 5-bromo-6-nitroquinazine, brain imaging, 57(ab)

camera-based imaging, 1796(ed)

"C acetate, assessment of myocardial blood flow, reperfused myocardial infarction, 54(ab)

"C CGP 12177 and "C hydroxyephedrine, assessment of cardiac autonomic dysfunction in idiopathic ventricular tachycardia patients, 171(ab)

"C cocaine

dopamine transporter occupancy and cocaine-induced subjective effects, 35(ab)

global pharmakokinetics modeling, nonhuman primate brain, 201(ab)

"C M HD, quantitative analysis, isolated hearts, cane and human, 86(ab)

"C PHEN and "C HED, cardiac neuronal function, unstable angina patients, 86(ab)

"C SCH 39166, dopamine receptor occupancy by dopamine agonist, 288(ab)

"C thymidine, tissue classification and segmentation using population-based kinetic functions, 205(ab)

cardiac

automated segmentation using polar transformations, 198(ab)

postinjection transmission measurements, 202(ab)

respiratory compensation, double-gated acquisitions, 114(ab)

cardiovascular, ejection fraction and myocardial volume determination, 55(ab)

cell proliferation, "F FLIT, 249(ab)

cell replication, gene expression associated with

cerebellar glucose metabolism in Alzheimer’s disease, "F-FDG, 925

cerebral blood flow, changes with age and gender, 129(ab)

cerebral metabolic alterations, ecstasy-induced experimental psychosis, 47(ab)

changes in CBF and oxygen metabolism, MRI white matter hyperintensities, Alzheimer’s disease, 1471

cholinesterase inhibitor effects, binding to nicotinic acetylcholine receptors, brain, 289(ab)

comparison to histopathology, proliferative activity in brain tumors, L-["I-

"CITYR, 1369

coronary artery disease, abnormal myocardial blood flow response in, 121(ab)

crossed cerebellar diaschisis in head injury, "F-FDG, 1717

"Cu teta-ocriotide, carcinoid tumor patients, 103(ab)

curved NaI(T1) detector for, 144(ab)

D2-like dopamine receptor density, Tourette syndrome, 1243

detector performance, BGO array with miniature position-sensitive phototube, accuracy of event positioning in, 197(ab)
differences in dopamine receptor availability, function of social status, monkey, 105(ab)
differentiate benign changes from sarcoma in Paget’s disease, "F-FDG, ""Tc-MDP bone scintigraphy, 1495
dopamine D1 receptor radioligand for, 76(ab)
dopamine nerve terminal imaging agents

fluorinated m-tyrosine analogs compared with 6-Fluoro-L-DOPA, 630

dopamine receptor binding potential, striata, primes smaller than humans, 271(ab)
dopamine terminal loss, methamphetamine-treated baboons, 94(ab)
dopaminergic responsivity, striatal and enhanced thalamic, detoxified cocaine abusers and, 36(ab)
down-regulation of cardiac muscarinic receptors, DFP induced, MQNB, 1430
dynamic, matched subspace filter for, cancer staging, 201(ab)
evaluation of Azmancor ("I)trimacinolone acetoni dioxide administration, 4(ab)
false-negative scan in metastatic carcinoid, "F-FDG, 1382

FDA involvement in regulatory and reimbursement issues, part II, 9N(2)
"F ABO, tumor imaging and skeletal muscle metabolic studies, 134(ab)
"F FHPG, pharmakokinetics in primates, 43(ab)
"F fluorocarazolol, high resolution beta-adrenergic receptor imaging of asthma, animal model, 176(ab)
"F fluorouracil, pharmakokinetics studies, blocking catabolism and, 176(ab)
"F NFEP, nicotinic acetylcholine receptors, 80(ab)
"F SET, non-specific binding, baboon and human necortex, 200(ab)
"F-BPA-Fr for boron neutron capture treatment planning, 1762
"F-FDG meningioma grading improved with fasting, 26
"F-FDG uptake in rat prostate adenocarcinoma during gemcitabine therapy, 1215
"F-FDG versus ""Tc-sestamibi, multiple myeloma, 1208
"F-FDG, Castleman’s disease differentiated from malignant lymphoma, 1211
"F-FDG, evaluation of retropertionel metastases before and after treatment of testicular cancer, 99
"F-FDG, quantitative analysis of breast
for imaging small animals, 7(ab)
migraine headache, central response and, sumatriptan and placebo effects, 281(ab)
ML-EM image reconstruction algorithms for, local convergence behavior characteristics of, 202(ab)
modification of cardiac sympathetic terminals chronic cocaine use, "C., hydroxycypridemine, 451
MRI and tissue sections, baboon brain atlas, 306(ab)
MRI and, temporal lob volume measurements, hypometabolism and post-surgical outcome, 22(ab)
multinuclearity brain, 3D phototogrammetrically derived surface, 310(ab)
multitracor studies during gene therapy of hepatoma cells, HSVGtK and GCV, and glucose metabolism, 1048
myocardial blood flow, mental stress, age and cholesterol effects on response, 121(ab)
myocardial kinetics of "C-EPI, noninvasive assessment of sympathetic innervation and function of the heart, 780
myocardial perfusion imaging with "Rb, 54(ab)
myocardial viability assessed, combined with SPECT for diagnostic and prognostic purposes, coronary artery disease, 742
negative myocardial uptake of "I-1BMIPP, free fatty acid metabolism, 548
neural correlates of traumatic remembrance, posttraumatic stress disorder, 282(ab)
negative systems, visual imagery and visual perception, 286(ab)
"N ammonia myocardial blood flow assessment, prognostic value in dilated cardiomyopathy patients, 171(ab)
quantiitation of myocardial blood flow, 93(ab)
"N cisplatin, synthesis in a full automated chemistry module, 113(ab)
NMR and, simultaneous acquisition in high field magnet, 45(ab)
Parkinson's disease, occipital hypometabolism in, 139(ab)
performance evaluation of whole-body scanner, 15(ab)
perfusion and vasodilator function after percutaneous transluminal coronary angioplasty for acute myocardial infarction, 770
perfusion tracers, lanthanum complexes as, "Ce""La generator system and, 183(ab)
phantom, realistic multimodality breast and axillary node, 203(ab)
pharmacokinetics of "F trovafloxacin, healthy subjects, 269(ab)
pharmokinetics and experimental imaging "Br-labeled anti-CEA MAb, 395
photon transmission data, spiral CT approach to, 113(ab)
potassium-39k distribution, normal human heart, 85(ab)
prediction of survival in head and neck neoplasms, "F-FDG, 1907
quantification cortical acetylcholinesterase inhibition, monkey and human, 146(ab)
region of interest, 210(ab)
quantification of metabolism with FDG and tyrosine, breast cancer imaging, standardized uptake value, 692
quantification of serotonin receptors, human brain, 95(ab)
quantifying and modeling physiologic processes, FDOPA, 1266(ed)
quantitation of cerebral blood volume, comparisons with SPECT, 919
quantitative brain, 2D versus 3D acquisitions, 195(ab)
quantitative imaging, H3-lk gene expression, 239(ab)
radioummaging based on, multistep pretargeting, 306(ab)
radiouclide contaminants, high-pressure water targets, 113(ab)
radiopharmaceuticals, safety study of, 112(ab)
receptor autoradiography and, selective distribution of dopamine receptors, thalamus, 81(ab)
receptor availability assessment, Logan graphical technique with standard input function for, 203(ab)
reinvention of, use of SPECT cameras, 13N(1) reperfusion, glucose and fatty acid utilization in stunned myocardium, 1835
resolution improvement, detector depth of interaction information, 45(ab)
serial, in vivo detector for measuring input function, primates, 203(ab)
simplification of dosimetry, "C-labeled radiopharmaceuticals, 654
simplified kinetic model for dynamic data, "Rb, myocardial blood flow, 660
simultaneous emission-transmission, deadtime correction technique for, 114(ab)
small animal continuous 3D detectors in, high-resolution scanner, 44(ab)
preliminary design study of imaging device, 44(ab)
protocol with avalanche photodiode arrays and LSO crystals, 45(ab)
smoothing of blood time-activity curves, kinetic analysis, 1161
SPECT and, thick crystal gamma camera design, use of retroreflectors in, 32(ab)
stable XE-CT and, quantitative cerebellar blood flow determination, 276(ab)
streak artifacts in, removal of, 199(ab)
"Tc, volume imaging scans, residual single photon activity and, 199(ab)
"Tc EC-ECD SPECT in misery perfusion, steno-occlusive disease, cerebral blood flow and metabolism, 791
three-dimensional imaging characteristics of the HEAD PENN-PET scanner, brain imaging and pediatric whole-body studies, 636
time-activity curve extraction, factor analysis approach, mice, 201(ab)
use in transplant evaluation, hibernating myocardium, 55(ab)
visual and semiquantitative analysis of scans in childhood epilepsy, "F-FDG, 1891
visualization of nicotinic acetylcholine receptors, "F-FPH, 1260
visualization of b-adrenergic receptors, new tracers for, 77(ab)
volumes and activities of small structures, posterior probability, 220(ab)
whole-body breast cancer detection, 78(ab)
clinical oncology, attenuation-corrected versus non-corrected images, 198(ab)
dual-head gamma camera, tumor detection, 77(ab)
ECAT EXACT HR+ system, scatter correction algorithms in, 197(ab)
modified dosimetry and point kernel convolution in, 199(ab)
OSEM versus EO and FBP reconstruction, lesion detection, 78(ab)
planar coincidence imaging, dual-head gamma camera, 202(ab)
whole-body imaging, transmission and emission scan duration optimization in, 196(ab)
zirconium-labeled MAb, distribution in tumor-bearing mice, 112
"Zn2Cu, from monoprotic tetradsate Schiff-base ligands, 183(ab)
Positron imaging, gamma camera sensitivity, high energy photons, method for measurement, 205(ab)
Positron volume imaging, attenuation correction, singles transmission for, 113(ab)
Posterior tibial tendinitis, bone scintigraphy, diagnosis of idiopathic or rheumatic-related posterior tibial tendinitis, 247
Practice expense, rule delayed, resource-based relative value units, 22N(6)
Practice guidelines diuretic renography in children, 1647
equilibrium radiouclide ventriculography, gated blood-pool imaging, 1658
"Ga-citrate imaging, evaluation of malignancy, 990
gallium scintigraphy in inflammation, 994
hepatobiliary scintigraphy, liver function, 1654
"In-leukocyte scintigraphy, inflammation/infection imaging, 997
pediatric sedation in nuclear medicine, 1640
radionuclide cystography in children, vesicoureteral reflux, 1650
renal cortical scintigraphy in children, 1644
SMM and ACR appropriate criteria, 22N(7)
"Tc-HMPAO-labeled leukocytes, scintigraphy for infection/inflammation, 987
Praseadomium-143, radiopharmaceutical therapy with, 6(ab)
Precursors, stannylated, radiochemical yields of, 309(ab)
Pressure rate product, "I-1BMIPP SPECT, myocardial washout and cardiac work during exercise, ischemic heart disease, 559
Pretargeting antibody-conjugated PNA, "Tc labeling and, tumor localization by, 189(ab)
two-step radioimmunotherapy, bisspecific antibody and, "I-labeled bivalent hapten, human medullary thyroid carcinoma and, mice, 30(ab)
Pretargeting protocols, infection imaging with "Tc-DTPA after anti-DTPA MAB priming, 901
Primary adrenal lymphoma, "Ga scintigraphy and, correlative imaging, 1770
Primary aldosteronism, scintigraphic assessment of transcatheter arterial embolization, therapeutic success using absolute ethanol, aldosteronomas, 237
Primary and secondary hyperparathyroidism, "Tc-tetrofosmin imaging to localize parathyroid glands, 706
Probe, portable, intraoperative tumor localization, breast tumors, 210(ab)
Probe system, time-of-flight, quantifying positron-emitting tracer in target region, 143(ab)
Procedure guidelines, Society of Nuclear Medicine manual, commission on Health...
Care Policy and Practice, 20(N(4))

Prognosis
cardiac death and risk stratification, exercise or
adrenaline sustained combined perfusion-
function protocols, 40(ab)
diabetic patients, rest **Tl/stress **Tc 8estamibi
dual isotope myocardial perfusion
SPECT, 40(ab)
incremental risk stratification, clinical history.
exercise treadmill and exercise
myocardial perfusion SPECT in, 40(ab)
myocardial viability, **Tl re-injection imaging
and, coronary angiography in patients
with chronic ischemic left ventricular
dysfunction, 165(ab)
risk stratification and
stress SPECT 5 years after bypass surgery
and, 40(ab)
stress SPECT in asymptomatic
patients, 41(ab)

Proliferation, comparison of histopathology and
L-1-15CIT R PET, brain tumors, 1369

Prospective payment system, hospital outpatient
services, Health Care Financing
Administration, 13N(2)

Prostate adenocarcinoma, **F-FDG PET, uptake in
rats during gemcitabine therapy, 1215

Prostate cancer
enhanced **In CYT-356 imaging, **Tc RBCs
and CT/SPECT image fusion, 232(ab)
evaluation, high resolution FDG PET, 128(ab)
imagining with **Tc-labeled monoclonal antibody
CYT-351, prostate-specific antigen, 675
**In CYT-356 imaging, vascular structure for
CT/SPECT, 136(ab)
initially limited, patterns of new metastatic bone
involvement, 303(ab)
low prostate-specific antigen level and, value of
baseline bone scan, 301(ab)

Prostate cryosutation, soft-tissue uptake of **Tc-
MIP, 525

Prostate-specific antigen (PSA), imaging prostate cancer with **99mTc
radioimmunoconjugates. 71(ab)

Protein kinase C, localization in brain, 78-
methoxy **C methoxy stauroporine
imaging for, 184(ab)

Protein synthesis rate, proliferation in brain
tumors, comparison of histopathology
and L-1-15CIT R, 1369

Psychosis, experimental, ecstasy-induced, cerebral
metabolic alterations, 47(ab)

PTCA, see Percutaneous transluminal coronary
angioplasty

Public relations, promotion of products, services,
practice, Society of Nuclear
Medicine, 28N(5)

Pulmonary artery pressure, lung perfusion scans
and hemodynamics, acute pulmonary
embolism and chronic thromboembolic
pulmonary hypertension, 980

Pulmonary circulation, perfusion and density
gradients, SPECT and transmission
tomography, attenuation corrections, 962

Pulmonary embolism
carbon in Technegas, carbon encapsulation and
extended lung retention time for, 186(ab)
clinical outcome of patients with intermediate
probability V/Q lung scans, 1593
computer program use in diagnosis, intermediate
classification minimization and,
6(ab)
diagnosis with DTPA V/Q scan, 1781
follow up, ventilation-perfusion mismatch
during, 123(ab)
lung perfusion scans and hemodynamics,
chronic thromboembolic pulmonary
hypertension, 980
nephrotic syndrome patients, pulmonary
ventilation and perfusion scans in,
298(ab)
optimizing scintigraphy, segmental anatomy of
lung, 1987
overmatched perfusion abnormalities, aerosol
V/Q scans, 122(ab)
permeagcns dosimetry and
biodistribution, 229(ab)
permeagens characterization of inhaled vapor
mixture, 187(ab)
probability, severity of photopenia in a perfusion
defect and, 123(ab)
scintigraphic model, stripe sign in, 299(ab)
segmental defect size underestimation, virtual
lung scintigraphy and, 38(ab)
**Tc MHI-Fab, detection of, 124(ab)
ventilation/perfusion scintigrams, Gestalt
interpretation, 299(ab)

Pulmonary hypertension, lung perfusion scans and
hemodynamics, acute and chronic
emboli, 980

Pulmonary perfusion agent, direct labeling of
**In-MAA, 1590

Pyelonephritis, scintigraphic detection, 1501(ab)
Pyridinium cross-link, markers of bone
resorption following **Sr-chloride
therapy, osseous metastasis, 1175

Quality control
hardware and software performance, SPECT
phantom, 208(ab)
high-voltage capillary electrophoresis,
radiopharmaceutical applications of,
177(ab)
new method, **Y/Sr generator production
and, 193(ab)
protocol, transmission-emission tomographic
systems, 214(ab)

Quantitative image analysis, breast imaging, **F-
FDG PET, 1186

Quantification
bone uptake measurements, conventional three-
phase bone scanning, 120(ab)
brain perfusion SPET maps, different
denominators, 214(ab)
center-of-rotation errors, point source
acquisitions, 219(ab)
cerebral glucose metabolic rate, FDG PET
studies, 94(ab)
functional dopaminergic system, automated
algorithm, 60(ab)
myocardial perfusion imaging, x-ray CT and
SPECT combined system, 1353
non-invasive, brain, anatomical information
from the transmission scan, 94(ab)
rCBF calibration with continuous infusion of
**Tc-ECD and dynamic SPECT
imaging, 1699
scatter and attenuation correction to, cerebral
blood flow, brain SPECT, 272(ab)
SPECT, scatter elimination, attenuation
correction, and resolution
recovery, 213(ab)

Quantitation
brain PET, 2D versus 3D acquisitions, 195(ab)
**C MHED PET, isolated hearts, canine and
human, 86(ab)

Improved brain PET images, sinogram Patlak
and new iterative reconstruction
method, 196(ab)

"N ammonia/** FDG PET, assessment of
myocardial viability, 55(ab)
scatter correction algorithms, whole-body PET
ECAT EXACT HR+ system and, 197(ab)
stress cerebral perfusion SPECT, maximal pixel
counts, 276(ab)

Quantitative SPECT
extracardiac activity complicating cardiac
imaging, simultaneous transmission-
emission approach, 1882
improved precision with nonuniform collimator
sensitivity, photon attenuation, ideal-
observer models, 151

Quantitative uptake, **Tc-antigranulocyte
antibody imaging in vertebral
osteomyelitis, photopenia, 211

R

Radiation dosimetry, radioimmunodetection and
radioimmunotherapy with monoclonal
antibodies, mathematical modeling, 731

Radiation pneumonitis, impaired permeability
detected by **Tc-DTPA lung
clearance, 966

Radiation therapy, dosimetry system for therapeutic alpha-particle
emitters, 1223
peptide receptor, pancreatic somatostatin
receptor positive tumor CA20948, 59(ab)

**Tl uptake and retention in intracranial
tumors, 223

**Tc-labeled DOTA-Tyr-octreotide, in tumor
bearing rodents, 18(ab)

Radiation-induced lung injury, altered
permeability detected by **Tc-DTPA
lung clearance, 966

Radioaerosol, intelligent delivery device, patients
with chronic obstructive airway
disease, 299(ab)

Radioaerosol deposition, bronchial obstruction
and presnetic sign, **Tc-phosphate
ventilation scan, 71

Radiobiological effectiveness,
radioimmunotherapy, fractionated
radiotherapy comparison, 59(ab)

Radiochemical phase, **Mg MAG3, comparison of European and U.S., 49(ab)

Radioimmuno PET, pharmacokinetics and
experimental imaging, **Br-labeled anti-
CEA MAb's, 395

Radioimmunoassay
anti-TPO, new thyroid antibody, autoimmune
thyroid disease, 150(ab)

CYFRA 21-1 as tumor marker, nasopharyngeal
carcinoma, 149(ab)

Radioimmunocugulates, tumor uptake,
increasing in a two-step pretargeting
approach, 233(ab)

Radioimmunoconjugates, potential and limitations with monoclonal
antibodies, radioimmunotherapy,
mathematical modeling, radiation
dosimetry, 731

**Tc labeling and biodistribution, Fv fragments,
monoclonal antibody, 294

Radioimmunoscintigraphy, **In DTPA antibody,
equivalence with specific mAb in colonic
tumor detection, mice, 191(ab)

Radioimmunotherapy
alpha-particle emitter labeled anti-CD33
antibody, leukemia patients, 231(ab)
bspecific antibody and **Tc-labeled bivalent
hapten, human medullary thyroid carcinoma and mice, 30(ab)
cancer pretargeting, streptavidin-CC49 monoclonal antibody and 111In/Y DOTA-biotin and, 188(ab)
CEA-expressing cancers, complete versus fragmented and "I-labeled antibodies for, influence of dose rate and renal secretion on toxicity and anti-tumor efficacy, 31(ab)
colon cancer and, 111-I-labeled bivalent hapten with anti-CEA x anti-iodum-DTPA antibody use in, 7(ab)
colorectal cancer and, "I- and "Y-labeled IgG versus chemotherapy, mouse model, 6(ab)
internalizing antibodies in, efficacy and toxicity of Auger electron versus beta emitters in, 7(ab)
"Cu and 111-I-labeled anti-CEA monoclonal antibodies, colorectal cancer, 847
dosimetric contribution to myelotoxicity, 1753(ed)
enhanced with extracorporeal whole-blood immunoadsorption, "I-labeled BRh6-biotin MAB, 895
fractionated radiotherapy comparison, 59(ab)
In M-X-DTPA humanized BRE-3 monoclonal antibody studies, advanced breast cancer, 252(ab)
"I and "Y labeled antitensascin MABS, glioblastoma, 60(ab)
"I anti-B1 lymphoma, prediction of kinetics, 251(ab)
"I anti-CD20, non-marrow ablative doses, 230(ab)
"I anti-CEA mAB, liver micrometastases and, 194(ab)
"I IgG50, red marrow dosimetry after, renal cell carcinoma, 225(ab)
"I LL2 (Anti-CD22), non-Hodgkin’s lymphoma, 59(ab)
"I-labeled anti-CEA murine, 858
"I-labeled MN-14F(ab)2 anti-CEA MAB, advanced medullary carcinoma, 47(ab)
intraperitoneally administered 111Lu CC49, ovarian cancer, 226(ab)
ovarian cancer and, "I-labeled anti-CEA monoclonal antibody treatment, 257
patient-specific beta dose estimates, voxel source kernel method for, 106(ab)
patient-specific dosimetry and, "I- and "Y-labeled, monoclonal antibody CC49, 512
pharmacokinetics and tumor response G250 antibody parameters for, 230(ab)
integrated model, 229(ab)
potential and limitations with monoclonal antibodies, radioimmunodetection, mathematical modeling, radiation dosimetry, 731
prediction of myelotoxicity, radiation doses to marrow from blood, marrow, 1374
rapid fractionation treatment protocol for, 118(ab)
release criteria for therapeutic amounts, published dosimetry data, 229(ab)
semiquantitative prediction of myelotoxicity, marrow image score, 1749
125I processing for, optimization of, 193(ab)
therapy for breast cancer using "In/"Y BrE-3, 1180
three-dimensional dosimetry for intralesional therapy, glioma, 1059
thrombocytopenia after, cell kinetics model, 118(ab)
tumor targeting and imaging properties of "In-labeled chimeric antibody, 1951
variables influencing tumor dosimetry, CEA-expressing cancers, anti-CEA and antimucin monoclonal antibodies, 409
"Y MX-DTPA HuBRe-3 and topotecan, breast cancer xenografts, 46(ab)
Radioiodinated androgen, 7[alpha]-"[I]IJDHT, ligand for the androgen receptor, receptor imaging, 402
Radioiodinated antibody, induced thyrotoxicosis, Jod-Basedow syndrome after administration, 1816
Radioiodinated benzamides, pharmacokinetics of "I-LMBA, scintigraphic detection of melanoma metastases, 127
Radioiodinated fatty acids, trapping mechanism and metabolism of PHIP A 3-10, rat myocardium, 1864
Radioiodine, use of residualizing radiolabel dilactitol-tyramine, radioimmunotherapy of lung cancer xenografts, 391
Radioiodine therapy, differentiated thyroid cancer in children and adolescents, 669
effects on skeletal muscle, subclinical hyperthyroidism, 262(ab)
electron injection and, nonsurgical ablation of autonomous thyroid nodules, 262(ab)
incremental, multi-nodular goiters, 261(ab)
intrahepatic thyroid dosage in, "I uptake test effects, 261(ab)
preservation of family members, NCRP guidelines, 264(ab)
sporadic nontoxic goiter, volume reduction, 372
Radioiodine uptake, false-positive scans in chest, 984
Radioisotope renography, "" Te-MAG3 scintigraphy in acute renal failure after transplantation, prognostic value, 475
Radioiodinated antibodies, clinical evaluation of "In-labeled chimeric T84.66, carcinoembrionic antigen, 1951
Radioiodinated antibody metabolism, tumor uptake of "Cu-labeled monoclonal antibody chCE7, radiolabeled antibody therapy, 536
Radioiodinated antibody therapy, tumor uptake of "Cu-labeled monoclonal antibody chCE7, radiolabeled antibody metabolism, 536
Radioiodinated peptides, lung carcinoemhrvonic carcinoma imaging, YIGSR, 1940
Radiometals, renal accumulation, trapping in lysosomes, 829(ab)
Radionuclide ""Ho therapy using topical skin patch, skin cancer and Bowen’s disease, 697
procedure guideline for diuretic renography, pediatrics, 1647
solid-phase labels for gastric emptying studies in cats, ""Te-disofenin, 495
Radionuclide angiography halo sign and Fourier phase analysis, detection of large pericardial effusion, 777
left ventricular function and perfusion in Becker’s muscular dystrophy, ""T1 SPECT, 563
Radionuclide cocktails, tumor therapy, broad range of sizes, 226(ab)
Radionuclide cystography, procedure guideline, pediatrics, 1650
Radionuclide therapy "F-ray emitters, release criteria for patients treated with, 310(ab)
dosimetry three-dimensional software systems, dose-volume histograms, 301
fusion of three-dimensional images, bremstrahlung SPECT and CT, "P infusion, 319
markers of bone resorption following "Sr-chloride therapy, metastatic prostatic cancer, pyridium cross-link, 1175
Radionuclide ventriculography procedure guideline, gated blood-pool imaging, cardiac function, 1658
sustained RV dyskinesia with RV infarction, tetrofosmin scintigraphy, 1421
Radioimmunopharmaceutical chemistry "F-labeled fluoromethylidoxide synthesis, fluoromethylation of radioimmunopharmaceuticals and, 177(ab)
carbon in Technegas, carbon encapsulation and extended lung retention time for, 186(ab)
Pertechnegas, characterization of inhaled vapor mixture, 187(ab)
Radioimmunopharmaceutical development, SNM award winners, 23(N)
Radioimmunopharmaceutical electron and photon transport, mouse model, 228(ab)
"F altanserin, brain pharmacokinetics, 56(ab)
"I Ofetumomab, stability of, scale-up radioiodination, 178(ab)
pediatric dosimetry, effective dose and estimation, 1982
PET, safety study of, 112(ab)
placental transfer, comparison in guinea pigs and mice, 227(ab)
positron emitting isotopes, high-pressure water targets, 113(ab)
production, new autosynthetic device for, 307(ab)
therapy, "Pr and, 6(ab)
Radioprotection, amifostine, salivary glands, rabbits treated with high-dose "I, 224(ab)
Radiosensitivity, secretory function of salivary glands, evaluation by scintigraphy, 71(ab)
Radiosynovectomy, chronic hemophilic hemarthrosis, synovitis and, 120(ab)
Radiosynoviorthesis, chronic hemophilic hemarthrosis, synovitis and, 120(ab)
first dosimetric data, 302(ab)
Radiotetherapy initial changes in "F-FDG uptake, 1384
lung injury detected by "Te-DTPA lung clearance, radiation pneumonitis, 966
topical application of radionuclides, "Ho, skin cancer and Bowen’s disease, 697
Rapid blood clearance of antibodies, optimizing delivery of residualizing label-antibody conjugates to tumor cells, 1392
Rat glioma, imaging pentose cycle glucose metabolism, PET, 617
Rat lungs, distribution of "Te-labeled microspheres cellular dosimetry, microautoradiography, 650
rCBF, see Regional cerebral blood flow
Reaction volume, clarification of definition, response to editorial, 341(e)
Receiver operating characteristic curve, hybrid method for measuring myocardial wall
thickness, gated PET, SPECT, 324

Receptor imaging

Effect of haloperidol on "I-HBZM brain SPECT imaging, schizophrenic patients, 203 radiolabeled DTPA cobalamin analogs, vitamin 812, 717 radiolabeled ligand for the androgen receptor, 7[alpha]-[[I]IDHT, 402 somatostatin receptors in canine insulinsomas, octreotide, 1036

Receptor recycling, ASGP-R and hepatic blood flow measurement using "Tc-GSA, receptor-mediated endocytosis, 1798 Receptor-binding radiopharmaceutical, sentinel node imaging, lymphoscintigraphy, 530

Receptor-mediated endocytosis, ASGP-R and hepatic blood flow measurement using "Tc-GSA, receptor recycling, 1798

Receptors, lung carcinoma imaging using radiolabeled peptide, YGSR, 1940

Recombiant tissue plasminogen activator, "Tc-labeled, detection of postoperative deep venous thrombosis, 219

Reconstruction

3D, correction of head motion artifacts, SPECT, 126(ab) attenuation map, collimated line sources, 216(ab) cardiac attenuation maps, SPECT systems, statistical algorithms for, 214(ab) generalized parametric, dynamic emission tomography, 102(ab) image, channelized hotelling observers, PET, lesion detection comparison, 78(ab) iterative algorithms, clinical value of, 222(ab) attenuation map resolution effects, cardiac SPECT, 213(ab) FDG PET, compared to filtered backprojection, 101(ab) influence on parameter estimation, 102(ab) ML-EM cone-beam, SPECT attenuation correction, 58(ab) supervised diffusion parameter selection for SPECT brain images, 218(ab) unmatched projector and backprojector pair in, 58(ab) non-uniform attenuation correction new Fourier method, SPECT, 218(ab) "Tc myocardial SPECT, 212(ab) OSEM myocardial, 57(ab) phantom evaluation, 57(ab) simultaneous iterative, attenuation and activity distribution, SPECT or PET, 101(ab) SPECT model-based scatter estimation for use in, 88(ab) pixelization effects, 223(ab) statistical, PET and coincidence SPECT whole-body acquisition, 102(ab) truncated fan beam transmission data, generalized natural pixel basis, 101(ab)

Red cell labeling, image quality and, gastrointestinal bleeding studies, 254(ab)

Reflex sympathetic dystrophy
bone scintigraphy and, 304(ab) scintigraphic staging of, role of dynamic vascular scan, 28(ab)

Region growing, quantitative bone metastases analysis, skeletal mass, 1401

Region of interest, automatically extracted, individual human brain, PET and SPECT data analysis, 210(ab) background corrections, "Tc-MAG3 renography, 74

Regional cerebral blood flow (rCBF) comparative study using "I-IMP SPECT, two-compartment model, microsphere model, 597 differences in "Tc-ECD clearance, brain SPECT, 1253 measurement, quantification of partition coefficient, "I-IMP and SPECT based on two-compartment model, 1248 repeated "Tc-HMPAO SPECT, state-dependent change, 6

Regional myocardial blood flow, potassium and thallium uptake in dogs, capillary permeability, 28(ab)

Regional myocardial ischemia, glucose uptake in ischemic border zone, double-tracer autoradiography, 1515

Regulatory issues, focus for nuclear medicine groups, FDA, EPA, NRC, 17N(2)

Reimbursement
coding and billing review for nuclear medicine procedures, 22N(1) nuclear medicine procedures, 24N(4) SNM seminars, 34N(9)

Reimbursement roadshows, course offered for effective coding and billing, 26N(10)

Relative renal function, effect of different background regions of interest, "Tc-MAG3 renography, 74

Relative value units, Balanced Budget Act of 1997, delaying new practice expense methodology, 24N(10)

Renal artery stenosis
captopril renal function imaging for, 82(ab) captopril renography without baseline, 83(ab) captopril renography, angiographic correlation, 83(ab) treatment with intravenous enalaprilat, versus oral captopril, 82(ab) unilateral, contralateral normal kidney, captopril renography role in, 295(ab)

Renal cell carcinoma
"I 125I antibody therapy, marrow and whole-body absorbed dose vs marrow toxicity after, 252(ab) red marrow dosimetry, after "I cG250, 225(ab) whole-body FDG PET versus conventional imaging, 145(ab)

Renal function, "Tc-EC clearance from single plasma sample, radionuclide renography, 1784

Renal imaging, procedure guideline for cortical scintigraphy in children, 1644

Renal parenchymal scintigraphy, "Tc-MAG3 SPECT, rapid evaluation of renal cortex and function, 478

Renal scintigraphy
comparison of "Tc-LL-EC isomers, "Tc-DD-EC, "Tc-DL-EC, 821 determination of effective renal plasma flow, compartmental analysis, 1285

Renal transplantation, "Tc-MAG3 renogram deconvolution, usefulness of measurement of initial uptake, 1295

Renal tubular injury, ifosfamide-induced alteration, "Tc-DMSA renal parenchymal imaging, 1811

Renal tubular uptake, D-lysine for reduction of "I-DTPAOC and "Y-DOTATOC during scintigraphy, 1929

Renography, hypertensive pathophysiology, interpretative approach during exercise, "Tc-MAG3, "In-DTPA, 1146

Renography, captopril angiographic correlation, 83(ab) evaluation of normal kidney in patients with unilateral renal artery stenosis, 295(ab)

GVH and Tmax after, diagnosis for renovascular hypertension, 83(ab)

renal artery stenosis, 83(ab)

Renovascular hypertension
captopril renography, 827(ed) detection of, EC and DTPA, 1662(Le)

Reperfusion, nonviable myocardium, "Tc-teboroxime kinetics, 274

Reperfusion injury, hyperperfusion of "Cu-PTSM in rat brain, transient global ischemia, 1130

Reproducibility, "I-IBF SPECT, studies of dopamine D2-receptor binding, simplified quantification, 31

Research and development projects, Defense Department awards, 28N(1)

Research radionuclides, availability in North America, 15N(7), 21N(8)

Residency programs, specialties facing cutbacks, nuclear medicine, 13N(4)

Residualizing radionuclides manipulation of blood clearance rate, catabolism of antibody in liver, optimizing RAIT, 1392 therapeutic advantageous of dilactotyl-tyramine in comparison to "I-labeled RS11, lung cancer xenograft, 391

Resistant index, ultrasound, comparison, complications of renal transplants, 49(ab)

Resolution improvement, PET volume imaging through 3-D iterative reconstruction, 1623

Restenosis radioactive stents to inhibit, after PCTA, 7(ab) therapy, intraarterial irradiation with "Re, 124(ab)

Retention index
differentiating histologic malignancy of brain tumors, periventricular "Tc-DMSA, SPECT, 20 role of "Tl in intracranial tumors after radiotherapy, 223 "Tc-DMSA and "Tl brain tumor imaging, histology and malignant grade correlation, SPECT, 1741

Revascularization, myocardial fatty acid uptake and function after revascularization, assessment using "I-BMIPP, 1503

Reversed ventilation perfusion mismatch, CHF in pediatric patient, hypoxic vasoconstrictive response, milronine, 1681

Reversible trapping, graphical analysis of 6-FD, rate of incorporation of tracer from plasma into kinetic component, COMT inhibition, 1568

Rhenium-188 bone pain palliation, cancer therapy and, 125(ab) intraarterial irradiation with, inhibition of restenosis, 124(ab)

Rheumatoid arthritis
adjuvant model, E-selectin upregulation in, 125(ab)

"I IAZA imaging, 300(ab)

"Sm EDTMP in, dosimetry and toxicity, 118(ab)

Rhodium-105, bone analog uptake, and retention in GRP receptor expressing...
tumors, 188(ab)

**Right lateral**, versus supine positioning, **Tc-MIBI** SPECT comparison with coronary arteriography, 1510

**Right ventricle**, identification of severe dysfunction by Tc-sestamibi gated SPECT, pulmonary emboli, 254

**Right ventricular function**, infarction, prognostic value of radionuclide measurements, 109(ab)

**Right ventricular infarction**, sustained RV dyskinesia, diagnostic value of radionuclide ventriculography, 1421

**Rim sign**, hepatic abscess demonstrated on hepatobiliary scan, ROL, 1282

**RMPI**, effects on spatial distribution, blood brain barrier permeability, brain tumor subregions, 93(ab)

**ROC curve**, analysis of imaging methods, "In pentetretide scanning, 103(ab)

**RTI-55**, dopamine transporter occupancy by, transporter inhibition and stimulation of locomotor activity, 61(ab)

**Rubidium-82**
kinetic model for dynamic PET data, myocardial blood flow, 660

PET

detection of coronary collaterals using myocardial perfusion imaging, dipyridamole, 39

S

**SAF**, internal dose estimation using the TLD method, continuous 0 inhalation, 1603

**Salivagram**, volume-dependent pulmonary aspiration, swallowed radionuclide bolus, 103

**Salivary glands**
accumulation and clearance of "I-l postoperative thyroid cancer patients, 266(ab)

"C-methionine transport enhanced by insulin, PET, 1967

radiation dose to, during "I treatment of thyroid cancer, 230(ab)

scan, prognostic value, peripheral facial nerve palsies patients, 257(ab)

scintigraphy, FDG PET and, parotid gland tumors, 242(ab)

secretory function, evaluation by scintigraphy, 71(ab)

**Samarium-153 EDTMP**
bone tumor therapy, 252(ab)

moderate and severe bone cancer pain, 251(ab)

rheumatoid arthritis, 118(ab)

**Sarcoidosis**, **Tc-MDP** uptake in hilar lymph nodes, 262

**Sarcoidosis Stage I**, **Tc-tetrofosmin** uptake, hilar lymphadenopathy, 1786

**Sarcomatoid carcinoma**, **Tc-MDP** uptake in primary breast adenocarcinoma, bone scintigraphy, 528

**Scandium-47**
"In and, CyDOTA immunoconjugates, development and evaluation, 189(ab)

optimization for processing, radioimmunotherapy, 193(ab)

**Scanners**, high-resolution, continuous 3D detectors in small animal PET, 44(ab)

**Scatter correction**

algorithms, whole-body PET ECAT EXACT HR+ system and, 197(ab)

attenuation and, quantitative analysis of 8-CT brain SPECT, 146(ab)

attenuation correction combined with, effect on **Tc** phantom studies, 221(ab)

Compton compensation for, "Tc cardiac SPECT, 219(ab)

SPECT, modified triple energy window, 215(ab)

Compton free imaging, acquisition and processing parameters in, 67(ab)

**DISA** SPECT, energy window cross-talk for, 89(ab)

dual-photopeak window method limitations, brain imaging, 1902

effects in quantitative regional cerebral blood flow studies, SPECT, 285(ab)

emission and transmission data, single isotope "Tc use in, SPECT, 218(ab)

evaluation, bone, brain SPECT, 212(ab)

global, high resolution PET, 114(ab)

improving energy resolution effects, SPECT, 89(ab)

model-based estimation, OSEM SPECT reconstruction, 88(ab)

reconstruction-based, out of field-of-view activity effects, cardiac SPECT, 88(ab)

simultaneous emission transmission cardiac studies, 89(ab)

tumor detection and, planar scintimammography, 66(ab)

**SCFy fragments**, monovalent constructs, tumor targeting and therapy, 231(ab)

**Schizophrenia**
effect of haloperidol on "I-IBZM brain SPECT imaging, 203

extra-stratal dopamine receptors, clozapine in, SPECT study, 90(ab)

measurement of dopamine receptors, choice of outcome measure in SPECT measurement, 95(ab)

regional cerebral blood flow changes, negative/positive symptoms, "Tc-hMPAO, SPECT, 181

temporal lobe perfusion asymmetries, neurophysiology, SPECT, 607

working and declarative memory, fronto-temporal cerebral blood flow change during, 282(ab)

**Schwannomas**, identification of somatostatin receptors, 827(ed)

**Scintigraphy**
abnormalities, accuracy of needle localization of, radio-directed biopsy system, 22(ab)

bronchial artery perfusion, in double lung transplantation with bronchial artery-internal mammary artery anastomosis, 5(ab)

evaluation of experimental colitis in rabbits gamma globulin, 1596

"In pentetretide, differentiation of thymic masses and, 17(ab)

measurement of colonic transit using labeled activated charcoal, comparisons with ion exchange pellets, 1807

radioisotope dynamic, compared to compartment and deconvolutional analysis, 207(ab)

**RSDS** staging, role of dynamic vascular scan, 28(ab)

"Tc-labeled peptidomimetic, fresh thrombus imaging, 26(ab)

ventilation perfusion planar versus SPECT, operational differences, 5(ab)

virtual pulmonary, "best view" of segmental anatomy in, 5(ab)

**Scintillation camera**
cesium iodide silicon photodiode gamma, design studies, 31(ab)

dual detector, simultaneous SPECT and coincidence imaging with, 208(ab)

dual-photopeak window, scanning line source for attenuation correction, SPECT, 217(ab)

dual-head, coincidence imaging parameters of, 221(ab)

photodiode readout, potential SPECT camera utilization, 31(ab)

pupil prevention method, 143(ab)

urine activity measurement with, glomerular filtration rate determination, 295(ab)

**Scintimammography**

breast SPECT, scintillation camera for, 32(ab)

dedicated breast imaging system, solid state detector array, 142(ab)

planar "F oxyglucose and "Tc tetrofosmin comparison, 68(ab)

impact of scatter correction on tumor detection in, 66(ab)

poor specificity, primary breast cancer in UK patients, 21(ab)

radionuclide-guided localization of nonpalpable breast lesions, "Tc-sestamibi, 1019

radiopharmaceuticals for, comparison, 233(ab)

"Tc DPD imaging, breast cancer detection reliability, 21(ab)

"Tc MIBI, breast cancer detection, European trial, 20(ab)

"Tc sestamibi early breast lesions, 234(ab)

primary breast lesions, 234(ab)

response of breast cancer to, 46(ab)

simultaneous acquisition of both breasts, dual head camera, 209(ab)

"Tc sestamibi and "Tc tetrofosmin, comparison, 233(ab)

"Tc tetrofosmin, primary breast lesions, 233(ab)

"Tc-sestamibi compared with contrast-enhanced MRI, breast cancer diagnosis, 58

**Sedation**, procedure guideline for pediatric medical procedures, 1640

**Segmental anatomy**, lung scintigraphy for PE, Monte Carlo simulation, 1987

**Seizures**
FDG PET scans, after temporal lobectomy, 92(ab)

rapidly propagating, location with ictal SPECT, 91(ab)

temporal lobe epilepsy, memory loss after surgery for, preoperative FDG PET scans as predictor of, 23(ab)

**Semiconductor detectors**, modular imaging arrays, multiplexer readout, 143(ab)

**Semiquantitative** prediction of myelotoxicity using marrow image scores, RIT, 1749

**Semisolid test meal**, accelerated gastric emptying in longstanding diabetic patients, supine position, 814

**Sentinel lymph nodes**, cancer staging with lymphoscintigraphy, gamma probe, 15N(ab)

**Sentinel node imaging** lymphoscintigraphy by receptor-mediated delivery of a nonparticulate imaging agent, receptor-
Serotonin, radiometabolites of \(^{18}F\) almitserin, identity and receptor binding, 287(ab)

Serotonin receptors
5-HT2A, \(^{11}C\) MCL 100,907 PET, brain, 81(ab)
blockade, schizophrenic patients treated with clonazepam and olanzapine, 107(ab)
cWAY, kinetic analysis, 80(ab)
\(^{18}F\) MPPF PET for imaging cat brain, 50(ab)
tissue distribution, rat, 56(ab)
\(^{18}F\) setoperone, binding potential estimation for, use of reference region graphical analysis method, 201(ab)

Serotonin transporters
bromine-76 labeled 5-bromo-6-nitroquinapizone, PET studies, 57(ab)
\(^{12}C\) MN-5652, binding potential, quantification of, 202(ab)
Parkinson's disease, \(^{11}C\) ICGT SPECT, 280(ab)
PET binding kinetics, kinetic modeling of \(^{12}C\) MCN5652X and, 196(ab)
precursors of, new route, 57(ab)
pressynaptic monoaminergic brain, simple detection system for, mouse, 288(ab)
living mouse brain, 207(ab)
Serotonin-1A receptor agonist, \(^{11}C\) LY274601, radiosynthesis and biodistribution, 56(ab)
Serum protein bound fraction, pharmacokinetics of \(^{11}I\) IMBA for melanoma imaging, radiiodinated benazines, 127

Sestamibi
detection of parathyroid hyperplasia, thymic carcinoma, and pituitary adenoma, MEN type I, 1,767
exercise-rest same-day SPECT imaging, detection of coronary artery disease, 206(ab)
extent of multiple myeloma versus sites of active tumor proliferation detected with \(^{18}F\)-FDG PET, 1208

Shelf-life, \(^{11}C\) liposomes, glutatione-HMPAO and, 179(ab)
Shoulder lesions, \(^{18}F\)-MDP patterns, bone scan, 1491

Sickle cell, scintigraphic evidence of pulmonary vascular occlusion, sickle cell disease, 1151

Sigma receptors, chelates, \(^{11}C\) ethylidenamines and, 186(ab)

Signal-to-noise ratio, weighted summation of \(^{18}F\)-water PET data, activation studies, 334

Simplified quantification, \(^{123}I\)-BF SPECT, studies of dopamine D2-receptor binding, reproducibility, 31

Simulations, PET, time-activity curve extraction, factor analysis approach, mice, 201(ab)

Simultaneous dual-isotope imaging, three-window transformation, cross-talk correction for SPECT, 1992

Sincalide, pretreatment, hepatobiliary scintigraphy in chronic cholelithiasis, 258(ab)

Single photon emission computed tomography (SPECT)
3D, functional brain imaging using optical flow, 135(ab)
511 keV collimator septal penetration effects, 220(ab)
geometric point response blurring, 2D effects, 219(ab)
tumor detection with, 206(ab)
AMI followed by \(^{11}C\)-sestamibi imaging and pathologic correlation, 1837
anterior opercular syndrome, isolated cortical atrophy, 1122
artifacts, cardiac hepatobiliary uptake of \(^{11}C\) Tc, 75(ab)
intestinal activity, 75(ab)
assessment of perfusion reserve, hemodynamics of cerebral watershed infarction, \(^{11}I\)-IMP, 1556
attenuation correction
Jaovaczk heart phantom and, 168(ab)
mean attenuation coefficients for, 67(ab)
using emission data alone, 68(ab)
attribution map reconstruction, collimated line sources, 216(ab)
benzodiazepine receptors in chronic CV disease, blood flow and metabolism comparisons, PET, 1693
bone
cardiac dedicated uniplanar fanbeam collimator in, 29(ab)
structural imaging versus, back pain management and, 29(ab)
bone allograft viability assessment, spinal surgery and, 28(ab)
bone scan, MRI comparison, osteomyelitis, 133(ab)
brain
acute cerebral infarction, urokinase, 280(ab)
cerebral blood flow in autism patients, 284(ab)
changes in rCBF after oral amphetamine challenge, 48(ab)
chronic lyme encephalopathy, 278(ab)
corticobasal degeneration, 274(ab)
diazepam challenge, 280(ab)
dopaminergic drug effects on blood flow, 48(ab)
effect of acute IV cocaine challenge on brain perfusion, 274(ab)
evaluation of cochlear implant in deaf subjects, 273(ab)
evaluation of depression, 828(ab)
high-resolution imaging using half fanbeam collimators with right-angle dual-camera SPECT system, 32(ab)

lesion localization in hemispatial neglect, 281(ab)
multi-modality, mid-sagittal plane in, 221(ab)
non-uniform attenuation correction, 213(ab)
perfusion after treatment of childhood acute lymphoblastic leukemia, 82
PET comparison, cerebral blood flow imaging, 216(ab)
scatter due to bone in, 212(ab)
stereotactic proportional coordinate system for, 212(ab)

supervised diffusion parameter selection for, 216(ab)
unidimensional and fixed regions of interest, 136(ab)

breast, scintillation camera for, 32(ab)
bremstrahling
clinical fusion of three-dimensional images, \(^{18}F\) activity, CT, 319
cannabinoid receptors, brain, 116(ab)
cardiac
anatomical variations affecting, female patients, 20(ab)
attenuation maps in, 217(ab)
chronically dysfunctional myocardium, 62(ab)
compensation for cross-contaminating effects, 88(ab)
iteratively reconstructed, attenuation map resolution and, 213(ab)
projection measurements, parameter estimation, 222(ab)
reconstruction-based scatter compensation, 88(ab)
reverse distribution in, 130(ab)
simultaneous emission transmission, scatter contamination in, 89(ab)

\(^{99m}Tc\), compston scatter theory, 219(ab)
cardiac dynamic, input function extraction using factor analysis in, 9(ab)
cerebral postischemic hyperperfusion, \(^{18}F\) Xe, 602 coincidence detection cameras to perform PET imaging, 13N(1)
compared with echotomography to evaluate myocardial perfusion imaging with \(^{11}C\) -sestamibi, 754

complex-partial seizures, 92(ab)
compton free imaging, scatter correction, 67(ab)
compton scatter correction in, modified triple energy window, 215(ab)
compton scatter data, determination of patient boundaries, 135(ab)
correlation with cellular density and proliferative activity, \(^{11}I\)-IMP, 1551

crossed cerebral diaschisis, hemispheric stroke, 271(ab)
curved NaI(Tl) detector for, 144(ab)
cylindrical systems, off-center FOV, sensitivity and uniformity, 219(ab)
defect severity, anthropomorphic phantom, 85(ab)
diabetes, childhood moyamoya disease, 276(ab)
diagnosis of head and neck cancer, \(^{99m}Tc\)-chloride, 873

differences between \(^{99m}Tc\)-HMPAO and \(^{99m}Tc\)-ECD in normal medial temporal lobe, 1109
dipyriramole scintigraphy and intravascular ultrasound postintervention, \(^{99m}Tc\)-MIBI SPECT, 553
discriminating frontal lobe-type dementia from Alzheimer's disease, \(^{99m}Tc\)-HMPAO, 929
dopamine transporter imaging and quantification, \(^{11}I\)-IPT in normal and Parkinson's disease, 1703
dosimetry
quantitative imaging and three-dimensional discrete Fourier transform convolution, 308
dual isotope
cross-talk correction technique for, 243(ab), 67(ab)
energy window cross-talk for correction, 89(ab)
iterative reconstruction, cross-contamination, 88(ab)
dual-headed system, transmission data acquisition, 220(ab)
dynamic "$^{18}$F BMIPP, stress "$^{18}$F SPECT versus, patients with ischemic heart disease, 165(ab)
dynamic, "$^{99}$Tc ECD continuous infusion, quantification of rCBF, 287(ab)
ECG gated
"$^{99}$Tc tetrofosmin radial long axial myocardial, ECG-gated blood pool SPECT versus, left ventricular ejection fraction estimation and, 163(ab)
ectopic lacrimal gland, "$^{123}$I-pertechnetate, 1498
electroconvulsive therapy and cerebral perfusion, catatonia, 251
emission/transmission, lung ventilation measurement, 296(ab)
enhanced gated perfusion, wall motion assessment, mycardium, 156(ab)
evaluation of coronary artery disease with dipyridamole "$^{99}$Tc-tetrofosmin, 44
evaluation of RV and LV volume and EF, phantom design, 1528
exercise myocardial perfusion, incremental risk stratification with clinical history, exercise treadmill and, 40(ab)
exercise-rest same-day sestamibi imaging, detection of coronary artery disease, 200
extra- striatal dopamine receptors, clozapine, 94(ab)
FDG
FDG PET and, myocardial viability imaging, intr individual comparison, 169(ab)
functional outcome after revascularization, 130(ab)
"F, collimator specific treatment for data, 211(ab)
gated sestamibi, serial reproducibility, LVEF measurement, 28(ab)
gated $"^{201}$TI, diagnostic and prognostic cost effectiveness for coronary artery disease, 164(ab)
gated "$^{99}$Tc MIBI, sublingual nitroglycerin in coronary syndrome, 140(ab)
gated thallium and sestamibi, first-pass radionuclide angiography, LVEF correlations by, 27(ab)
"$^{186}$Gd, "$^{99}$Co, and "$^{11}$I comparison, attenuation correction, 222(ab)
generalized parametric image reconstruction for, 102(ab)
high resolution pinhole, thyroid diseases and, 16(ab)
ictal location of rapidly propagating seizures, 91(ab)
use in extratemporal epilepsy, 92(ab)
ictal "$^{99}$Tc HMPAO brain, evaluation of hypothalamic hamartomas in gelastic epilepsy, 22(ab)
ictal and interictal, MRI coregistration to, seizure foci localization in children by, 12(ab)
ictal rCBF, seizure focus localization in sensorimotor epilepsy and, 23(ab)
image infarcts in, multiead gamma cameras, 217(ab)
"In CYT-356, vascular structure for, prostate, 136(ab)
"$^{11}$BF, dopamine receptor binding with, 286(ab)
"$^{18}$F-B-CIT, imaging of dopamine transporters in Parkinson's disease, 1
"$^{18}$F-B-CIT, measurement of dopamine transporters in Parkinson's disease, 1453
"$^{18}$F-BMIPP myocardial washout and cardiac work during exercise, pressure rate product, ischemic heart disease, 559
"$^{125}$I-IMP comparison of methods to measure regional cerebral blood flow, microsphere model, two-compartmental model, 597
IMT
amino acid uptake in cerebral gliomas, compared to MET-PET, 517
"I iomazenil benzodiazepine receptor occupancy, depression, 282(ab)
GABA benzodiazepine receptor in alcohol dependence, 107(ab)
"I 11D0I dosimetry, human glioma, 210(ab)
"$^{99}$TI pinhole, analytical model of, 58(ab)
"$^{99}$TI renal blood flow, 82(ab)
interictal partial epilepsy diagnosis, 91(ab)
temporal lobe epilepsy, 280(ab)
iterative reconstruction
ML-EM cone-beam, 58(ab)
unmatched projector and backprojector, 58(ab)
lateralization of temporal lobe blood flow, perfusion asymmetries in schizophrenia, neurophysiology, 607
monoamine oxidase B exploration by, 181(ab)
motion correction algorithms for myocardial perfusion scintigraphy, "$^{117}$TI, 785
multimodality visualization
combination of complementary data for diagnostic information, magnetic resonance brain images, 624
myocardial attenuation correction, 84(ab)
attenuation-corrected, misalignment effects, 28(ab)
discordant perfusion and function after infarction, 110(ab)
effect of nonuniform attenuation correction on defect detection in, 19(ab)
local impact of attenuation using intrinsically dual energy processing in, 19(ab)
pre-CABG "$^{99}$TI rest/gated dipyridamole stress "$^{99}$Tc MIBI/"$^{117}$TI 24 hour redistribution, comparison with post-CABG SPECT wall motion improvement prediction, 3(ab)
reconstruction using EM and OSEM, with distance-dependent resolution compensation and post-reconstruction filtering, 20(ab)
simultaneous attenuation and collimator-detector response compensation and, 19(ab)
myocardial gated, LVEF assessment, two-month comparison, 27(ab)
myocardial perfusion imaging with combined system, x-ray CT, 1535
mean and variability of myocardium in, 168(ab)
rest "$^{99}$TI/stress "$^{99}$Tc sestamibi dual isotope, incremental prognostic value in diabetic patients, 40(ab)
role of history of coronary artery disease and patient sex in cardiac risk and catheterization referral, 164(ab)
myocardial perfusion normal database, polar map technique, attenuation, 155(ab)
myocardial viability assessed, combined with PET for diagnostic and prognostic purposes, coronary artery disease, 742
myocardial viability studies, "F-FDG PET, 582
nuclear medicine data processing methods, community-wide evaluation, 215(ab)
OSEM reconstruction
neuronal image analysis, comparison of "$^{99}$Tc-HMPAO and "$^{99}$Tc-ECD, statistical parametric mapping, 1721
normal subjects imaging with "$^{99}$Tc-HMPAO and "$^{99}$Tc-ECD, anatomical standardization, 587
myocardial, 57(ab)
phantom evaluation, 57(ab)
ocular melanoma imaging, radiolabeled benzamides, 870
Pentavalent "$^{99}$Tc-DMSA images, differentiating histologic malignancy of primary brain tumors, 20
phantom, hardware and software performance, quality control, 208(ab)
photodiode readout of scintillator crystals, potential utilization of, 31(ab)
pinhole
diagnosis of bone and joint diseases, 304(ab)
diagnosis of skeletal disorders, 301(ab)
pediatric skeleton, 306(ab)
skeletal disorders, 222(ab)
preclinical prediction, Alzheimer's disease, 70(ab)
pulmonary perfusion and density gradients, transmission tomography, attenuation, 962
quality control, field uniformity, 206(ab)
quantification region of interest, 210(ab)
scatter elimination, attenuation correction, 213(ab)
quantification of cerebral blood flow and partition coefficient, "$^{125}$I-IMP, 1248
quantification of cerebral blood volume, comparisons with PET, 919
quantitative assessment of cerebral blood flow, Alzheimer's disease, computer assisted image processing, 1095
quantitative bone, bone loss prediction, patients with hyperparathyroidism, 17(ab)
rCBF
abnormalities and severity of autistic disorder, 13(ab)
after anterior circulation vasospasm, balloon angioplasty versus papaverine infusion for, 36(ab)
"$^{125}$I-IMP autoradiography, cerebral infarction, SAH, 1107
 "$^{99}$Tc-HMPAO, positive and negative symptoms in drug-na"ve schizophrenics, neuroleptic treatment, 181
reconstruction
model-based scatter estimation for, 88(ab)
pixelization effects, 223(ab)
reconstruction of Compton-camera camera images, 58(ab)
renal, "$^{99}$Tc DMSA, 296(ab)
rest-redistribution "$^{99}$TI imaging and rest "$^{99}$Tc-sestamibi, stable coronary artery disease, ventricular dysfunction, 419
role in "Ga citrate evaluation of abdomen, 115(ab)
scatter compensation techniques, improving energy resolution effects, 89(ab)
septal perfusion and wall thickening in patients with left bundle branch block, ""Te-
sestamibi gated tomography, 545
serotonin receptor blockade, schizophrenic patients, 107(ab)
slit/slit collimator for, stationary array of planar detectors in, 8(ab)
spine, ankylosing spondylitis, 133(ab)
spino cerebellar degeneration in Lyme disease, HMPAO, 1120
stress
5 years after bypass surgery, incremental prognostic value and risk stratification, 40(ab)
after recent PTCA, 130(ab)
asymptomatic patients and, incremental prognostic value and risk stratification, 41(ab)
stress cerebral perfusion, quantitation, 276(ab)
striatal dopamine receptor occupancy, antipsychotic actions, 107(ab)
studies in Parkinson's disease, multiple system atrophy, and Huntington's disease, ""Te-
epidepride, 1711
synthesis and, putative vesamcel receptor-binding radiotracer ""Te MIBT, 181(ab)
""Te: DMSA
and ""Te brain tumor imaging, histology and malignant grade correlation, 1741
comparative study, detection of renal scars, 49(ab)
""Te ECD
brain imaging in misery perfusion, stenocclusive disease, PET comparisons, 791
presurgical localization with interstitial and posticular brain scans, medically intractable complex partial seizures, 23(ab)
""Te gated perfusion study, end-diastolic versus summed images, coronary artery disease detection, women, 15(ab)
""Te HMPAO
basal ganglia perfusion in Tourette's syndrome, 188
brain scan, regional stability of cerebral blood flow, within and between subjects variance, 6
cerebral blood flow during cognitive meditation, 95(ab)
crossed-cerebellar diaschisis in cerebral infarction, MRT, 14
medial temporal lobe during anesthesia, 273(ab)
post-ictal difference-image perfusion and, epilepsy area localisation and, 22(ab)
reproducibility of RCBF with, 1217(ab)
systemic lupus erythematosus with CNS involvement, 1112
""Te MIBI post-stress and 24-hour gated, transient prolonged stunning by diprydamole stress, 15(ab)
""Te-MAG3 scintigraphy
rapid evaluation of renal parenchyma, 478
""Te MIBI
AdVEGG123 gene therapy assessment, in coronary artery disease, 42(ab)
supine versus right lateral imaging, comparison with coronary arteriography, 1510
""Te myocardial, methods for non-uniform attenuation correction, 212(ab)
""Te-sestamibi
images to detect resting LV dysfunction, cavity-to-myocardium count ratio, 760
resting left ventricular systolic function measurement by, resting versus post-stress images, 14(ab)
""Te-tetrofosmin uptake in sarcoidosis, hilar lymphadenopathy, 1786
""Te-tetrofosmin, imaging of single solid lung masses, 1015
temporal lobe blood flow measurements, MRI-guided, Alzheimer's disease, 914
""Te distribution in lower legs, chronic exertional compartment syndrome, 972
""Te imaging and intravascular ultrasound, myocardial perfusion in heart transplant recipients, graft atherosclerosis, 760
""Te, optimum sampling schedule, 223(ab)
gated attenuation correction, effects of length of transmission scan, 64(ab)
prediction of myocardial viability after bypass, 155(ab)
""Te uptake in CMV encephalitis, AIDS, 1386
thoracic and abdominal image fusion with CT, endocrine carcinoma, 1234
three-dimensional, structured bias, interaction of penalized objective function and system matrix, 2(ab)
three-headed system, transmission data acquisition apparatus for, 219(ab)
three-window transformation, cross-talk correction, dual-isotope imaging, 1992
transaxial, two one-dimensional Compton cameras of finite extent for, 32(ab)
transmission image imaging, simultaneous emission, scanning point sources, 216(ab)
transmission scans, multiple line-source array for, 215(ab)
two-head systems, asymmetric fan-beam transmission CT on, 212(ab)
ultra high resolution pinhole, 217(ab)
ultra-fast gated myocardial perfusion, 3-head gamma camera and cerebral collimators, 28(ab)
validation of quantitative defect size, rest ""Te-sestamibi myocardial perfusion imaging, 1441
ventilation perfusion planar versus, scintigraphy, operational differences, 5(ab)
vertical axis-of-rotation, half-cone beam collimation, breast cancer, 220(ab)
volumes and activities of small structures, posterior probability, 220(ab)
volumetric analysis of cerebral hyperperfusion, ""Te-HMPAO, CBF, 1447
whiplash syndrome, 276(ab)
whole-body acquisition, accelerated statistical reconstruction, 102(ab)
""Te brain, improved sensitivity to cerebrovascular stress studies. 37(ab)
Single solid lung masses, SPECT imaging, ""Te-tetrofosmin, 1015
Single-sample method, measurement of GFR with ""Te-DTPA, plasma clearance, urinary clearance, 1290
Sjogren's syndrome, with xerophthalmia, radionuclide dacrocyostegyostoma in evaluation of, 257(ab)
Skeletal flow, Fluoride kinetics of skeleton measured with ""F-Fluoride PET, 1970
Skeletal mass, quantitative bone metastases analysis, image segmentation, 1401
Skeletal metastases, facet osteoarthritis sign at lower lumbar spine, negative predictive value of, 302(ab)
Skin cancer, topical application of radionuclides, ""Ho, Bowen's disease, 697
Skull, hypertelorism frontalis interna, marrow scintigraphy, 1283
Sn-117m DTPA, bone pain therapy, safety and efficacy parameters, 46(ab)
SNM, see Society of Nuclear Medicine
Society of Nuclear Medicine (SNM)
1997 annual meeting press conference, 30N(8)
1997-1998 election results, 30N(6)
44th annual meeting, San Antonio, 26N(5)
archives established, 42N(5)
European collaboration, 32N(3)
FDA and NRC update, 101N(1)
misson statement, lines from the president, 20N(7)
procedure guidelines manual, 42N(5)
theme of 1997 meeting, 15N(8)
year-end summary, 28N(9)
Soft tissue tumor
malignant and bening, ""Te scintigraphy in differentiation, 302(ab)
primary, malignant or benign, FDG PET differentiation, 242(ab)
""Te and ""Te-MIBI, comparisons in malignant and benign lesions, bone tumor, 501
Solid waste contamination, outpatients treated with ""Te, 26N(9)
Somatostatin
analogus
""In DTPA-octreotide imaging, D-lysin and renal uptake, 191(ab)
""In labeled DTPA octapeptides, receptor binding and tissue distribution, rats, 190(ab)
biodistribution, 103(ab)
identification of receptors in schwannomas, 827(ab)
radiotracers in canine insulinomas, octreotide, 1036
Somatostatin receptor imaging, malignant somatostatinoma imaging, ""In-octreotide, 886
Somatostatin receptor scintigraphy
false-positive scintigraphy, accessory spleen, 1979
management of patients with neuroendocrine gastroenteropancreatic tumors, ""In-octreotide, 853
Somatostatin receptors
adrenal gland imaging following ACTH therapy, ""In-DTPA octreotide, 1489
ANCA-associated vasculatitis, detection of pulmonary manifestations by ""In octreotide imaging, 38(ab)
""Cu teta-octreotide PET, carcinoid tumor patients, 103(ab)
""In OctreoScan targeted to, evaluation of potential ligand-octreotide radiopharmaceuticals, 190(ab)
""In labeled DTPA-D-Phe1-octreotide, tumor imaging, 18(ab)
pancreatic, peptide receptor radionuclide therapy in rat, 59(ab)
radiat ion dosimetry for ""In-octreotide, 1919
scintigraphy
""In pentetreotide, staging Hodgkin's lymphoma, 102(ab)
detection of extrapancreatic gastrinoma with, 237(ab)
scintigraphy, new sites revealed by, Zollinger Ellison syndrome, 104(ab)
specificity of ""In-DTPA-D-Phe-pentetreotide, ectopic secreting carcinoma, Cushing
tumors with, "**Tc** P829 peptides for, 236(ab)

Somatostatinoma, somatostatin receptor imaging with "**In**-pentetreotide, 886

**Sparganosis**, findings of "**Tc**-HMPAO cerebral perfusion SPECT, 939

**Specificity, MIBG** scintigraphy, neural crest tumors in childhood, 1352

**SPECT**, see Single-photon emission computed tomography, somatostatin receptor imaging with "**In**-pentetreotide, 886

Spectral analysis, applied to radioisotope dynamic scintigraphy, compared to compartment and deconvolutional analysis, 207(ab)

**Sphincter of Oddi** spasm, role in biliary dyskinesia, qualitative cholescintigraphy to differentiate disease entities, 1824

**Spinocerebellar Specificity**.

**Standardised Sports Split**

**Splenectomy**.

**Sterically**

**Staurosporine**.

**radiolabeled**.

**hiotin radioactive, scintigraphy and**, 386(ab)

**radioactive**, scintigraphy and, 386(ab)

**dyness**

**dynamic syndrome**

**compartment**

**exertional evaluation**

**orthosomatopally**

**transfusion**

**biochemical gliomas**

**assess**

**breast antigen**.

**lower hypertension**, scintigraphy in, 426(ab)

**imaging**

**in**

**localization**

**immunoscinligraphy with**

**misery**

**MIBC**(ah)

**controlled findings**

**antibody**

**efficacy, 71(ab)**

**radiocolloid**

**biotinylated to**

**to**

**biotin**

**radioactivity**

**quantitative imaging with**

**Tc-EC"D**

**in**

**dose cardiac**

**myocardial**

**function of**

**Tc-IMP**

**autoregulatory method with**

**SPECT, cerebral infarction, 1102(ab)**

**Supine position**, accelerated gastric emptying after semi-solid meal, insulin-dependent diabetics, 814

**Surfactant**, inhaled, effect on pulmonary deposition and clearance of "**Tc** DTPA, 298(ab)

**Surgery**, lung resection, patients with chronic lung disease, lung scintigraphic patterns in, 38(ab)

**Survival**, prediction of, "**Tc**-FDG PET, head and neck neoplasms, 1907

**Swallowed bolus**, volume-dependent pulmonary aspiration, salivary gland, 103

**Sympathetic nervous activity**

"**I**-MIBG uptake, effects of cilazapril and verapamil in cardiomyopathic hamsters, 1540

**myocardial imaging in normal subjects, vagal tone, 49**

**Sympathetic nervous system**

**cardiac autonomic dysfunction, idiopathic ventricular tachycardia and**, "**C** CGP 12177 and "**C** hydroxyephedrine PET assessment, 171(ab)

**denervation, myocardium, PET imaging of metabolic abnormalities, canine, 54(ab)**

**myocardial, modulation of, MIBG scintigraphy detection of, 64(ab)**

**Systemic disease, myocardial involvement, "**In** antimyosin antibody imaging in diagnosis, 168(ab)**

**Systemic lupus erythematosus, CNS involvement, "**Tc**-HMPAO brain SPECT, 1112

**Systemic sclerosis, "**In**-AMA scintigraphy for diagnosis of myocardial damage, 1759

T

**Taxol, "**Sr** effect enhancement and, human prostatic carcinoma lobular tumor model, 195(ab)**

**Technegas**

**physical and chemical nature of, "**Tc**-pertechnetate, 1327

V/Q scintigraphy and lung function testing, metal stent implantation, 1584

**Technetium-99m**

**analogs, D2 receptor binding benzamides, 99(ab)**

**antigranulocyte antibody, bone marrow scintigraphy using, malignant lymphoma, 10(ab)**

**biotin labeled with, 142(ab)**

**bombesin analogs, synthesis and evaluation, 87(ab)**

**detection of focal infection, granulocytopenic rats, 270(ab)**

**detection of postoperative deep venous thrombosis, labeled recombinant tissue plasminogen activator, 219**

**diaminedithiolate complexes, binding with serotonin receptors, 100(ab)**

**dual isotope, simultaneous "**F, cross-talk correction, 243(ab), 67(ab)**

**erythrocyte labeling with, antineoplastic agent effects, 307(ab)**

**ethylene diamines, gamma receptor chelates and, 186(ab)**

**evaluation of platelet receptor-binding peptides, potential use of P748 as imaging agent for detection of venous thrombosis, 105**

**flow versus uptake in canine model of myocardial ischemia, comparison with "**Tc**, 1847**

**gated dipiridamole stress, pre-CABG "**Tc**24 hour redistribution,"**Tc** rest myocardial SPECT, comparison with post-CABG SPECT in wall motion improvement prediction, 3(ab)**

**hepato-biliary uptake of, cardiac artifacts due to, SPECT, 75(ab)**

**human immunoglobulin G, via the nicotinyl hydrazine derivative, 157(ab)**

**human serum albumin microspheres, safety analysis of hepatocyte transplantation, 258(ab)**

**HYNIC peptide labeled, N52 as co-ligand, 188(ab)**

**imaging prostate cancer, monoclonal antibody, prostate-specific antigen, 675**

**incorporation into hepatocytes, bilirubin effects, 51(ab)**

**infection, bacterial specific imaging with, 157(ab)**

**labeling and biodistribution of anti-TAC disulfide-stabilized Fv fragment, 294**

**labeling MAG3, alternative NHS-MAS3 and, 185(ab)**

**labelling, breast cancer oncogene CAPL, 87(ab)**

**liposomes, "**Ga** citrate versus, detection of hyperoxia-induced lung inflammation, rats, 185(ab)**

**multigated blood pool studies, "**Tc** SPECT myocardial perfusion studies versus, left ventricular ejection fraction calculation, 16(ab)**

**myocardial perfusion and function imaging at rest dual isotope gated SPECT,"**Tc**, 432**

**myocardial SPECT, effect of nonuniform attenuation correction on defect detection in, 19(ab)**

**nucleotides labeled with, tumor imaging agents, SCID mouse breast tumor model, 8(ab)**

**oxochromenium mixed ligand complexes, synthesis and biodistribution data of, 184(ab)**

Subject Index • 1997 571
Technetium-99m-disofenin. 

Ttchnetium-99m uptake, specific high accumulation, affinity agent, labeled in.

breast imaging. biomolecule to imaging. antillhrin antibody, background.

chronic tumor-bearing complexes and.

dM444. DMP444, platelet GPIIb/IIIa antagonist labeled with, arterial thrombus detection, 18(ab)

Technetium-99m-DMP-HAS, compared to ~Tc-labeled RBCs for equilibrium radionuclide ventriculography, 1521

Technetium-99m DMSA brain tumor imaging histology and malignant grade correlation, Tc, 1741

In-OCT and, preoperative staging of primary medullary thyroid cancer, 237(ab) kidney, children with vesicoureteral reflux, 50(ab)

renal parenchymal imaging, effects of ifosfamide on renal tubules, 1811 renal SPECT, 296(ab) SPECT, comparative study, detection of renal scars, 49(ab) uptake, kidney, nephron-sparing surgery, 293(ab)

Technetium-99m DTPA aerosols, alveolo-capillary permeability and ventilation studies of, 180(ab) evaluation, pancreas-renal transplant, 254(ab) infection imaging after anti-DTPA monoclonal antibody priming, 901 pulmonary deposition and clearance, inhaled osteomatrix, 298(ab) radiation-induced lung injury, detection of impaired permeability, lung clearance, 966 single-sample method to measure GFR, plasma clearance, urinary clearance, 1290

Technetium-99m DTPA-folate, folate-receptor-targeted radiopharmaceutical, synthesis, 87(ab)

Technetium-99m DTPA-galactosyl human serum albumin fractional liver uptake and blood concentration, 253(ab) postprandial effect on asialo-glycoprotein imaging, 260(ab)

Technetium-99m ECD brain, selective neuronal loss in dementia, 71(ab) brain SPECT in misery perfusion, steno-occlusive disease, PET comparisons, 791 brain tumor diagnosis, surrounding edema, 159(ab)

cerebral imaging discrepancies, HMPAO SPECT, 592 continuous infusion, dynamic SPECT and, quantification of rCBF, 287(ab) differences between regional distribution of two tracers in normal brain, ~Tc-HMPAO, hippocampus, SPECT, 1109 differences in ~Tc-HMPAO, normal hippocampus, 277(ab)

evaluation of cerebral blood flow, during transient global anemia, 273(ab) follow-up rCBF SPECT, pediatric encephalitis and encephalopathy, 277(ab) in vitro metabolism of, hydrophilic conversion mediated by enzymes, 1731 mitochondrial encephalomyopathies, without cognitive impairment, 284(ab) normal brain perfusion pattern in children, 1115 quantification of rCBF with continuous infusion of cerebral perfusion tracer, dynamic SPECT, 1699 scatter and attenuation correction, improved SPECT quantification and image quality, triple-energy window, 157 SPECT imaging of normal subjects, ~Tc-HMPAO, anatomical standardization, 587 localization of seizure foci, 290(ab) presurgical localization with interictal and postictal brain scans, medically intractable complex partial seizures, 23(ab) regional differences in clearance on brain SPECT, 1253 ~Tc-HMPAO and, mismatched uptake, subacute cerebral infarction, 275(ab) versus ~Tc-IMP, acetazolamide challenge test in patients with chronic occlusive cerebrovascular disease, 1463

with acetazolamide enhancement, cerebral complications in coronary bypass surgery, 271(ab)

Technetium-99m-ethylindocyanine alternative agent to detect renovascular HTN, 1662(e) simplified clearance from single plasma sample, effective renal plasma flow, 1784

Technetium-99m exametazime SPECT image analysis to measure rCBF, comparison with ~Tc-ECD, 1721 stabilized, leukocyte labeling with, plasma effects, 112(ab)

Technetium-99m furulofin compounding, microwave-oven heating and, 178(ab) functional imaging of MDR in tumors, 1915 Technetium-99m-galactosyl-neoglycoalbumin, distinction between hepatic focal nodular hyperplasia and malignant liver lesions, 1912

Technetium-99m gluconate, uptake, apoptotic versus necrotic cell death and, 192(ab)

Technetium-99m glucarate, marker of necrosis, myocardial infarction, 98(ab)

Technetium-99m GSA assessment of liver function, partially hepatectomized rats, 259(ab) measuring ASCCP receptor imaging, 26(ab)

Technetium-99m hydroxynapthyl aminoquinoline uptake. cats, 49(ab) Technetium-99m hydroxyquinoline uptake, with, 49(ab)

Technetium-99m iodide imaging and, 142(ab) Technetium-99m iodosobenzene, melanoma imaging, 86(ab)

Technetium-99m-bicisate, SPECT image analysis to measure rCBF, comparison with ~Tc-HMPAO, 1721

Technetium-99m biotin. ~Tc In leukocytes versus, inflammation imaging, patients with, 132(ab)

Technetium-99m carbonyl, versatility in biomolecule labeling, 180(ab)

Technetium-99m chymotactic peptides accumulation, eosinophilic infiltrates, 258(ab) high affinity antagonist, infection imaging, 268(ab) specific localization, infection imaging, 269(ab)

Technetium-99m colloidal albumin gamma probe and, detection of nonpalpable breast lesions, 235(ab) sentinel node identification in breast cancer, lymphoscintigraphy and gamma imaging, 36(ab)

Technetium-99m complexes biokinetics, tumor-bearing mice, 241(ab) uptake, sensitive and multidrug resistant carcinoma cells, 241(ab)

Technetium-99m-DD-EC, comparison of ~Tc-LL-EC isomers as renal imaging agent, 821

Technetium-99m DISIDA cholescintigraphy, recurrence of intrahepatic stones, biliary retention significance in, 259(ab)

outcome of hepatobiliary scan in neonatal hepatitis syndrome, extrahepatic biliary atresia, 1279

Technetium-99m-disofenin, gastric emptying studies in cats, solid-phase labels, 495

Technetium-99m-DL-EC, comparison of ~Tc-LL-EC isomers as renal imaging agent, 821

Technetium-99m DMP 44, platelet GPIIb/IIIa antagonist labeled with, arterial thrombus detection, 18(ab)

Technetium-99m-DMP-HAS, compared to ~Tc-labeled RBCs for equilibrium radionuclide ventriculography, 1521
Technetium-99m-human labeling procedure, 775(ab)
leukocytes
infected hepatic aspiration diagnosis, 303(ab)
systemic vasculitis patients, 297(ab)
leukocytes labeled with, "Co compared with,
SPECT, 278(ab)
lymphocytes labeled with, decreased
chemotaxis, apoptosis relations, 270(ab)
practicing guideline for infection/inflammation
scintigraphy, 987
SPECT
frontal lobe perfusion and mental
performance after surgery, 215(ab)
localization of epileptogenic zones, 277(ab)
relative brain flow, 243(ab)
reproducibility of cerebral blood flow
measurements, state-dependent change, 6
SPECT and MRI studies in cerebral
infarction, crossed-cerebellar
diachisis, 14
SPECT imaging of normal subjects, "Tc-ECD,
anatomical standardization, 587
SPECT studies of regional cerebral blood flow
changes, positive and negative symptoms in
drug-naive schizophrenics, 181 white
blood cells, colonoscopy and biopsy
versus, bowl inflammation assessment
with, 24(ab)
Technetium-99m-HMPAO-labeled leukocytes,
relationship of decreased chemotaxis to
apoptosis, 1417
Technetium-99m-human serum albumin,
head and neck hemangiomas, perfusion and
blood-pool scintigraphy, "Tc-RBCs, 882
Technetium-99m-L, L-Ethylidenecysteine
comparison of isomers in rats and humans, renal
scintigraphy, 821
evaluation as radiopharmaceutical in patients
with chronic renal failure, 809
monoamide derivative of, synthesis and
biological evaluation, mice, 186(ab)
Technetium-99m-labeled hexamethylpropylene
amine oxime, volumetric analysis of
cerebral hyperperfusion, SPECT, brain
phantom, 1447
Technetium-99m-labeled microsphere,
distribution in rat lungs, cellular
dosimetry, 650
Technetium-99m-labeled red blood cells,"Tc-
DMP-HAS comparisons, gated blood-
pool imaging, 1521
Technetium-99m MAG3 absolute cardiac output measurement
with, 166(ab)
bifunctional chelator, "Tc peptide labeling
with, 189(ab)
clearance, one-point blood sampling
methods, 293(ab)
exercise renography in hypertensive pathology,
"Tc-DTPA, 1146
flow and renographic analysis, renal
transplants, 296(ab)
"1 OIH comparison, model analyses, 295(ab)
kit formulations, comparison of European and
U.S., 49(ab)
quantification of renal function, adults and
children, 294(ab)
rapid evaluation of renal parenchyma, SPECT,
cystic nephritis, ectopic, growth-adenoma kidney, 478
renal depth correction, 294(ab)
renogram deconvolution in kidney
transplantation, initial tracer
uptake, 1295
soft-tissue uptake
prostate cancer, 525
transplant percent uptake, ERPF
clearance, 296(ab)
Technetium-99m MAG3 biocytin
as a new hepatobiliary agent, bilirubin-conjected
mice, 50(ab)
differential diagnosis, hepatobiliary
toxicity, 254(ab)
Technetium-99m-MDP bone scintigraphy,
differentiate benign changes from
sarcoma in Paget's disease, "Tc-FDG, 1495
Technetium-99m mebrofenin
bidirectional blood-hepatocele
transport, 209(ab)
quantiative scintigraphic imaging, adult liver
transplant patients, 51(ab)
Technetium-99m-meritiadine
acute renal failure after transplantation
use of scintigraphy as marker of viability and
progress, 475
Technetium-99m-norhex-panal-
propyleneamine oxime, potential
imaging agent, cerebral glucose
content, 1125
scintigraphic determination of effective renal
plasma flow, 1285
Technetium-99m-methylene diphosphonate
euthesophathies and spondyloarthropathies, bone
scan findings, 2003
patterns in patients with painful shoulder
lesions, bone scan, 1491
Technetium-99m MIBI
assessment of neoadjuvant chemotherapy, breast
scintigraphy, 1546
brain tumor diagnosis, surrounding
edema, 159(ab)
compared to FDG PET, brain tumor recurrence
versus radiation necrosis, 158(ab)
compared with "Tc-tetrofosmin uptake,
musculoskeletal sarcomas, 682
compared with "Tc-chloride scintigraphy in
lung cancer, 1358
comparisons of parathyroid imaging
techniques, 834
comparison with "Tc, evaluation of
radiotherapy for primary lung cancer, 299(ab)
detection of coronary artery disease, 122(ab)
dipyridamole scintigraphy and intravascular
ultrasound postintervention, SPECT, 553
discordant uptake on brain SPECT images,
"Tc-HMPAO, 828(ab)
education of bone and soft-tissue lesions,
assessment of tumor response to
chemotherapy compared with "Tc, 501
evidence of viable myocardium, comparison of
methods, 63(ab)
post-stress and 24-hour gated SPECT, transient
prolonged stunning by dipyridamole
stress, 15(ab)
scintigram, Ewing sarcoma evaluation,
children, 13(ab)
sclerotherapy, parathyroid glands, 267(ab)
scintimammography, breast cancer detection,
European trial, 20(ab)
SPECT, AdVEGG 121 gene therapy assessment,
in coronary artery disease, 42(ab)
systolic count increase in gated myocardial
SPECT, 1067
"Tc and, intracellular accumulation in Ehrlich
carcinoma cells, 187(ab)
"Tc chloride and, palpable breast mass
detection, immunohistochemical
characteristics and, 21(ab)
thyroid cancer metastases
scintigraphic evaluation compared with "Tc
and "I, 352
thyroid scintigraphy
endemic goiter area, adenoma versus
malignant tumor, 62
Technetium-99m NOET
first-pass myocardial extraction fraction
for, 65(ab)
interaction with blood elements, potential
mechanism of myocardial redistribution,
persusion imaging agent, 138
spleen cell uptake, 186(ab)
Technetium-99m P280
compared to contrast venography, localization
of acute deep venous thrombosis, 9(ab)
detection of deep venous thrombosis, patients
with prior history, 9(ab)
early and delayed imaging with, acute deep vein
thrombosis, 123(ab)
safety and efficacy, localization of acute deep
veins thrombosis, 9(ab)
Technetium-99m P483H, diagnosis,
osteomyelitis, 132(ab)
Technetium-99m P829
peptide, imaging tumors possessing
somatostatin receptors, 236(ab)
SSTR binding peptide, Hodgkin's and non-
Hodgkin's lymphoma
assessment, 236(ab)
Technetium-99m peptide conjugates, synthesis,
ternary ligand system, 100(ab)
Technetium-99m-perchtechnetate
ectopic lacrimal gland, differential diagnosis,
SPECT, 1498
properties of technegas, lung, 1327
scintigraphic detection of ectopic gastric
mucosa in jejunum and ileum,
gastrointestinal bleeding, 818
Technetium-99m-phytate, radioaerosol
deposition, bronchial obstruction sign, 71
Technetium-99m PMT, dynamic scintigraphy
and, quantification of chronic liver
disease, 253(ab)
Technetium-99m-PNA, in vivo hybridization,
pharmacokinetics, 907
Technetium-99m-pyrophosphate, myocardial
necrosis by electrocution, "Tc SPECT
and echocardiography, 250
Technetium-99m-Q, transport selectivity, MDR1
and MDR3 p-glycoprotein, 87(ab)
Technetium-99m Q4, washout, human
hearts, 165(ab)
Technetium-99m Q12, compounding, microwave-
oven heating and, 178(ab)
Technetium-99m red blood cells
head and neck hemangiomas, perfusion and
blood-pool scintigraphy,"Tc-HSA-
D, 882
intra pancreatic accessory spleen, diagnosed
using "Tc-HDRBC SPECT, 494
Technetium-99m sestamibi
AMI followed by SPECT imaging and
pathologic correlation, thrombolytic
therapy, 1837
and "Tc-tetrofosmin

Subject Index • 1997 591
kinetics in normal subjects and patients with CAD, liver clearance, 428 cardiac SPECT, gastrointestinal uptake, dipiridamole and exercise stress effects, 156(a)
coronary artery disease, comparison of various imaging stress tests, 74(ab)
cavity-to-myocardium count ratio in detection of rest/stress left ventricular dysfunction, SPECT, 766 cellular uptake mechanism, classifying as passive or secondary transport, 1170(e)
compared with \(^{99m}\text{Tc}\)-tetrofosmin, parathyroid scintigraphy, 831 comparisons of parathyroid imaging techniques, 834 CYFRA 21-1 as tumor marker, lung cancer, 149(ab)
dipiridamole-modulated scintigraphy, response to chemotherapy in small cell lung cancer, 240(ab)
efflux rate, predictor of outcome of therapy in advanced breast cancer, 241(ab)
evaluation of therapy response in children with untreated malignant lymphomas, \(^{99m}\text{Tc}\)-Tc-99m MIBI, 154(ab)
gated SPECT
dysfunctional myocardium, 96(ab)
Fourier phase tomography for body contours, 63(ab)
identification of severe right ventricular dysfunction, pulmonary emboli, 254 gated SPECT perfusion study, end-diastolic versus summed images, coronary artery disease detection, women, 15(ab)
\(\text{Y}\)-daunomycin comparisons, myocardial cellular retention, MDR reversing agents, 1674
intestinal activity, cardiac artifacts, myocardial perfusion imaging, 75(ab)
kinetics, myocardial viability and, 175(ab)
left ventricular volume assessment using ECG-gated SPECT, \(^{99m}\text{Tc}\)-tetrofosmin, 53 monitoring response to therapy in patients with nasopharyngeal cancer, \(^{99m}\text{Tc}\)-Tc-99m MIBI, 1009
multidrug resistance, \(\text{P}\)-glycoprotein, transport activity of, hexakis effects, 141(ab), 369
myocardial perfusion imaging
comparison of SPECT and echocardiography, 754
gallbladder nonvisualisation during, 74(ab)
myocardial SPECT, pharmacological stress and, adenosine triphosphate versus dobutamine in, 162(ab)
P-glycoprotein inhibitor PSC833 effects on, 241(ab)
parathyroid abnormal gland localization, primary hyperparathyroidism, 150(ab)
patients with stable coronary artery disease and ventricular dysfunction, compared with rest-redistribution \(^{99m}\text{Tc}\) imaging, SPECT, 419
preoperative prediction of response to doxorubicin, breast cancer, 234(ab)
quantification of left ventricular function, \(^{99m}\text{Tc}\) myocardial gated SPECT, 958
radioisotope-guided localization of nonpalpable breast lesions, stereotactic prebiopsy, 1019
rejection as an index of P-glycoprotein expression, breast cancer, 1348
right lateral imaging versus supine, comparison with coronary arteriography.
\(^{99m}\text{Tc}\)-Tc-99m-tetrofosmin, differentiation, malignant and benign lesions, soft tissue, 302(ab)
scan, 227
scintigraphy compared with contrast-enhanced MRI, breast cancer diagnosis, 58
scintimammography
early breast cancer, 234(ab)
poor specificity in primary breast cancer patients, UK, 21(ab)
primary breast lesions, 234(ab)
severe LV dysfunction, nitrate effects on perfusion and function, 75(ab)
simultaneous \(^{99m}\text{Tc}\) Tc-99m, \(^{111}\text{In}\)-Tc-111m, SPECT, 236(ab)
SPECT, resting left ventricular systolic function measurement by, resting versus post-stress images, 14(ab)
stress, simultaneous rest \(^{99m}\text{Tc}\) myocardial perfusion SPECT and, coronary artery disease detection, 166(ab)
stress-induced pulmonary uptake, sustained versus transient, 140(ab)
\(^{99m}\text{Tc}\) Tc-99m, \(^{123}\text{I}\)-Tc-123I uptake, parathyroid scans, 297(ab)
triple head simultaneous Tc transmission Tc emission, assessment, 218(ab)
uptake
cells exhibiting multidrug resistance, 253(ab)
osteogenic sarcomas, correlation with multidrug resistance, 241(ab)
in tumor tissue to determine presence of multidrug resistance, influence of \(\text{P}\)-Glycoprotein, 1003
validation of quantitative defect size, rest myocardial perfusion SPECT, 1441
wall thickening, compared to FDG PET for myocardial viability, 96(ab)
Technetium-99m-sulfur colloid,
reticuloendothelial system scintigraphy, patients with Gaucher disease on enzyme therapy, 890
Technetium-99m-teboroxine, kinetics of, refurshed nonviable myocardium, 274
Technetium-99m-tetraphenyl porphyrin
sulfonate, skeletal scintigraphy for osteomyelitis detection, \(^{99m}\text{In}\)-WBC, 1999
Technetium-99m-tetrofosmin and \(^{99m}\text{Tc}\)-Tc-99m, kinetics in subjects with and without CAD, liver clearance, 428
compared with sestamibi, parathyroid scintigraphy, 831
compared with \(^{99m}\text{Tc}\)-MIBI uptake, early lesions, detection of coronary artery disease, 122(ab)
detection of coronary artery disease, myocardial SPECT during vasodilatation with diprydiamole, 44

differentiated thyroid carcinoma, postoperative follow-up without thyroid hormone withdrawal, 348
differentiating effects from attenuation artifacts in, gated cine-images for, 139(ab)
early and late images, as marker of stunned myocardium, recent myocardial infarction patients, 162(ab)
follow-up scan, differentiated thyroid cancer, 236(ab)
gated SPECT and cine MRI to assess LV contraction, 438
imaging of lung masses, SPECT, 1015
left ventricular volume assessment using ECG-gated SPECT, \(^{99m}\text{Tc}\)-Tc-99m, 53
localization of parathyroid gland, 706
myocardial viability assessment with, MRI functional recovery definition versus, 164(ab)
scintimammography, primary breast lesions, 233(ab)
SPECT
dobutamine infusion with, hibernating myocardium, 62(ab)
viability in severe left ventricular dysfunction, 97(ab)
\(^{99m}\text{Tc}\) and, myocardial kinetics of, effects of no flow and reperfusion on, 3(ab)
uptake, impact of stress protocol, myocardial perfusion imaging, 73(ab)
uptake in sarcomas, \(^{131}\text{I}\)-Tc-131I, 1786
Technetium-99m TRODAT-1
ingaging of dopamine transporter, kinetic modeling of, 61(ab)
SPECT, comparison with \(^{123}\text{I}\) IPT, imaging of dopamine transporters, 288(ab)
Technology Assessment, managed care and nuclear medicine, 13N(7)
Telemedicine, interactive nuclear medicine image display system, Java programming language, 210(ab)
Temporal lobe
MRI-guided SPECT measurements, Alzheimer’s disease, 914
perfusion asymmetries in schizophrenia, lateralization of blood flow, SPECT, 607
Teratoma, evaluation of retroperitoneal metastasis before and after chemotherapy, FDG-PET, 99
Testicular neoplasms, evaluation of retroperitoneal metastases before and after chemotherapy, FDG-PET, 99
Thallium, 24-hr delayed scan, after acute myocardial infarction, 62(ab)
automatic quantitative left ventricular ejection fraction and qualitative regional function assessed with gated myocardial perfusion SPECT, 749
\(^{111}\text{C}\) methionine or \(^{18}\text{FDG}\) for, most useful tracer for malignancy grade of glioma, 158(ab)
compared with fine needle aspiration biopsy, evaluation of thyroid nodules, 265(ab)
comparison of adenosine triphosphate and diprydiamole, detection of CAD with \(^{99m}\text{Tc}\) scintigraphy, 577
differentiation, malignant and benign lesions, soft tissue, 302(ab)
dobutamine as a pharmacologic stress agent for SPECT imaging in patient with left bundle branch block and normal coronary arteries, 424
evaluation of benign and malignant bone and soft-tissue lesions, Tc-MIBI scintigraphy, 501
evaluation of therapy response in children with untreated malignancy, Tc-sestamibi, 243
evidence of viable myocardium comparison of methods, 63(ab) revascularization effects on survival, 63(ab) follow-up, supratentorial gliomas, 237(ab) gated SPECT count density and filter requirements for accurate measurement of LVEF, 27(ab) diagnostic and prognostic cost effectiveness for coronary artery disease, 164(ab)
glucose-loading myocardial SPECT, 573 improved fatty acid uptake and myocardial function after revascularization, assessment using 18F-BMIPP, 1503 late redistribution imaging after rest injection, detection of viable myocardium, 1073 monitoring response to therapy in patients with nasopharyngeal cancer, Tc-sestamibi SPECT, 1009 myocardial necrosis by electrocution, Tc-pyrophosphate scintigraphy, echocardiography, 250 myocardial perfusion and function imaging at rest, blood-pool dual-isotope gated SPECT, Tc, 432 myocardial SPECT, ATP and, pharmacological stress, 174(ab) prediction of postoperative recurrence, thyroid carcinoma, 265(ab) quantification of left ventricular function, Tc-sestamibi myocardial gated SPECT, 958 re-injection prognostic value of, 1667(le) redistribution-reinjection images, 199 9MPA SPECT versus, myocardial viability evaluation, 162(ab) rest, gated dipyrinamide stress Tc mibi/Tc-99mHMPAO 24 hour redistribution myocardial SPECT, comparison with post-CABG SPECT on wall motion improvement prediction, 3(ab) rest-redistribution imaging and rest Tc-sestamibi SPECT, stable coronary artery disease and ventricular dysfunction, 419 simultaneous Tc-sestamibi SPECT, CNS lymphoma, 115(ab) simultaneous stress Tc-sestamibi and, myocardial perfusion SPECT, coronary artery disease detection, 166(ab) SPECT differential diagnosis of brain tumors, 116(ab) regional myocardium blood flow assessment, 165(ab) rest redistribution in, effect of different thresholds, 162(ab) reverse redistribution regions on, oxidative metabolism by 13C acetate PET in, 170(ab) SPECT imaging and intravascular ultrasound, myocardial perfusion in heart transplant recipients, graft atherosclerosis, 760 SPECT imaging for chronic exertional compartment syndrome in lower extremities, 972 SPECT motion correction for artifacts, myocardial perfusion, 785 SPECT myocardial perfusion studies, Tc-MIBI multigated blood pool studies versus, left ventricular ejection fraction calculation and, 16(ab) Tc-MIBI and, intracellular accumulation in Ehrlich ascites tumor cells, 187(ab) Tc sestamibi versus, gated perfusion SPECT, 15(ab) Tc tetrofosmin and, myocardial kinetics of, effects of no flow and reperfusion on, 3(ab) thyroid cancer metastases, evaluation of Tc-MIBI scintigraphy for early detection of recurrence, 1(1), 352 total-body scintigraphy in the follow-up of differentiated thyroid cancer, 1(1), 868 tumor detectability with, thyroid cancer metastases, 237(ab) uptake and retention in intracranial tumors after radiotherapy, 223 in CMV encephalitis, AIDS, 1386 mitochondrial Na-K ATP synthesis and, 182(ab) nuclear DNA content, clinical behavior and, metastatic thyroid cancer and, 17(ab)
Thallium-201-chloride brain tumor imaging histology and malignant grade correlation, Tc-DMSA, 1741 compared with Tc-MIBI scintigraphy in lung cancer, 13, 1385 delayed positive uptake in non-Hodgkin’s lymphoma, AIDS, 1213 scintigraphy and MRI, predictors of response for extremity osteosarcoma, 293(ab) SPECT imaging, diagnosis of head and neck cancer, 873 Tc-MIBI and, palpable breast mass detection, immunohistochemical characteristics and, 21(ab) versus Tc-MIBI, parathyroid adenomas, 151(ab) Thallium-201-SPECT, left ventricular function and perfusion, Becker muscular dystrophy, radionuclide angiography, 563 Therapy acute liver necrosis induced by I-131-IMIBG, metastatic carcinoid tumor, 1024 monitoring treatment response in patients with nasopharyngeal cancer, TI and Tc-sestamibi SPECT, 1009 Thracobadominal, SPECT-CT image fusion in endocrine carcinoma, 1234 Three-dimensional dosimetry, patient-specific software modules, dose-volume histograms, 301 Three-dimensional image, determining glioma resectability, cortical function and structure, glioma resection, 1563 Three-dimensional volume imaging characteristics of the HEAD PENN-PET scanner, adult brain and pediatric whole-body studies, 636 resolution improvement through iterative reconstruction, PET, 1623 Thrombocytopenia, after radioimmunotherapy, cell kinetics model, 118(ab) Thromboendarterectomy, lung perfusion scans and hemodynamics, pulmonary embolism, 980 Thrombolytic therapy, AMI followed by Tc-sestamibi SPECT and pathologic correlation, 1837 Thrombosis imaging, potential use of Tc-99m-HMPAO, GPIIb/IIa receptor, visualization of pulmonary embolism and deep venous thrombosis, 105 Thrombus, imaging, Tc-labeled peptidomimetic and, 26(ab) Thymic rebound, Ga SPECT patterns, children, 13(ab) Thymus false-positive FDG-PET imaging, child with Hodgkin’s disease, 889 mediastinal uptake of radioiodine therapy, thyroid cancer, young patients, 152(ab) Thyroglobulin characterization by epitope-specific IRMA. thyroid cancer, 148(ab) Tc treatment in differentiated thyroid cancer, predicting efficacy, 1362 serum assay, accuracy in, 149(ab) TI and TI scintigraphy in the follow-up of differentiated thyroid cancer, 686 Thyroid Hurthle cell carcinoma, imaging with FDG PET, 160(ab) imaging, thyrotoxicosis, routine oblique views, 150(ab) incidental lesions, endocrine goiter, importance of scintigraphy, 263(ab) nodules TI scintigraphy or fine needle aspiration biopsy in, 265(ab) autonomous, nonsurgical ablation, 262(ab) trapping only type, prevalence study, 151(ab) scintigraphy, subclinical hyperthyroidism, 308(ab) TI and TI scintigraphy, 263(ab) Thyroid cancer differentiated children and adolescents, age, sex, and thyroidology effects, 265(ab) evaluation of TI therapy for, 16(ab) follow-up with Tc tetrofosmin scan, 236(ab) iodothyronines in urine after TI whole-body scintigraphy, 267(ab) TI prediction of postoperative recurrence, 265(ab) elevated thyroglobulin, FDG PET in, 160(ab) false-positive whole body TI scan, 265(ab) intrahepatic duct dilatation, 1977 hepatic visualization on TI whole-body scan, metastasis, 1191 TI ablative therapy for, 46(ab) TI treatment, radiation dose to salivary glands during, 230(ab) TI treatment, retrospective biological dosimetry, 377 limits of detectability, TI, I and TI comparison, 78(ab) management, extensive thyroidectomy, prognostic significance, 263(ab) medullary anti-CEA monoclonal antibodies, 264(ab) anti-CEA monoclonal antibodies for noninvasive imaging, 232(ab) TI in DTPA-D-Phe-l-octreotide and TI DMSA scans for staging of, 237(ab) TI in octreotide localization of, 151(ab) radioimmunotherapy with anti-CEA monoclonal antibodies, 267(ab) metastases TI in pentetreotide, TI sestamibi, and TI scan in, 236(ab) detectability with TI, 237(ab)
metastatic

\[^{131}I\] and \[^{123}I\] comparison in scanning uptake, 150(ab)

\[^{131}I\] therapy, recovery after, metastatic thyroid cancer, 226(ab)

\[^{207}Tl\] uptake, nuclear DNA content and clinical behavior in, 17(ab)

metastatic medullary, anti-CEA antibodies versus octreotide for detection of, 9(ab)

predicting efficacy of \[^{131}I\] treatment, thyroglobulinin, 1362

radioiodine negative tumor tissue, FDG PET or sestamibi use in, 153(ab)

radioiodine therapy, physiological uptake in thyroid, young patients, 152(ab)

research developments and therapeutic options, bone pain palliation, 19N(11)

serum thyroglobulin in, epitope-specific IRMA, 148(ab)

\[^{89}Tl\]/\[^{99m}Tc\] MIBI scan, normal variants, 267(ab)

treatment with \[^{131}I\] therapy, rapid bedside TSH assay, 264(ab)

Thyroid carcinoma, \[^{3}I\], false-positive scans, mucoccele, 1022

Thyroid disease

autoimmune, clinical role of anti-TGPO in, 150(ab)

high resolution pinhole SPECT in, 16(ab)

Thyroid hormones, basal, suppressed, after surgery, 262(ab)

Thyroid stimulating hormone, rapid bedside assay, thyroid cancer, 264(ab)

Thyroid tumors, false-positive findings, MIBI, 1501(le)

Thyroid volume, quantification of, 1002(le)

Thyroiditis, chronic, diffuse FDG uptake in, 16(ab)

Thyrotoxosis, common clinical entity, 263(ab)

Time-of-flight, multiprobe system, quantifying positron-emitting tracer in target region, 143(ab)

Tin-117m, new agent for intractable bone pain, 193(ab)

Tin-117m(DTPA), pharmacokinetics and imaging characteristics, metastatic bone pain, 230

TLD, internal dose estimation, continuous inhalation of \[^{131}I\]-labeled gases, steady state technique, 1603

Tomographic equilibrium gated blood-pool scintigraphy, absolute right and left ventricular volume and ejection fraction, 942

Tomographic multigated analysis, sestimibi tomograms, partial volume limit and patient data, 27(ab)

Tomography, initial changes in \[^{15}F\]-FDG uptake during radiotherapy, glucose metabolism, 1384

Tourrette's syndrome

basal ganglia dopamine release in, 12(ab)

basal ganglia perfusion, \[^{99m}Tc\]-HMPAO SPECT, 188

D2-like dopamine receptor density measured by PET, neuropsychology, 1243

Tracer kinetic modeling, requirements and implementation of flexible tool, interactive software, 1818

Transcatheter arterial embolization, scintigraphic assessment of therapeutic success, absolute ethanol, treatment for aldosteronomas, 237

Transcranial Doppler sonography, acetazolamide-activated SPECT and, correlation in aneurysmal subarachnoid hemorrhage patients, 36(ab)

Transitional cell carcinoma, incursion and uptake of skeletal imaging agent, \[^{99m}Tc\]-HMPD, 1206

Transmission CT, scatter and attenuation correction, \[^{99m}Tc\]-ECD, brain SPECT, 157

Transmission tomography

fan-beam transmission CT, two-head SPECT systems, 212(ab)

pulmonary perfusion and density gradients, SPECT, attenuation correction, 962

Transplantation

heart changes in coronary flow reserve after, 172(ab)

nitric oxide synthase upregulation in, detection and comparison using \[^{15}F\] FEU1, 175(ab)

PET use to establish hibernating myocardium, 55(ab)

sympathetic cardiac reinnervation after, 111(ab)

hepatocytes, safety analysis, \[^{99m}Tc\] human serum albumin microspheres, 258(ab)

kidney complications, flow velocity index and resistive index comparison, 49(ab)

evaluation with \[^{99m}Tc\] MAG3, 296(ab)

scarring in, \[^{99m}Tc\] DMSA SPECT use in, 50(ab)

liver, adult patients, \[^{99m}Tc\] mebrofenin imaging in, 51(ab)

lung, with bronchial artery-intestinal mammary artery anastomosis, bronchial artery perfusion scintigraphy in, 5(ab)

pancreas, evaluation by \[^{99m}Tc\] DTPA scintigraphy, 25(ab)

Transvenous pacemaker, first-pass phase of radionuclide angiocardiogram, detection of subclavian vein thrombosis, 101

Trapping mechanism, metabolism of radiodinated HPHA 3-10, rat myocardium, 1864

Triphenylphosphonium, \[^{15}F\]-3, enhanced uptake, malignant cell lines, 117(ab)

Triple-energy window scatter correction, improved quantification and image quality, \[^{99m}Tc\]-ECD, brain SPECT, 157

Tumor, see under specific types

Tumor detection

511 keV SPECT, simulation study, 206(ab)

cancer staging and, matched subspace filter in dynamic PET for, 201(ab)

Tumor dosimetry, radioimmunotherapy of CEA-expressing cancers with anti-CEA and antinimucin monoclonal antibodies, 409

Tumor grading, prediction of survival with \[^{15}F\]-FDG PET, head and neck neoplasms, 1907

Tumor hypoxia, FDG uptake per regional blood flow, \(^{15}O\) water as indicator of, 68(ab)

Tumor imaging

antibody type and time for, use of imaging figure of merit to select, 10(ab)

breast, intraoperative localization with a portable probe, 210(ab)

intraperitoneal, \[^{99m}Tc\] GSA and, 185(ab)

mitochondrial function diagnosis, \[^{13}C\] PTSM and, 183(ab)

potential use of synthetic laminin derivative radiodinated peptide, YIGSR, 1940 technetium-99m complexes for, 241(ab)

\[^{99m}Tc\]-MIBI and \[^{99m}Tc\]-tetrofosmin uptake, musculoskeletal sarcomas, 682

unsulfated DTPA-cholceystokinin analogs and, as ligands for cholecystokinin-B receptor expressing human tumors, 17(ab)

vascularized, \[^{123}I\] VEGF-165 and, 187(ab)

Tumor markers, S100 IRMA, malignant melanoma, 148(ab)

Tumor pretargeting, role of avdin/streptavidin on monoclonal antibody internalization, 1378

Tumor quantitation, software application for measurement of tumor activity in sequential whole-body scintigraphic images, \[^{15}Tc\]-sestamibi, 356

Tumor response, pharmacokinetics and G250 antibody parameters for, 230(ab)

radioimmunotherapy, integrated model, 229(ab)

Tumor targeting

folate binding protein associated with, \(^{123}I\) in DTPA folate use for, 133(ab)

\[^{99m}Tc\]-DTPA-folate, folate-receptor-targeted radiopharmaceutical synthesis, 87(ab)

Tumor-seeking agent, receptor imaging via radiolabeled DTPA cobalamin analogs, vitamin B12, 717

Tumor-seeking agents

\[^{131}I\] choline, 250(ab)

\[^{15}F\]-labeled choline analogue, 2-fluoroethyl-dimethyl-2-oxoethylammonium, automated synthesis, 44(ab)

Tumor-to-normal tissue ratio, extracorporeal immunoadsorption compared to avidin chase, biotinylated \[^{123}I\]-Re-chiBR96, 1934

Two compartment model, cerebral blood flow and partition coefficient using \[^{131}I\]-IMP, SPECT, 1248

Two-compartment model, \[^{123}I\]-IMP SPECT, comparison of methods to measure regional cerebral blood flow, microsphere model, microsphere model, 597

Two-step immunoscintigraphy, non-small-cell lung cancer staging, bispecific antibody, carcino-embryonic antigen, 507

U

Ulcereative colitis, leukocyte apheresis treatment in, \[^{99m}Tc\] leukocytes imaging for, 159(ab)

Ultrasound, DMSA and detection of renal cortical scarring and renal length measurement, pathological correlation, 24(ab)

Undifferentiated lymphoma, delayed positive thallium uptake, AIDS, 1213

Unstable angina, \[^{13}N\]-MBIPP imaging as a guide for interventional strategy, PTCA, 1407

Uptake-I, myocardial sympathetic innervation changes in response to hypoxia, \[^{99m}Tc\], MBIG, desipramine, 954

Urea breath test, documentation of presence and eradication of helicobacter pylori, 1141

Urinary bladder, medical versus surgical therapy, nuclear uroflowmetry, 49(ab)

Urinary clearance, single-sample method to measure GFR, \[^{99m}Tc\]-DTPA, plasma clearance, 1(ab)

Urinary growth hormone, diagnosis and therapy monitoring, acromegaly, 148(ab)

Uroflowmetry, nuclear, medical versus surgical therapy, 49(ab)

Urokinase, intracarotid arterial therapy, acute cerebral infarction, brain perfusion

621 The Journal of Nuclear Medicine
V

V79 cells, survival and DNA damage, exposure to \(^{109}\)At and astatodeoxyuridine, 227(ab)

Variable dose rate irradiatot, characteristics of a \(^3\)C system to simulate internal radionuclide patterns, mercury attenuator, dosimetry, 727

Vascular abscess, radionuclide evaluation, chronic hemodialysis patients, 308(ab)

Vascular endothelial growth factor receptors. \(^{125}\)I, vascularized tumor imaging and, 187(ab)

Vasculities, ANCA-associated, detection of pulmonary manifestations by \(^{125}\)In octreotide imaging, 38(ab)

Vasculitis, systemic, scintigraphy with \(^{99}\)Tc HMPAO leukocytes in, 297(ab)

Vasoactive intestinal peptide, \(^{125}\)I-labeled, derivative, biodistribution, mouse model of breast cancer, 239(ab)

Ventricular perfusion scintigraphy, assessment of metal stent efficacy, lung function testing, 1584

Ventricular scan, prestenotic bronchial radioaerosol deposition, \(^{99}\)Tc-phytate, 71

Ventricular scintigraphy, evaluation of eustachian tube function, \(^{125}\)I-Xe, 66

Ventricular/perfusion imaging aerosol, automated perfusion abnormalities in, 122(ab)

evaluation of pulmonary embolism, nephrotic syndrome patients, 298(ab)

Gestalt interpretation, suspected pulmonary embolism, 299(ab)

low probability lung scans, long-term outcome, modified PIOPED criteria, 123(ab)

mismatch, follow-up of pulmonary embolism, 123(ab)

probability of pulmonary embolism, severity of photopenia in a perfusion defect and, 123(ab)

Ventricular/perfusion lung scan, clinical outcome of patients with intermediate probability results, follow-up of PE and DVT patients, 1593

Ventricular volume, evaluation of RV and LV using a mathematical cardiac torso phantom, gated SPECT, 1528

Ventriculotomy, treatment, heart failure, 108(ab)

Ventriculography, radionuclide evaluation of new surgical treatment of heart failure, 108(ab)

preoperative contrast and, prognosis after coronary artery bypass graft, 110(ab)

Vertebral osteomyelitis, imaging with \(^{99}\)Tc-antigranulocyte antibodies, photopenic lesion, 211

Vesamicol receptor \(^{125}\)I MBT binding, synthesis and monkey SPECT of, 181(ab)

radioiodinated (-)-M-iodovasamicol, evaluation, resynaptic marker of cholinergic neurons, 182(ab)

Vesico-ureteral reflux diagnosis, during renal scintigraphy, 291(ab)

procedure guideline for radionuclide cystography, pediatrics, 1650

radioisotope voiding cystography, grading system in, 292(ab)

Vest ambulatory monitoring of left ventricular function, congestive heart failure, 948

incarcination of, positional limitations, 1672(ed)

Viable myocardium, prognostic value of thallium reinfarction after stress-redistribution imaging, previous myocardial infarction and left ventricular dysfunction, 195

Vietnam, nuclear medicine practice, 17N(1)

Vigabatrin, attenuation of brain dopamine concentration changes, cocain-induced, 11(ab)

Vision, impression and perception, neural systems that underlie, PET study, 286(ab)

Vitamin B12, receptor imaging with radiolabeled DTPA cobalamin analogs, transcobalamin II, 717

Volume reduction, radioiodine therapy in sporadic nontoxic goiter, 372

Volume visualization, multimodality display, combination of complementary data for diagnostic information, SPECT and magnetic resonance brain images, 624

Vulva, cancer, sentinel node detection by lymphoscintigraphy and gamma detection probe, 33(ab)

Wall thickening, myocardial abnormalities in patients with left bundle branch block, \(^{123}\)I-sestamibi gated tomography, septal hyperfunction, 545

Ward Valley, update on transfer of federal land to the state of California, 28N(10)

Washout ratio, \(^{11}\)M-BMIPP SPECT, cardiac work during exercise in normal and ischemic hearts, pressure rate products, 559

Watershed infarct, assessment of cerebral perfusion reserve using \(^{11}\)IMP SPECT, carotid artery disease, 1556

Whiplash injury, functional brain imaging, 1002(le)

Whiplash syndrome, SPECT and PET studies, 276(ab)

White blood cells, \(^{18}\)F-FDG, \(^{123}\)I-Tc-T1-201 scintigraphy for detection of osteomyelitis, \(^{18}\)F-FDG, 1999

White matter hyperintensity, CBF and oxygen metabolism changes, MRI, Alzheimer’s disease, 1471

Whole-body image registration, tumor quantitation and monitoring, \(^{99m}\)Tc-sestamibi planar scintigraphy, software, 356

Whole-body PET, lymphoma and Hodgkin’s disease staging, FDG imaging, 343

Whole-body scintigraphy, post-operative follow-up of differentiated of thyroid carcinoma, \(^{123}\)I-tetrofosmin, 348

Wilson’s disease, nigrostriatal dopaminergic damage, \(^{131}\)I 8-CIT SPECT, 147(ab)

Wrist fracture localization, digital overlay of bone scintigrams and radiographs, 1600

traumatized, digital overlay of bone scintigram and radiograph in, 301(ab)

X-ray photoelectron spectroscopy, use of pertechnetes as ventilation agent, compared to technegas, 163

Xenon-133 brain SPECT, improved sensitivity to cerebrovascular stress studies, 37(ab)

cerebral blood flow and, multimodal approach, 278(ab)

cerebral postischemic hyperperfusion, SPECT, 602

SPECT, thoracic ischemic lung volume reduction surgery, 298(ab)

ventilation scintigraphy of middle ear, eustachian tube function, 66

Y

Yttrium, mAb labeling, CHX-DTPA isomers for, stability and biodistribution of, 192(ab)

Yttrium-86 PET and, measurement of octreotide in baboons, 60(ab)

Yttrium-90 antisense oligonucleotides, cancer gene therapy and, 193(ab)

DOTA-Tyr-octreotide labeled with, radiotherapy in tumor bearing rodents, 18(ab)

\(^{131}\)I-labeled IgG and, versus chemotherapy, in colorectal cancer, 6(ab)

radioassay use of radionuclide dose calibrator, liquid scintillation, 723

radioimmunotherapy for breast cancer, BrE-3, 1180

“Sr and, generator production, new quality control method and, 193(ab)

Yttrium-90 biotin, dosimetric evaluation, glioma patients, 224(ab)

Yttrium-90 DOTA-biotin, streptavidin-CC49 monoclonal antibody and, cancer pretargeting with, 188(ab)

Yttrium-90-octreotide, D-lysine for reduction of renal uptake of radioactivity during scintigraphy, \(^{131}\)I-DTPAOC, 1929

Z

Zr-89, radioimaging monoclonal antibodies, distribution in tumor-bearing mice, PET, 112

Zirconium-88, radioimaging monoclonal antibodies, distribution in tumor-bearing mice, PET, 112

Zollinger-Ellison syndrome, somatostatin receptor scintigraphy in, 104(ab)
Listed below are the companies that have advertised in this issue. Simply circle the numbers of those companies you are interested in, fill out the information below, and mail or FAX this to the Society of Nuclear Medicine, Advertising Department, 1850 Samuel Morse Drive, Reston, VA 20190, Fax 703-708-9015. We will forward this information to the advertiser(s).

<table>
<thead>
<tr>
<th>Reader Svc. No.</th>
<th>Advertiser</th>
<th>Telephone No.</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>Amersham Healthcare</td>
<td>847/593-6300</td>
<td>11A-12A</td>
</tr>
<tr>
<td>23</td>
<td>Capintec, Inc.</td>
<td>201/825-9500</td>
<td>2A</td>
</tr>
<tr>
<td>34</td>
<td>Du Pont Pharma</td>
<td>800/343-7851</td>
<td>8A-10A</td>
</tr>
<tr>
<td>59</td>
<td>Gensia Automedics, Inc.</td>
<td>619/622-3815</td>
<td>17A-20A</td>
</tr>
<tr>
<td>153</td>
<td>Pinestar Technology, Inc.</td>
<td>800/682-2226</td>
<td>Inside Back Cover</td>
</tr>
<tr>
<td>181</td>
<td>Siemens Medical Systems</td>
<td>847/304-7700</td>
<td>Inside Front Cover and 1A</td>
</tr>
<tr>
<td>192</td>
<td>Toshiba Medical Systems, Inc.</td>
<td>714/669-5513</td>
<td>Back Cover</td>
</tr>
<tr>
<td>215</td>
<td>Wick Publishing</td>
<td>303/782-5208</td>
<td>7A</td>
</tr>
<tr>
<td>231</td>
<td>XETEX</td>
<td>408/745-6654</td>
<td>7A</td>
</tr>
</tbody>
</table>

### Reader Information Form

<table>
<thead>
<tr>
<th>SNM Meetings</th>
<th>SNM Membership Information</th>
<th>SNM Book Order Information</th>
</tr>
</thead>
</table>

YOUR NAME: __________________________ TITLE: __________________________

INSTITUTION: __________________________ DEPT: __________________________

ADDRESS: __________________________

CITY: __________________________ STATE: __________________________ ZIP: __________________________

PHONE: __________________________ FAX: __________________________

PRIMARY SPECIALTY: __________________________ SECONDARY SPECIALTY: __________________________

**CHECK ONE ANSWER IN EACH CATEGORY**

**Employer**

- [ ] Hospital
- [ ] 500 patients plus
- [ ] 300-499 patients
- [ ] 200-299 patients
- [ ] 100-199 patients

**Employer**

- [ ] Private Clinic
- [ ] R&D Commercial
- [ ] University
- [ ] Government
- [ ] Other

**Purchase Authority**

- [ ] Recommend
- [ ] Specify
- [ ] Purchase

**Reason for Inquiry**

- [ ] Immediate Purchase
- [ ] General Information
- [ ] Budgeting Information

**SNM Member**

- [ ] Yes
- [ ] No

**JNM/JNMT Subscriber**

- [ ] Yes
- [ ] No